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Abstract 
 
CLINICAL PHARMACOLOGY OF MS-275, A HISTONE DEACETYLASE 
INHIBITOR 
 
By Milin R. Acharya, M.A., Ph.D. 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2005 
 
Directors: Jürgen Venitz, M.D., Ph.D., Associate Professor, Department of 
Pharmaceutics, Virginia Commonwealth University, Richmond, VA and William D. 
Figg, Pharm.D., MBA, Head, Clinical Pharmacology Research Core & Molecular 
Pharmacology Section, National Cancer Institute, National Institutes of Health, Bethesda, 
MD 
 
 
The goal of this escalating single-dose phase I research study was to determine the safety, 
tolerability, pharmacokinetics, pharmacodynamics as well as in vitro metabolism and 
plasma protein binding of MS-275, a novel histone deacetylase inhibitor, in patients with 
solid tumors and lymphomas. A validated LC/MS assay was developed to quantitate MS-
275 in plasma, human liver microsomes and urine. The pharmacokinetic (PK) evaluation 
was done using a non-compartmental approach. In-vitro plasma protein binding profile of 
MS-275 was characterized by a validated micro-equilibrium dialysis method. In vitro 
phase I and phase II hepatic metabolism of MS-275 were evaluated using human liver 
 
 xxii
microsomes. A correlative covariate analysis was performed in an effort to explain the 
wide inter-individual variability among patients. 
Results from the study demonstrate that the validated LC-MS assay is specific, 
accurate, precise and sensitive. MS-275 demonstrates a substantial inter-individual PK 
variability in systemic exposure and clearance; exposures increase in near-proportion, 
while peak concentrations increase more than-proportionally with an increase in dose. 
Mean apparent oral clearance (CL/F) is independent of dose and exhibits apparent dose-
independent PK behavior over the studied dose range. Oral absorption is highly variable. 
MS-275 has a 50-fold longer half-life in humans compared to pre-clinical species. PK/PD 
analysis showed significant correlation between occurrence of DLT and higher systemic 
exposures. Although there was an increase in the acetylation of histone H3 and H4 over 
time, preliminary analysis showed no significant correlation between PK parameters and 
change in % histone acetylation after 24 hours. MS-275 is moderately bound to plasma 
proteins. Hepatic phase I and II metabolic pathways are only minor routes of elimination, 
and MS-275 is neither a substrate for liver-specific organic anion transporting proteins, 
OATP1B1 and OATP1B3, nor a substrate for gastrointestinal efflux transporters ABCB1 
(P-gp) or ABCG2. No significant correlation was found between CL/F and demographic, 
body measures and other clinical covariates, and inter-patient variability in CL/F 
remained similar in magnitude even after correcting dose for body surface area (BSA) or 
other body measures. BSA is not a significant predictor of MS-275 PK, and flat-fixed 
dosing can be used in the future. 
 
 CHAPTER 1 
 
Introduction to Histone Deacetylase (HDAC) Inhibitors and MS-275 
 
1.1 Background 
 In eukaryotic cells, DNA has been conserved throughout evolution in a condensed 
and densely packed higher order structure called chromatin. Chromatin, present in the 
interphase nucleus, comprises of regular repeating units of nucleosomes, which represent 
the principal protein-nucleic acid relationship. The major components of chromatin are 
nucleic acids (DNA and RNA) and associated proteins including histones, which are 
positively charged at neutral pH, and non-histone chromosomal proteins, which are acidic 
at neutral pH. Within the nucleus, chromatin can exists in two different forms; 
heterochromatin, which is highly compact and transcriptionally inactive form, or 
euchromatin, which is loosely packed and is accessible to RNA polymerases for 
involvement in transcriptional processes and gene expression. A nucleosome is a 
complex of 146 nucleotide base pairs of DNA wrapped around the core histone octamer 
that helps organize chromatin (Figure 1.1). The histone octamer is composed of two 
copies each of H2A, H2B, H3 and H4 proteins that are very basic mainly due to 
positively charged amino-terminal side chains rich in amino acid lysine. Post-
translational and other changes in chromatin like acetylation/deacetylation at lysine 
residues, methylation at lysine or arginine residues, phosphorylation at serine resides, 
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ubiquitylation at lysines and/or ADP ribosylation are mediated by chemical modification 
of various sites on N-terminal tail (Figure 1.2).1-3  
 
 
 
Figure 1.1 Organization of chromatin 
 
 3
 
Adapted as is from 4 
a) Core proteins of nucleosomes are designated H2A (histone 2A), H2B (histone 2B), H3 
(histone 3) and H4 (histone 4). Each histone is present in two copies, so the DNA wraps 
around an octamer of histones. b) Lysines (K) in the amino-terminal tails of histones are 
acetylation/deacetylation sites for HATs and HDACs. Acetylation neutralizes the charge 
on lysines. A, acetyl; C, carboxyl terminus; E, glutamic acid; M, methyl; N, amino 
terminus; P, phosphate; S, serine; Ub, ubiquitin. 
 
Figure 1.2 Structure of histones in nucleosomes  
 
The structural modification of histones is regulated mainly by acetylation/ 
deacetylation of N-terminal tail and is crucial in modulating gene expression, as it affects 
the interaction of DNA with transcription-regulatory, non-nucleosomal protein 
complexes. The balance between the acetylated/deacetylated states of histones is 
mediated by two different sets of enzymes; histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). HATs preferentially acetylate specific lysine substrates among 
other non-histone protein substrates and transcription factors, impacting DNA-binding 
 4
properties and in turn, altering gene transcription. HDACs restore the positive charge on 
lysine residues by removing acetyl groups and thus are involved primarily in the 
repression of gene transcription by compacting chromatin structure (Figure 1.3).  Thus, 
open lysine residues attach firmly to the phosphate backbone of the DNA, preventing 
transcription. In this tight conformation, transcription factors, regulatory complexes, and 
RNA polymerases cannot bind to the DNA. Acetylation relaxes the DNA conformation, 
making it accessible to the transcription machinery. High levels of acetylation of core 
histones are seen in chromatin-containing genes, which are highly transcribed genes; 
those genes that are silent are associated with low levels of acetylation. Since 
inappropriate silencing of critical genes can result in one or both hits of tumor suppressor 
gene (TSG) inactivation in cancer, theoretically, the reactivation of affected TSGs could 
have an enormous therapeutic value in preventing and treating cancer.5 
 
 
Adapted as is from 3 
Figure 1.3 Acetylation and deacetylation of lysine due to HAT and HDAC 
activity 
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1.2 Histone acetylases and deacetylases: classification and function 
 The equilibrium steady state level of acetylation is tightly controlled by the 
opposing effects of both HATs and HDACs, which in turn regulate the transcription 
status of not just histones but also of other substrates such as p53. 6 Several groups of 
proteins with HAT activity have been identified, including GNAT (Gcn5- related N-
acetyl transferase) family, MYST (monocytic leukemia zinc finger protein) group, TIP60 
(TAT-interactive protein) and the p300/CBP (CREB-binding protein) family. HATs act 
as large multiprotein complexes containing other HATs, co-activators for transcription 
factors, and co-repressors. 7-11 HATs, which bind non-histone protein substrates and 
transcription factors, have been called factor acetyltransferases. Acetylation of these 
transcription factors also affects their DNA binding properties and gene transcription. 12, 
13 HAT genes may be over expressed, translocated, or mutated in both hematological and 
epithelial cancers. 14-16 Translocations of HATs, CREB-binding protein (CBP), and p300 
acetyltransferases, in frame into genes have given rise to many hematological 
malignancies. 17, 18  
 There are three major groups or classes of mammalian HDACs based on their 
structural homology to the three distinct yeast HDACs: Rpd3 (class I), Hda1 (class II), 
and Sir2/Hst (class III). Class III HDACs consist of the large family of sirtuins (silent 
information regulators) (SIRs) that are evolutionarily distinct, with a unique enzymatic 
mechanism dependent on the cofactor NAD+, and are virtually unaffected by all HDAC 
inhibitors in current development. 19, 20 Class I and II HDACs contain active site zinc as a 
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critical component of their enzymatic pocket, have been extensively described to have an 
association with cancers, and are thought to be comparably inhibited by all HDAC 
inhibitors currently in development. The Rpd3 homologous class I include HDACs 1, 2, 3 
and 8, are widely expressed in tissues and are primarily localized in the nucleus. Hda1 
homologous class II HDACs 4, 5, 6, 7, 9a, 9b and 10, are much larger in size, display 
limited tissue distribution and can shuttle between the nucleus and cytoplasm, suggesting 
different functions and cellular substrates from Class I HDACs. 21, 22 HDACs 6 and 10 
are unique as they have two catalytic domains, while HDACs 4, 8 and 9 are expressed to 
greater extent in tumor tissues and have been shown to be specifically involved in 
differentiation. 23 There is some evidence that certain inhibitors display a variable degree 
of HDAC specificity, and hence it would be imperative to identify differences in HDAC 
functions to better target and tailor specific drugs compounds. 6, 24-26 HDACs usually 
interact as constituents of large protein complexes that downregulate genes through 
association with co-repressors; like nuclear receptor corepressor (NcoR), silencing 
mediator for retinoid and thyroid hormone receptor (SMRT), transcription factors, 
estrogen receptors (ER), p53, cell-cycle specific regulators like retinoblastoma (Rb), E2F 
and other HDACs, as well as histones, but they can also bind to their receptor directly.20, 
27, 28 
1.3 Chromatin Modification and Cancer 
 DNA gene expression is controlled by an assembly of nucleoproteins that 
includes histones and other architectural components of chromatin, non-histone DNA-
bound regulators, and additional chromatin-bound polypeptides. Changes in growth and 
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differentiation leading to malignancy appear to occur by alterations in transcriptional 
control and gene silencing. It is becoming increasingly apparent that imbalances of both 
DNA methylation and histone acetylation may play an important role in cancer 
development and progression. 1, 4, 14, 29 Unlike normal cells, in cancer, changes in genome 
expression are associated with the remodeling of long regions of regulatory DNA, 
including promoters, enhancers, locus control regions, and insulators, into specific 
chromatin architecture. These specific changes in the DNA architecture result in a 
general molecular signature for a type of cancer and complement its DNA methylation-
based component. The changes in the infrastructure of chromatin over a target promoter 
are more profound than those observed by these enzymes acting independently. 30, 31 
Apart from acetylation, histone tails undergo other modifications including 
phosphorylation, ubiquitylation and adenosine diphosphate ribosylation. These other 
areas of modifications have not yet been explored enough to identify their roles in 
epigenetic modifications. 32 
 Disruption of HAT and HDAC function is associated with the development of 
cancer and malignant cells target chromatin-remodeling pathways as a means of 
disrupting transcriptional regulation (Figure 1.4). 15 Of the various hypotheses describing 
deregulation mechanisms, the following three have been put forth frequently: i) 
disordered hyperacetylation could activate promoters that are normally repressed, leading 
to inappropriate expression of proteins, ii) abnormally decreased acetylation levels of 
promoter regions could repress the expression of genes necessary for a certain phenotype 
and iii) mistargeted or aberrant recruitment of HAT/HDAC activity could act as a 
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pathological trigger. Even though there have been no direct alterations in HDAC genes 
demonstrated in cancer, the association of HDACs with various oncogenes and tumor 
suppressor genes is now well-established, as is the potential for HDAC involvement in 
tumorigenesis. 33  
 
 
 
 
Adapted as is from 3 
 
Figure 1.4 Chromatin modifications and its role in cancer 
 
1.4 Histone deacetylase inhibitors as anticancer agents 
The findings of recruitment of HDAC enzymes in cancer have provided a 
rationale for using inhibition of HDAC activity to release transcriptional repression as a 
viable option towards achieving eventual therapeutic benefit. 16 Inhibition of HDAC 
function can release dysregulation of genes involved in cell cycle progression, 
differentiation and apoptosis. HDAC inhibitors block the deacetylation function, causing 
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cell cycle arrest, differentiation, and/or apoptosis of many tumors. 17 Several HDAC 
inhibitors have exhibited potent antitumor activity in human xenograft models, 
suggesting their usefulness as novel cancer therapeutic agents. Several are currently in 
phase I/II clinical trials, both in hematological malignancies and in solid tumors (Figure 
1.5). Compared to agents used initially, some of the newer agents are effective in-vitro or 
in-vivo at nanomolar concentrations and are relatively less toxic. A wide range of 
structures inhibit activity of class I/II HDAC enzymes, and with a few exceptions these 
can be divided into structural classes including: (1) carboxylates (short chain fatty acids), 
(2) small-molecule hydroxamates, (3) electrophilic ketones (epoxides), (4) cyclic 
peptides and (5) benzamides and (6) other hybrid compounds. Table 1.1 describes the 
various compounds, their activities in cell lines and pre-clinical murine models and their 
current clinical status. 
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Table 1.1  Classes of HDAC inhibitors 
 
Class Short Name Other name  
In-vitro cell 
culture activity 
(concentration) 
In-vivo pre-
clinical activity 
(murine or 
human 
xenograft 
model) 
Clinical 
trial 
status 
(Phase) 
PA phenylacetate Yes (µM) Leukemia, glioblastoma I/II 
PB sodium phenylbutyrate Yes (µM) 
Prostate, 
endometrial  I/II 
VA valproic acid Yes (mM) Brain, melanoma I/II 
Carboxylate
s (Short 
chain fatty 
acids) 
AN-9 
Pivanex, pivaloyl 
oxymethyl 
butyrate 
Yes (µM) NSCLC, leukemia I/II 
SAHA suberonyl anilide hydroxamic acid Yes (nM) 
Lung, prostate, 
melanoma I/II 
CBHA 
m-
carboxycinnamic 
acid 
bishydroxamic 
acid 
Yes  Neuroblastoma - 
SBHA 
suberic 
bishydroxamic 
acid 
Yes Melanoma, sarcoma - 
Pyroxami
de - Yes (µM) - I 
TSA trichostatin A Yes (nM) Cervical, hepatoma,   
Oxamflat
in - Yes (µM) Melanoma  
Hydroxamic 
acids (HA)  
NVP-
LAQ824 - Yes (nM) 
Colon, multiple 
myeloma I 
TPX 
 Trapoxin A & B Yes (nM) - - 
AOE 
2-amino 8-oxo-
9,10-epoxy 
decanoic acid 
- - - 
Electrophilli
c ketones 
(epoxides) 
Depudeci
n - Yes (mM) - - 
Apicidin - Yes (nM) Melanoma, leukemia - Cyclic 
peptides FK-228, FR90122
8 
Depsipeptide Yes (nM) 
Melanoma, 
colon, sarcoma, 
fibrosarcoma, 
I/II 
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 lung, gastric  
MS-275 MS-27-275 Yes (µM) 
Leukemia, 
colorectal, 
gastric, 
pancreatic, lung, 
ovarian 
I/II 
Benzamides 
CI-994 N-acetyl dinaline Yes (indirect effect) 
Colorectal, 
pancreatic, 
mammary, 
prostate, 
sarcoma, 
leukemia  
I 
CHAPs  
cyclic HA- 
peptides (TPX-
TSA analogues) 
Yes (nM) Melanoma, lung, stomach, breast - 
Scriptaid TPX-HA  Yes (nM) - - 
Tubacin - - - - 
JNJ1624
1199 - - - - 
A-
161906 - Yes (nM) - - 
3-CI-
UCHA 
6- (3-
chlorophenylurei
do)caproic 
hydroxamic acid 
- - - 
Other hybrid 
compounds 
PXD101 - Yes (nM) 
Breast, prostate, 
ovarian, colon, 
NSCLC 
- 
 
 Comprehensive reviews on the structure, medicinal chemistry and structure-
activity relationships of more than 80 different HDAC inhibitors and analogues have 
been previously published or reviewed. 26, 33-44 Despite the structural distinctiveness, all 
of these HDAC inhibitors can be broadly characterized by a common pharmacophore that 
includes key elements of inhibitor-enzyme interactions.26 Most of these compounds were 
designed to have three basic components: a hydrophobic cap that blocks the entrance to 
active site, a polar site and a hydroxamic acid type zinc-binding active site separated by a 
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hydrophobic spacer that has optimal length spanning the hydrophobic pocket on the 
enzyme (Figure 1.5). 45   
 
 
 
Adapted as is from 45 
 
Figure 1.5 Structures of various classes HDAC inhibitors 
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1.4.1 Short chain fatty acids 
Dimethyl sulfoxide was one of the first compounds identified to be active in 
transformation and cell differentiation. As a result of this, several compounds were 
synthesized and screened for activity in differentiation, growth arrest and or apoptosis.4 
Valproic acid, a well-tolerated antiepileptic, is effective in-vitro as a HDAC inhibitor at 
relatively high (millimolar) concentrations and has much weaker affinity. It has been 
shown to selectively induce proteasomal degeneration of HDAC2 and is antiangiogenic 
in-vitro and in-vivo.46-48 It also has been shown to have antigrowth activity of human 
endometrial cells and also to inhibit proliferation and induce apoptosis in acute myeloid 
leukemia cells expressing P-glycoprotein and multi-drug resistance protein MRP1. 49, 50 51 
Valproic acid has been recently shown to inhibit angiogenesis in-vitro and in-vivo and 
markedly affects genes relevant in proliferation and apoptosis. 48, 52  
 Phenylacetate (PA) can penetrate the CNS and when tested in solid tumors, 
showed antitumor effects mediated by histone acetylation. PA is a metabolite of 
phenylbutyrate (PB) after β-oxidation in the liver and kidney 53, 54. PB, a well studied 
member of the short chain fatty acids, can arrest cells in G1–G0 by inducing p21WAF1 and 
other cdk-2-associated cell cycle proteins, alter levels of expression of activation and 
chemotaxis proteins such as urokinase-plasminogen activator, induce apoptosis, inhibit 
telomerase, and increase MHC class I expression, in various tumor models. 55 However, 
the short chain fatty acids have a low potency due to their short side chains, limiting their 
contact with the catalytic pocket of HDACs. 56 In human CCRF-CEM, acute T-
lymphoblastic leukemia cells, butyrate and other HDAC inhibitors caused G2/M cell 
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cycle arrest as well as apoptotic cell death. 57 Butyrates induce histone acetylation and 
granulocyte maturation in AML, selectively inhibiting growth in human prostate cancer 
and cervical carcinoma cells. 58-60 Butyrates have been under extensive clinical evaluation 
in both hematologic malignancies and solid tumors. Butanoic acid or its prodrug pivaloyl 
oxymethyl butyrate (AN-9) is currently undergoing phase I/II clinical trial after it showed 
10-fold more potent activity than SB in leukemia tumor cell lines. 61-63 The antineoplastic 
activity of AN-9 stems from rapid hydrolysis and release of butyrate, permitting efficient 
delivery to subcellular targets. 64, 65 In spite of their overall weak activity of SCFA, 
several agents with known safety profile such as valproic acid have been studied 
clinically owing to their approved use for alternative medical conditions. 66-68  
1.4.2 Hydroxamic acids 
This is the broadest class of inhibitors with high affinity for HDAC, which inhibit 
both HDAC I and II. Inhibitors containing hydroxamic acid (HA) residues bind with high 
affinity to the HDAC catalytic site, blocking the access of the substrate to the zinc ion. 69 
The general structure of these substances consists of a hydrophobic linker that allows the 
hydroxamic acid moiety to chelate the cation at the bottom of the HDAC catalytic pocket, 
while the bulky part of the molecule acts as a cap for the tube. Most of the compounds in 
this group are very potent (functioning at nanomolar to micromolar concentrations in-
vitro) but are reversible inhibitors of class I/II HDACs. 
 Trichostatin A (TSA) was one of the first HDAC inhibitors to be described and is 
widely used as a reference in research in this field. 70, 71 It was originally developed as an 
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antifungal agent but is relatively unstable and due to its toxicity to patients and lack of 
specificity for certain HDACs has been responsible for the search for other substances. 24, 
72 The design of many synthetic drugs has been inspired by TSA structure (the aromatic 
cap , hydroxamic acid functionality and hydrophobic linker between them). TSA blocks 
in-vitro proliferation and triggers apoptotis in hepatocellular carcinoma cells, blocks cell 
cycle progression in HeLa cells and differentiation in ovarian cancer cells by changing 
p21 tumor suppressor gene and DNA-binding Id1 protein. 73-75 TSA has also been shown 
in-vivo to suppress growth of pancreatic adenocarcinoma cells and ACHN renal cell 
carcinoma via cell cycle arrest in association with p27, or apoptosis. 76, 77 TSA is more 
sensitive in estrogen receptor alpha (ERα-) positive breast cancer cells in inhibiting 
HDAC.78 
 Simple hydroxamic acid derivatives such as suberoylanilide hydroxamic acid 
(SAHA) and pyroxamide have activity at submicromolar concentrations. 79-81 SAHA is a 
second-generation polar-planar compound that induces growth arrest, differentiation 
and/or apoptosis and is under clinical investigation in both hematological and non-
hematological malignancies. 80, 82-84 In studies with breast cancer cells, SAHA inhibited 
clonogenic growth and induced apoptosis, while in malignant human hemotopeoitic cells, 
SAHA induced marked toxicity but showed relatively minor maturation activity. 85, 86 
SAHA also showed antiproliferative and pro-apoptotic actions in several mouse 
xenografts and cancer cells including prostate, bladder carcinoma and myeloma. SAHA 
also induced CDK inhibitor p21WAF1/Cip1, and the inhibitory activity was independent 
of p53 status. 87-91 Pyroxamide is another compound in this class that induced terminal 
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differentiation in murine erythroleukemic cells and caused growth inhibition in prostate 
carcinoma, bladder and neuroblastoma cells via apoptosis. 41, 92, 93 In experiments with 
SAHA and butyrates, a model has been proposed in which induction of apoptosis in 
Bcr/Abl+ cells by HDIs involves coordinate inactivation of the cytoprotective 
Raf/MEK/ERK pathway in conjunction with the ROS-dependent activation of JNK. 94  
 Oxamflatin is another compound in the same class which induces transcriptional 
activation of junD causing cell cycle arrest and morphological changes similar to TSA. 95 
Scriptaid was found to be one of the most potent analogues in a search for substances that 
augment signal transduction pathways and when screened in human and animal tumor 
cells, showed similar antiproliferative effects as SAHA 35, 96 NVP-LAQ824, a cinnamic 
HA has been shown to inhibit HDAC in-vitro and to cause transcriptional activation of 
p21 promoter in reporter gene assays as submicromolar concentrations in multiple 
myeloma. 97 NVP-LAQ824 was selective in its action as it required longer exposure and 
higher concentrations to retard growth of normal human fibroblasts. 98 Another HA 
analogue, suberic bishydroxamate (SBHA) was shown to regulate expression of multiple 
apoptotic mediators and induce mitochondria-dependent apoptosis in melanoma cells. 99 
PXD101 is a novel hydroxamate-type inhibitor of HDAC activity in nanomolar ranges in 
leukemia cells. It was shown to delay growth for xenografts of cisplatin-resistant ovarian 
tumor cells and had marked increase in acetylation of histone and showed good antitumor 
activity 100 
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 Newer compounds such as cyclic HA peptides (CHAPs), and a structural 
combination of HA like TSA and the cyclic tetrapeptides like trapoxin, inhibit isoform 
selective HDACs at nanomolar concentrations. 101, 102 One of the CHAP derivatives 
inhibited growth in four of five human tumor lines implanted into nude mice and shows 
great promise as therapeutic agent with higher selective inhibition of HDAC. 103 
1.4.3 Cyclic peptides 
 Cyclic peptides having epoxyketone (epoxides) may act by chemically modifying 
an active site nucleophile with the epoxy group and forming H-bonds with ketone. These 
chemicals are supposed to trap HDACs through the reaction of the epoxide moiety with 
the zinc cation or an amino acid (forming a covalent attachment) in the binding pocket. 
However, the lability of the epoxide functionality prevents significant in-vivo activity, 
which makes them of little pharmacologic interest. The only HDAC inhibitors in this set 
of compounds are a number of natural products with significant in-vitro activity, such as 
Trapoxin A, B (TPX), depudecin and 2-amino 8-oxo-9,10-epoxydecanoic acid (AOE). 
TPX is a hybrid molecule containing cyclic peptide (acts as hydrophobic cap) and 
epoxyketone moiety that has shown irreversible inhibition of mammalian HDACs at 
nanomolar ranges. 103-105 Cyclic tetrapeptides such as apicidin, which has an ethyl ketone 
moiety, as well as FK228 (also referred to as depsipeptide, FR901228) inhibit HDACs at 
nanomolar concentrations. Apicidin is a fungal metabolite that is able to inhibit HDACs 
and proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. 106 It is 
postulated that apicidin interacts with the catalytic site and has been shown to inhibit cell 
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proliferation in several human cancer cell lines due to its anti-invasive and anti-
angiogenic activity. 107-111 FK228 is a natural product derived from Chromobacterium 
violaceum that exhibits potent antitumor activity through currently unknown mechanism 
of action. 112 One hypothesis proposes that the disulfide bridge is reduced inside the cell 
or organism and the 4-mercaptobut-1-enyl residue then fits inside the HDAC catalytic 
pocket, chelating Zn2+ in a manner similar to that of other inhibitors. In cultured cells, it 
is able to induce histone hyperacetylation and growth arrest at nanomolar concentrations. 
In human leukemia cells, FK228 had IC50 values at nanomolar concentrations and 
induced apoptosis ex-vivo in cells from patient with chronic lymphocytic leukemia. 113-116  
In addition, FK228 has been shown to be antiangiogenic by modulating expression of c-
myc and other regulatory genes. 117 FK228 is currently undergoing extensive evaluation 
in clinical trials. 117-120 
1.4.4 Benzamides 
 The synthetic benzamide derivatives include a structurally diverse group of 
compounds such as MS-275 and CI-994. CI-994 has shown efficacy in solid tumors in 
murine models but does not inhibit HDAC directly. The mechanism of its action is 
unknown, but it appears to inhibit both histone deacetylation and cellular proliferation at 
the G1–S transition phase. 121-123 MS-275 and some of its derivatives inhibit HDACs in-
vitro at micromolar concentrations, but the mechanism is not clearly understood. It is 
believed that the diaminophenyl group is very important for the inhibitory behavior; 
probably, both amino functionalities chelate the metallic ion in the catalytic site. MS-275-
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associated HDAC-inhibitory activity is accompanied by an increase in expression of 
cyclin dependent kinase inhibitor p21WAF1/Cip1 and accumulation in G1-phase. 124, 125 
MS-275 displays anti-proliferative activity in several human cancer cell lines including 
breast, colorectal, leukemia, lung, ovary and pancreas. MS-275 suppressed growth of 
several pediatric cancer cell lines in dose-dependent manner, as well as tumors 
transplanted in nude mice. 126 MS-275 and CI-994 are undergoing clinical trials. There 
are reports of novel nonhydroxamate sulfonamide anilides similar in structure to MS-275 
that have shown lower toxicity and comparable antiproliferative activity.34, 127 Currently, 
focus is on development of novel compounds based on core structures of HA or 
benzamide platform, which may have better HDAC inhibitory profile and lower toxicity 
compared to parent compounds. 
1.5 Mode of action of HDAC inhibitors in cancer cells 
 Even though a number of HDAC inhibitors have shown considerable promise in 
preclinical models, the mechanism of action has not been fully evaluated. The most 
widely accepted proposed mechanism of action is described in detail in Figure 1.6. 
HDAC inhibitors are effective in affecting cell cycle arrest, apoptosis, anti-angiogenesis 
and differentiation in cultured and transformed cells from both hematologic (leukemias, 
lymphomas and myelomas) and epithelial (breast, bladder, ovarian, prostate and lung) 
tumor sources. The change that occurs after treatment with HDAC inhibitors (growth 
arrest, terminal differentiation, or apoptosis) appears to be dependent upon the tumor cell 
line rather than the specific HDAC inhibitors used. 32 The HDAC family is divided into 
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the Zn-dependent (Class I and Class II) and Zn-independent, NAD-dependent (Class III) 
enzymes. The Zn-dependent enzymes have been the focus of intense research, whilst 
Class III enzymes have been recently implicated in acetylation and regulation of key cell 
cycle proteins such as p53. 128 129 Interestingly, a number of studies have shown that 
HDAC inhibitors are relatively non-toxic to normal cells or tissues, but exhibit selective 
cytotoxicity against a wide range of cancer cells. 130, 131 It has been postulated that 
defective cell cycle checkpoint regulation of neoplastic cells may render them susceptible 
to HDAC inhibition-induced apoptosis. 16, 132  
 
 
 
Adapted as is from 4 
When histones are acetylated, the DNA that is tightly wrapped around a deacetylated 
histone core relaxes. Specific sites in the promoter region of a subset of genes that recruit 
the transcription factor complex (TFC) with HDAC and that the accumulation of 
acetylated histones in nucleosomes leads to increased transcription of this subset of genes 
(for example, CDKN1A, which encodes WAF1), which, in turn, leads to downstream 
effects that result in cell-growth arrest, differentiation and/or apoptotic cell death and, as 
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a consequence, inhibition of tumor growth. Ac, acetyl group; HAT, histone 
acetyltranferase. 
 
Figure 1.6 Proposed mechanism of action of HDAC inhibitors 
As noted earlier, histone acetylation is known to precede gene transcription, and 
among the genes that are consistently upregulated because their promoters are associated 
with acetylated histones, is the cell cycle gene CDKN1A, which encodes cyclin-
dependent kinase (CDK) inhibitor p21WAF1. The CDK inhibitor WAF1 inhibits cell-cycle 
progression by blocking CDK activity and the arrest of the cell cycle in G1 stage. Most 
HDAC inhibitors namely, butyrates, TSA, depsipetide, oxamflatin, MS-275 and SAHA 
induce expression of p21. 86, 106, 125, 133-142 Some cDNA microarray studies have shown 
that treatment with TSA or SAHA alters the expression of a selective subset of 
approximately 2% of cellular genes that are either upregulated or downregulated. 143-145 
The genes that are usually affected by these inhibitors are CDKN1A and CDKN2A where 
the latter encodes genes of cell cycle regulation such as p16, cyclin E and thioredoxin 
binding protein 2.85, 146 Thus, gene promoters have specific sites, such as SP1, which bind 
HDAC containing transcription complexes and repress gene transcription. 147, 148 
Inhibition of HDACs will activate these silenced genes, contributing to growth arrest, 
differentiation and/or apoptosis of transformed cells.   Treatment with HDAC inhibitors 
triggers both the intrinsic and the extrinsic pathway of apoptosis by sensitizing tumor 
cells to the death ligands. 32 Several HDAC inhibitors, including SB, SAHA and MS-275 
induce mitochondrial permeability where pro-apoptotic molecules such as cytochrome c, 
are released into the cytosol, resulting in eventual activation of caspase-dependent 
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apoptotic cascades (both receptor and mitochondria-mediated). 149-152  Upregulation and 
induction of a conformational change of the pro-apoptotic proteins are some of the 
HDAC inhibitor-induced upstream events that may trigger the mitochondrial pathway of 
apoptosis as is described for MS-275 and SB or as is proposed in case of SAHA, may not 
require key caspases such as caspase-8 and caspase-3. 153, 154 Recently, reactive oxygen 
species (ROS) have been identified as a major cell death mechanism of several HDAC 
inhibitors.153, 155 There is some evidence that HDAC inhibitors may induce acetylation of 
non-histone proteins such as heat shock protein hsp90. Depsipeptide, SAHA and 
LAQ824 lower the threshold for apoptosis by inducing the acetylation hsp90 and thus 
affect oncoproteins such as Bcr-Abl and FLT-3. 156, 157 This eventually results in the 
inhibition of its chaperone association with important pro-survival client proteins such as 
Erk, Akt and c-Raf. 94 SAHA and oxamflatin were also shown to kill both ABCB1 
positive and negative cells, whereas FK228 was shown to be substrate for ABCB1.158 
These data may provide insight into defining rational approaches to chemotherapy, where 
the genetic profile of tumor is matched with the functional profile to promote favorable 
clinical response. 
 Induction of the cell cycle inhibitor plays an important role in the induction of 
differentiation by HDAC inhibitors. SAHA and sodium butyrate were shown to induce 
differentiation of leukemia and breast cancer cells. 66, 67 Induction of the expression of 
other molecules involved in differentiation, such as gelsolin, an actin binding protein 
involved in cell morphology and structural changes was observed during treatment with 
HDAC inhibitors. 74, 106, 159, 160 In addition to pro-apoptotic and cytostatic activities, 
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another mode of tumor regression following treatment with HDAC inhibitors may be by 
indirect inhibition of angiogenesis. In in-vitro models, depsipeptide blocked potently the 
hypoxia-stimulated proliferation, invasion, migration, adhesion, and tube formation of 
bovine aortic endothelial cells. 117 Effective concentrations were comparable to cytotoxic 
concentrations, and there was an indication of possible modulation of gene transcription 
as evidenced by the expression of angiogenic-inhibiting factors such as von Hippel 
Lindau and neurofibromin 2 and the suppression of angiogenic-stimulating factors such 
as vascular endothelial growth factor (VEGF). 115, 161  Other HDAC inhibitors like 
apicidin, TSA, butyrate and newer analogue LAQ824 were all shown to inhibit 
angiogenesis through VEGF inhibition. 48, 110, 162-164 
 Such insights into the mechanisms by which HDAC inhibitors interfere with 
cancer cell growth and survival has prompted the search for combination strategies to 
optimize therapy. 
 
1.6 Combination therapy of HDAC inhibitors with other drugs in-vitro 
Silencing of genes that affect growth and differentiation has been shown to occur 
by aberrant DNA methylation in the promoter region and by changes in chromatin 
structure that involve histone deacetylation. 165, 166 DNA methylation and histone 
deacetylation appear to act as synergistic layers for the transcriptional silencing of genes 
in cancer.167-169 Such findings have great implication in development of combination 
therapies. 
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 Epigenetic mechanisms, such as DNA methylation and histone deacetylation, may 
also play a role in loss of estrogen receptor alpha (ER) expression in ER negative human 
breast cancer cells. Previous studies showed that pharmacologic inhibition of these 
mechanisms using the DNA methyltransferase inhibitor, 5-aza-2’deoxycitidine (AZA), 
and TSA, resulted in expression of functional ER mRNA and protein.170  Scriptaid, a 
novel TPX-HA analogue, inhibits tumor growth in-vitro and in-vivo and, in conjunction 
with AZA, acts to re-express functional ER.171 In another study, TSA was shown to 
sensitize ER alpha negative antihormone-unresponsive breast cancer cells to tamoxifen 
treatment, by upregulating its activity.172  The in-vitro antineoplastic activity of 5-aza-
2’deoxycitidine (AZA), in combination with TSA or depsipeptide, on the human myeloid 
leukemic cell lines produced a greater inhibition of growth and DNA synthesis and a 
greater loss of clonogenicity than either agent alone.173 Similar results were noted with 
PB and AZA combination in lymphoid leukemic cells.174 Another study found that when 
AZA was combined with PB, murine lung tumor development was significantly reduced 
>50%, while no effect was observed with PB alone. 175  
 Chromatin DNA is tightly packed, and hence accessibility to the drug target may 
reduce the efficiency of these anticancer drugs. When six cancer cell lines were pre-
treated with TSA or SAHA followed by exposure to anticancer drugs like etoposide (VP-
16), campothecin, cisplatin, doxorubicin, 5-fluorouracil, cyclophosphamide or ellipcitine, 
there was more than 10-fold sensitization of cells for VP-16. The data suggest that 
loosening-up the chromatin structure by histone acetylation can increase efficiency of 
several anticancer agents. 176 SAHA significantly potentiated the DNA damage by 
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topoisomerase II inhibitors; however, synergy was dependent on the sequence of drug 
administration and expression of target. Pre-exposure of cells to SAHA for 48h was 
synergistic, whereas shorter period of exposure abrogated synergy, and pre-treatment 
with topoisomerase II inhibitor showed antagonistic effects. 177 
 Inhibition of cell survival signals and proliferation by inhibitors of tyrosine kinase 
activity, in combination with HDAC inhibitors is another mechanism to induce 
differentiation and/or apoptosis.178 The cytotoxic effects following the introduction of 
SAHA with imatinib mesylate showed accumulation of acetylated histones H3 and H4, 
induction of p21 and p27, and, following SAHA treatment, there was a decline in the 
mRNA and protein levels of Bcr-Abl, resulting in G1 arrest and apoptosis of leukemic 
cells. Co-treatment with imatinib mesylate and SAHA caused significantly more down-
regulation of tyrosine kinase activity of Bcr-Abl and apoptosis of these cells when 
compared to treatment with SAHA alone. These findings suggested that co-treatment 
with SAHA and imatinib mesylate or arsenic trioxide are cytotoxic to Bcr-Abl positive 
acute leukemia cells, and these agents may be a promising therapeutic strategy against 
imatinib mesylate-refractory Bcr-Abl positive acute leukemia. 179, 180 Similar results were 
achieved on combined exposure of Bcr/Abl positive human myeloid leukemia cells to 
imatinib (gleevec, STI571) and SAHA, leading to diverse perturbations in signaling and 
cell cycle-regulatory proteins, associated with a marked increase in mitochondrial 
damage and cell death. 179 SAHA and PB were also shown to synergistically induce 
apoptosis in human leukemic cells when co-treated with hsp90 antagonist 17-allylamino-
17-demethoxygeldenamycin (17-AAG). 181 Similar cumulative inhibitory effects were 
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noted on combined treatment of SB and flavopiridol, where interruption of HDAC-
mediated p21(WAF1/Cip1) induction by flavopiridol-potentiated apoptosis. 182, 183 
Recently, the same group of researchers showed that MS-275 acts synergistically with 
fludarabine to increase the apoptotic activity in leukemia cells. 184 Moreover, proteasome 
inhibitor bortezomib interacts synergistically with SB or SAHA to cause oxidative injury 
and apoptosis in Bcr/Abl positive multiple myeloma and leukemia cells sensitive and 
resistant to imatinib. 185, 186 
 LAQ824 lowers expression and promotes proteasomal degradation of Bcr-Abl 
and induces apoptosis of imatinib-sensitive or refractory chronic myelogenous leukemia-
blast crisis cells.187 Recent studies show that LAQ824 can also promote degradation of 
mutant FLT-3 and induce apoptosis of AML cells carrying the mutated FLT-3. The 
addition of the Flt-3 kinase inhibitor PKC412 had a synergistic effect on apoptosis in 
AML cells with mutant FLT-3.188 The combination of SAHA or LAQ824 with various 
cytotoxic agents such as taxotere, trastuzumab, gemcitabine and epothilone B, enhanced 
the cytotoxic effects in breast cancer cells, while the combination of 5-fluorouracil and 
other chemotherapy agents with PB also enhanced the cytotoxic effects in colorectal 
cancer cells. 189-191 In two separate studies, SAHA also potentiated sensitizing melanoma 
cells to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis by 
simultaneous activation of intrinsic and extrinsic pathways. 192, 193 In another study, VA 
was shown to increase cellular sensitivity to estrogens, progestins and other hormone 
nuclear ligands, by functioning as activator of p42/p44 mitogen-activated protein kinase 
(MAPk). 194 TSA upregulated RECK glycoprotein that negatively regulates matrix 
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metalloproteinases (MMPs) and inhibits tumor metastasis and angiogenesis by 
specifically inhibiting MMP-2.195 Radiotherapy is an effective treatment for several 
cancers but causes cutaneous radiation syndrome. PB, TSA and VA were shown to 
decrease skin fibrosis and tumorigenesis by suppressing aberrant expression of TGF-beta 
and TNF-alpha. 196 In human gastric and colorectal cancer cells, depsipeptide, MS-275 
and CBHA all augmented radiation-induced cell death. 197 Moreover, HDAC inhibitors 
have shown synergism when combined with all-trans retinoic acid (ATRA) to overcome 
the block in differentiation due to specific translocations associated with acute 
promyelocytic leukemia. 83, 198, 199 
1.7 HDAC inhibitors in clinical trials 
 Based on promising non-clinical data, several HDAC inhibitors are currently 
being investigated in early phase trials in humans, both as single agent and in 
combination with known cytotoxic compounds. HDAC inhibitors such as PA, PB, VA, 
AN-9, SAHA, LAQ824, pyroxamide, FK228, MS-275 and CI-994 are in clinical trials in 
patients with various metastatic or refractory solid tumors in advanced stages and those 
with hematologic malignancies like acute myeloid leukemia (AML), acute lymphocytic 
leukemia (CLL), chronic myeloid leukemia (CML), chronic lymphoid leukemia (CLL), 
or lymphomas.  
Details about phase of development, major toxicities, pharmacokinetics and preliminary 
data on pharmacodynamics and clinical response of various HDAC inhibitors used as 
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single agents or given in combination with agents that are undergoing clinical 
development are summarized in Table 1.2 and Table 1.3 respectively. 
1.8 Future direction 
 The concept of mechanism-based therapeutic development of novel anticancer 
agents is now being fully recognized, since targeting of abnormalities specific to cancer 
has shown to offer new directions. The first generation of HDAC inhibitors in clinical 
trials has shown encouraging antitumor effects, with acceptable safety profiles. There 
may be significant repercussions in success or failure of an anticancer agent, when 
targeting a specific subtype of HDAC without having a broader understanding of 
mechanism of action and the differential role each enzyme play in chromatin remodeling 
in cancer cells. Although, none of these agents in clinical trials were developed to be 
selective inhibitors of individual HDAC subtype, they do show some target selectivity. 129 
For example, MS-275 showed in-vitro selective inhibition of HDAC1 and HDAC3, but 
was inactive against HDAC8. 200 Similarly, FK228 has activity against class I (HDAC1 
and HDAC2) enzymes, but not against class II (HDAC4 and HDAC6). 201 The challenge 
remains to develop specific inhibitors of class I HDACs that are primarily located within 
the nucleus and class II HDACs that are known to shuttle between nucleus and cytoplasm 
21, 56. Recent findings using siRNA techniques to understand HDAC isotypes as potential 
targets, suggested that class I HDAC enzymes may be more relevant targets for 
intervention in oncology. 37 In any case, chromatin modifying enzymes have provided an 
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increasingly validated therapeutic target and there is now compelling evidence that these 
compounds exhibit efficacy in human diseases.  
 Phase I and phase II clinical trials with HDAC inhibitors have been completed, 
and others are being initiated. Most of these have been able to identify suitable doses for 
treatment with relatively low toxicity and reasonable efficacy in various cancers. 
Remission appeared to be transient in some of the patient trials, suggesting a need for 
determination of optimal dosing regimens.32 Based on preliminary clinical data and the 
apparent cytostatic mechanism of action, most HDAC inhibitors, with the possibly 
exception of FK228 in the treatment of renal cell carcinoma, seem to fit more as 
combination treatment with existing chemotherapy regimens along with being used in 
other mechanism-based agents. Nonetheless, various questions still remain to be 
answered: 1) what role do altered HAT or HDAC activities have in conjunction with 
tumorigenesis? Is it a direct effect or is an epigenetic adaptive phenomenon?; 2) why are 
tumor cells more resistant to HDAC inhibitors than normal cells, and is there a possibility 
that there may be increased HAT/HDAC activity in tumors?; 3) is modification of 
histone(s) the only mechanism leading to anti-neoplastic effects or are there targets 
responsible that are yet undefined?; and 4) what is the target specificity of HDAC 
inhibitors? 112 Unraveling specific roles of HDAC isozymes during human tumorigenesis 
will provide further incentive for the development of more specific HDAC inhibitors, 
potentially those enhancing clinical activity as well as decreasing aspecific toxicities. 
Also, optimizing potential interactions with other rationally designed and integrated 
therapeutic agents remains a promising premise for exploration. In addition, there is a 
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general current lack of knowledge on the pharmacokinetics and biodistribution of various 
HDAC inhibitors studied clinically. Current evidence suggests that novel formulations 
and drug delivery strategies that allow better targeting may significantly enhance the 
therapeutic potential of HDAC inhibitors.45  
1.9 Conclusion 
 A wealth of recent data has become available suggesting that histone modification 
is a promising therapeutic strategy affecting many of the hallmark traits of cancer. 202 
Drugs such as HDAC inhibitors that have pleiotropic actions in modulating multiple 
genes, pathways and biological features of malignancy, might prove to be suited for 
dealing with multiple oncogenic abnormalities seen with most cancer types.33 Although 
the clinical development of novel HDAC inhibitors seems certain, their actual value will 
greatly depend on identification of molecular and cellular predictors of toxicity and 
elucidation of their mechanism of action as anticancer agents. 
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Table 1.2 HDAC inhibitors in clinical trials as single agents 
 
Name 
(Ref) 
Phas
e N 
Tumor 
type 
Route of 
administration / 
dosing regimen 
DLT and 
adverse events MTD/PK results 
Clinical 
response/outcome 
PA203   I 17 Solid tumors 
IV bolus (60-150 
mg/kg), target level 
200-400g/ml x 2 
weeks 
CNS depression, 
emesis, 
confusion, 
lethargy 
Non-linear PK, evidence 
of metabolic induction, 
99% PA converted to PG 
and eliminated in urine, 
CNS penetration 
3/9 SD x 2 months in 
HRPC, 1/6 SD >9 
months in 
glioblastoma 
PA204   I 18 Solid tumors 
IV 1 h infusion b.i.d. 
125 and 150 mg/kg x 
2 weeks every 4 
weeks 
CNS 
depression 
PA induced own 
clearance (27%), MTD 
125 mg/kg, Cmax 2500 
g/ml 
1 PR glioblastoma, 
1 HRPC with 50% 
post-therapy PSA 
decline 
PA205, 206  II
43 
& 
9 
Recurrent 
malignant 
gliomas 
IV infusion 
400mg/kg/day, 
comapared 2 
schedules, 2weeks 
every 2 weeks or 12-
day every 2 days 
Max 450 mg/mg/day 
Fatigue, malaise, 
somnolence, 
disorientation, 
weakness, 
nausea, vomiting 
& 
granulocytopenia 
No differences in plasma 
concentration between 2 
treatments, no apparent 
induction of PA 
metabolism  
For schedule 1, PR 
3/40 (7.5%), SD in 
7/40 patients 
(17.5%), PD < 2 
months 30/40 patients 
, For schedule 2, 1/7 
SD, 6/7 PD 
PB207  I 24 
Refractor
y solid 
tumors 
IV infusion 120-h 
every 3 weeks, 
dose 150 – 515 
mg/kg/day 
Neurocortical 
somnolence, 
confusion, 
hypokalaemia, 
hyponatreamia, 
fatigue, nausea 
MTD =410 mg/kg/day, 
plasma CL increased 
continuously after 24h, 
PA accumulated when 
Vmax was less than 
dosing rate 
No CR, 2 SD, 
reduction in bone 
pain  
PB208  I 28 
Refractor
y solid 
tumors 
Oral dose TID 9-45 
g/day in 5 dose levels 
Grade 1 – 2 
dyspepsia, 
fatigue, 
neurocortical 
nausea, 
vomitting, 
MTD 27 g/day, 
bioavailability 78%, 
biologically active 
concentrations (0.5mM) 
No CR, PR, 7 
patients (25%) with 
SD > 6 months 
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hypocalcaemia 
PB67  I 27 
Myeloid 
dysplesia, 
AML 
IV infusion for 7 day 
every 28 days 
Neurocortical 
somnolence, 
confusion,,slurre
d speech, 
hyperammonaem
ia 
MTD 375 mg/kg/day 
No CR, PR, 
hematological 
improvements, 
increased neutrophils 
in 3, decreased blasts 
in 3 
AN-962  I 28 
Advanced 
solid 
tumors 
IV infusion, 6 h x 5 
days every 21 days at 
doses 0.047 - 3.3 
g/m2/day 
No DLT, nausea, 
vomiting, fatigue, 
vision 
disturbance, 
anorexia, fever 
MTD 3.3 g/m2/day based 
on volume of maximum 
lipid formulation 
administerable 
1 PR, no increase in 
fetal hemoglobin 
AN-963  II 47 Refractory NSCLC 
IV infusion, 2.34 
g/m2/day over 6 h x 3 
days every 21 days 
Grade 1-2 fatigue 
(34%), nausea 
(17%), dysgeusia 
(11%) 
- 
3/47 PR, 14 patients 
with SD > 12 weeks 
(30%), median 
survival 6.2 months, 
1-year survival of 
26% 
VA209  I 26 
Progressi
ve 
cancers 
IV infusion 1 h split 
twice daily x 5 days 
every 2 weeks at 30-
120 mg/kg/day 
Grade 3/4 
neurotoxicity, no 
severe 
hematological 
MTD 60 mg/kg, PBMC 
showed hyperacetylation 
Neurotoxicity is 
dose-limiting 
SAHA21
0 I 37 
Solid 
tumor 
and 
hematolo
gic 
malignan
cy (B)) 
IV infusion, (A) 2 h x 
3 days every 3 weeks, 
at 75-900 mg/ m2/day 
(B) 2 h x 5 days 
every 1-3 weeks 300-
900 mg/ m2/day for 
3-15 days 
(A) No DLT in 
8/8, (B) Grade 
3/4 
thrombocytopeni
a and neutropenia 
in hematological 
patients 
MTD on (B), 300 mg/ 
m2/day 
t1/2 = 21-58 min, AUC 
increased with dose, 
accumulation of 
acetylated histones in 
PBMC after 4 h at all 
dose levels 
1 PR in refractory 
Hodgkin’s disease & 
SD > 6 months in 2 
patients with bladder 
cancer 
SAHA21
1 I 15 
Advanced 
refractory 
leukemias 
Orally TID x 14 days 
every 21 days at 100-
250 mg 
No DLT, nausea, 
vomiting, 
diarrhea, 
Histone hyperacetylation 
at all dose levels 
1 CR at dose level 3 
after 2 courses, 2 
AML, 1 MDS patient 
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or MDS anorexia, 
headache, 
fatigue, 
dyspepsia 
had decrease in 
marrow blasts to < 
10%  
SAHA21
2 I 39 
Advanced 
cancers 
Oral, daily or BID at 
200-600 mg 
Thrombocytopeni
a, fatigue 
Prolonged plasma 
concentrations <10 h with 
single dose 
Prolonged duration of 
acetylated histones in 
PBMC (>10 h), 
objective response in 
patients with larynx, 
renal cancer and 
lymphoma 
SAHA21
3 II 13 
SCCHN 
(metastati
c head 
and neck 
cancers) 
Oral, daily at 400 mg 
No DLT, grade 
3-4 
thrombocytopeni
a, anemia, 
anorexia 
- 
No PR or CR, 1 MR 
based on tumor 
shrinkage,  
Depsipe
ptide118 I 33 
Advanced 
cancers 
IV infusion 4 h, 
weekly x 3 every 
with 1 week off at 1-
17.7 mg/m2
Grade 3 
thrombocytopeni
a, fatigue, nausea, 
vomiting, 
anorexia at dose 
above 5 mg/ m2, 
subtle ECG 
changes 
MTD 13.3 mg/ m2/day 
No decrease in 
cardiac enzymes of 
ejection fraction 
Depsipe
ptide119, 
214 
I  37
Advanced 
or 
refractory 
cancers 
IV infusion 4 h on 
days 1 and 5 every 21 
days at dose 1-24.9 
mg/m2
Grade 3 fatigue, 
nausea, vomiting, 
grade 4 
thrombocytopeni
a, cardiac 
arrhythmia 
MTD 17.8 mg/m2 over 4 
h over 4 h t1/2(a) =0.42 h; 
elimination  t1/2(b) =8.1h, 
mean CL=11.6 L/h/m2 , 
inhibition of cell cycle in 
PC-3 cells 
Increased acetylation 
of histones in Sezary 
cells, no effect on 
histones after 7 h, 
1PR in colon cancer x 
6 months, 1 CR in 
peripheral T-cell 
lymphoma, 3 PR in 
CTCL 
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Depsipe
ptide120 I  20
CLL and 
AML 
IV infusion on days 
1, 8, 15 at 13 mg/m2
Fatigue, nausea, 
progressive 
constitutional 
symptoms 
Increases in histone 
acetylation by 100%, p21 
promoter H4 acetylation, 
p21 protein  
No cardiotoxicity, 
need to explore other 
schedules due to 
progressive toxicity 
CI-
994123 I  53
Solid 
tumors 
Orally on schedule 
(A)  x 2 weeks,  
(B) x 8 weeks 
followed by 2 weeks 
rest  
Schedule (A) 
thrombocytopeni
a, neutropenia, 
increased LFT, 
creatinine, (B) 
thrombocytopeni
a, nausea, 
vomiting 
Schedule (A) MTD 15 
mg/m2/day, no 
cumulative toxicities, (B) 
MTD 8 mg/m2/day, t1/2 = 
7.4-14.1 h, inverse 
relationship between 
platelet nadir and AUC, 
low effect of food on 
absorption 
Both schedules, 1 PR 
in NSCLC x 2years, 
3 SD in NSCLC, 
colorectal and renal 
cancer 
MS-
275215 I  30
Solid 
tumors 
and 
lymphom
as 
Orally on schedule 
(A) daily x 28 days 
every 6 weeks, (B) 
weekly x 4, every 6 
weeks at 2-12 mg/m2
Schedule (A) 
severe GI 
toxicity, (B) and 
(C) fatigue, 
nausea, vomiting, 
anxiety 
thrombocytopeni
a, headache 
MTD on  (A) 2 mg/m2, 
(B) 10 mg/m2, histone 
acetylation at all dose 
levels 
Schedule (A) 
intolerable, 15 SD on 
(B),  
MS-275   I 33
Hematolo
gic 
malignan
cy 
Orally q7 day for 4 
weeks every at 4-10 
mg/m2
Sepsis, severe 
line infections at 
10 mg/m2 ,  
neutropenia, GI 
toxicity 
MTD at 8 mg/m2    1 PR in patient with AML 
MS-
275216 I  17
Solid 
tumors 
and 
lymphom
as 
Orally on schedule 
(A) 2-6 mg/m2 
biweekly, (B) 2 
mg/m2 twice weekly 
x 3 weeks with 1 
week off, (C) 4 
mg/m2 weekly for 3 
No drug related 
DLT, grade 1-3 
hypohosphatemia
, asthenia, 
nausea, anorexia 
MTD not reached on (A), 
(B) not pursued, rapid 
absorption with Tmax 
0.5- 2h, dose-dependent 
increase in exposure, 
biphasic elimination with 
t12=100h 
1 PR on (A) in 
melanoma, 3 SD in 
Ewing’s sarcoma, 
rectal carcinoma and 
melanoma 
 
 35
weeks with 1 week 
off 
LAQ82
4217 I  21
ALL, 
AML, 
CLL, 
CML, 
MDS 
IV infusion, 3h on 
days 1-3 of 21 day 
cycle at 6-80 mg/m2 
in 6 dose levels 
Thrombocytopeni
a (cerebral 
bleeding), grade 
2 
hyperbilirubinem
ia 
MTD 36 mg/m2 ,dose-
proportional increase in 
exposure, t1/2=9-18 h, 1.5 
fold accumulation at day 
3, Cmax after 1.5h , not at 
end of infusion in >50% 
patients, indicates non-
linear PK 
No QTc 
prolongation, ECG 
<400 msec, 1CR in 
M1 AML, 6 SD, 
histone acetylation at 
>12 mg/m2 doses 
LAQ82
4218 I 28 
Advanced 
solid 
tumors 
IV infusion, 3h on 
days 1-3 of 21 day 
cycle at 6-100 mg/m2 
in 7 dose levels 
Grade 3/4 
transient 
transaminitis, 
fatigue, 
hyperbilirubinem
ia, nausea,  
thrombocytopeni
a,  
Dose-proportional 
increase in 
exposure,t1/2=8-14 h, 
Cmax after 1.5h , not at 
end of infusion in >50% 
patients, indicates non-
linear PK 
1 ECG > 500msec, 3 
SD, histone 
acetylation at > 12 
mg/m2 doses 
LBH589
219 I 13 
Advanced 
solid 
tumors 
IV infusion, 30 min 
either on (A) days 1-3 
and 8-10 of 21 day 
cycle at 1.2 -7.2 
mg/m2, (B) days 1-3 
or 15-17 of 28 day 
cycle at 2.4-4.8 
mg/m2
Prolonged grade 
2 
thrombocytopeni
a in (A), grade 3 
neutropenia, 
anemia, 
hypoglycemia 
Exposure increased 
proportionally with dose, 
t1/2 =15-20 h 
6 SD, increased 
histone acetylation 
after first dose 
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Table 1.3 HDAC inhibitors in combination therapy with other agents 
 
Name 
(Ref) 
Phas
e N 
Tumor 
type 
Route of 
administration / 
dosing regimen 
DLT and 
adverse events MTD/PK results 
Clinical 
response/outcome 
CI-994 
+ 
gemcita
bine220 
I  20 Advanced cancers 
Gemcitabine IV 
infusion weekly x 3 
with 1 week off at 
1000 mg/m2, CI-994 
orally daily x 21 days 
escalating at 2-8 
mg/m2  
Grade 4 
thrombocytopen
ia (30%) at 8 
mg/m2
MTD 6 mg/m2 oral x 
21days with 1000 
mg/m2 gemcitabine, 
rapid absorption, Cmax 
within 2 hours of 
dosing 
2 MR, 12 SD with 
median 105 days, 
4 PD 
CI-994 
+ 
capecita
bine221 
I  54 Advanced cancers 
Schedule (A) IV 
capecitabine twice 
daily at 1650 
mg/m2/day, CI-994, 2-
10 mg/m2 orally x 2 of 
3 weeks, (B) CI-994 x 
5 of 6 week , (C) 
capecitabine 2000 
mg/m2/day, CI-994  
orally x 2 of 3 weeks 
Thrombocytope
nia,  
MTD 6 mg/m2 (10 mg) 
with capecitabine 2000 
mg/m2/day, 
PK of CI-994 unaltered 
by capecitabine  
No correlation 
between BSA and 
PK parameters, 
platelet nadir best 
predicted by  
Cmax 
CI-
994222 II   32 NSCLC
Orally, daily at 8 
mg/m2  
Thrombocytope
nia, 
fatigue,anorexia
, nausea, 
vomiting, 
paresthesia 
- 
 2 PR, 8 SD > 8 
weeks, 
median survival 30 
weeks 
CI-
994223 II  48
Renal cell 
carcinoma 
Orally, daily at 8 
mg/m2
Thrombocytope
nia, 
fatigue,anorexia
, nausea, 
vomiting, 
- 
 26 SD for >8 
weeks, median 
survival = 48 
weeks 
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paresthesia 
CI-
994224 II  17
Advanced 
pancreatic 
cancer 
Orally, daily at 8 
mg/m2
Thrombocytope
nia, asthenia, 
anorexia 
- 
2 SD for 6 weeks, 
No objective 
response, 
cytostatic 
mechanism 
CI-994 
+ 
carbopla
tin or 
paclitax
el 225 
I 21 
Refractory 
solid 
tumors 
Oral CI-994 daily x 7 
or 14 days every 21 
days (4-6 mg/m2/day), 
Carboplatin every 21 
days Paclitaxel 
175-225 mg/ m2 every 
21 days 
DLT=neutropen
ia,thrombocytop
enia diarrhea & 
weakness 
MTD; CI-994 4 mg/ 
m2/day with paclitaxel 
200 mg/m2. carboplatin 
1 CR bladder 
2 PR NSCLC, 
6 SD 
PB+AC     I 6 Solid tumors 
AC 25 mg/m2 o.d.days 
1 –14 PB 400 
mg/kg/day Cl days 6 
and 13 every 5 weeks 
ND ND
No change in pre 
or post – tumor 
specimens for 
methyltransferase 
or GST 
PB+ RA - 5 APL 
RA(30-90 mg/ 
m2/day)+PB 
(150-400 mg/kg/day) 
ND ND 1/5 cytological CR 
AN-9 + 
docetax
el 226 
II  12 Advanced NSCLC 
AN-9 IV infusion 6h/ 
day for days 1-3 at 1.5-
2.5 g/m2, docetaxel on 
day 4 at 75 mg/m2, 
regimen repeated every 
3 weeks 
No DLT, 
adverse events 
unrelated to 
AN-9, grade 3 
neutropenia due 
to docetaxel in 
9 (75%) 
patients 
MTD 2.5 g/m2 with 75 
mg/m2 docetaxel  
3 PR, decrease in 
tumor size,  
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1.10 MS-275  
 A series of synthetic benzamide derivatives with HDAC-inhibitory activity both 
in-vitro and in-vivo were discovered by Mitsui pharmaceuticals (now, Schering AG). One 
of these, MS-275, a pyridyl carbamate, induces chromatin and protein hyperacetylation 
and antitumor activity through its two HDAC interaction sites. MS-275 is structurally and 
functionally unique, particularly with respect to its ability to induce cytotoxicity (Figure 
1.7). The hypothesis is that MS-275’s unique inhibition of HDAC activity modulates 
expression of a specific set of genes in malignant cells resulting in differentiation, growth 
arrest, and/or apoptotic cell death. The information obtained from translational research 
in clinical trials may help to identify critical targets of HDAC inhibitors in solid tumors. 
Limited toxicity observed in animal studies, especially during the 28-day dosing 
schedule, gave initial hope for MS-275 to be a potentially well-tolerated 
chemotherapeutic agent. 
 Preclinical pharmacology studies with MS-275 indicated a peak plasma 
concentration within 10 minutes when administered IV bolus, and 30 to 40 mins when 
administered orally.  The MS-275 half-life (T1/2) in plasma of approximately 1 hr was 
similar in rats, mice and dogs, irrespective of administration route.  Approximately 81% 
of drug was bioavailable with oral administration, and preclinical toxicity was minimal to 
the parenchymal organs.  The dose limiting toxicity (DLT) was myelosuppression in all 
species.  In an oral daily schedule over 28 days, the maximal tolerated dose (MTD) was 6 
mg/m2 for dogs and 18 mg/m2 for rats.  Adverse events, mostly gastrointestinal 
 
 39
disturbances, fatigue, nausea and vomiting were usually observed during the 3rd and 4th 
week of dosing. In-vitro, human bone marrow sensitivity to MS-275 was similar to rats. 
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Figure 1.7 Structure of MS-275 
 
 
1.10.1 Physico-chemical properties  
Structure: Figure 1.7 depicts the structure of MS-275 
Names: MS-275, MS-27-275 (NSC 706995),  
Molecular Formula:  C21H20N4O3
Molecular Weight:  376.41 
Route of administration: Oral (by mouth). MS-275 exhibits good oral bioavailability, with 
comparable absorption as a tablet and a capsule (bulk powder). Dogs pretreated with 
pentagastrin to reduce gastric pH exhibited enhanced absorption and a decrease in individual 
variations of Cmax and area under the curve (AUC).   
Dose formulation: MS-275 is supplied as round orange (0.1 mg), light brown (1.0 mg), or 
intense yellow (5 mg) coated tablets. The film coating is an aqueous solution consisting of 
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hydroxypropylmethyl cellulose, talc, titanium dioxide, and one or two ferric oxide pigments 
as coloring. Each tablet contains mannitol, carboxymethylstarch sodium, hydroxypropyl 
cellulose, potassium bicarbonate and magnesium stearate. 
1.10.2 Mechanism of action 
 MS-275, by inhibiting histone deacetylation, plays a major role in 
acetylation/deacetylation of histone proteins within the nucleosome. Inhibition of histone 
deacetylases induces histone hyperacetylation that, in turn, leads to gene expression in 
diverse hematopoietic and malignant cell lines in-vitro and in-vivo (Figure 1.8). Among 
the genes whose expression is induced by MS-275 is p21WAF-1/CIP-1, independent of 
p53 activity. The induction of p21, in turn, is thought to be responsible for the cell cycle 
arrest (at least in part through reduction of retinoblastoma protein phosphorylation) and 
antiproliferative activities of MS-275 seen in multiple malignant cell types. In addition to 
its ability to bypass p53-dependent pathways, MS-275 also appears to be independent of 
the presence and magnitude of multidrug resistance–1 (MDR1) gene/protein expression. 
There have been numerous in-vitro and in-vivo studies that have shown that MS-275 
possesses antitumor activity.35, 124-127, 227, 228 It has been recently shown that MS-275 
preferentially inhibits HDAC1 but not HDAC6 which is reported to be responsible for 
tubulin deacetylation and for which a specific inhibitor has been recently reported in 
literature.229 A structural analogue with 3-aminophenyl substitution showed none of the 
activities found for MS-275, indicating that the binding of 2-aminophenyl group of MS-
275 to an unidentified site on HDAC molecules is important for its HDAC inhibitory 
function.124 As shown in Figure 1.8, there was a dose-dependent decrease in radiolabelled 
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acetic acid released relative to control or 3’-aminophenyl substituted compound, 
indicating higher acetylation activity due to inhibition of HDACs. 
 
 
 
 
 
Data and figure adapted from 125 
A) Compound 1 is 2’-aminophenyl substituted MS-275 and compound 2 is 3'-amino 
derivative. B) Inhibition of human histone deacetylase by MS-275 when activity was 
measured using radiolabelled acetic acid either in the presence of MS-275 ( ) or 
compound 2 ( ) or in the absence of the agent ( ). 
 
Figure 1.8 Hyperacetylation of histones on treatment with MS-275 
 
 
1.10.3 In-vitro activity (molecular and cellular) 
 In National Cancer Institute’s (NCI) 60 cell-line screen, MS-275 displayed a 
unique pattern of cytotoxicity in comparison to available anticancer agents, and displayed 
potent anti-proliferative activity.230 Furthermore, cDNA microarray analysis suggested 
MS-275 promotes gene expression which subsequently favors growth arrest and 
differentiation. In addition, antitumor activity has been observed in myeloma, 
promyelocytic leukemia and SCLC models in studies at NCI. MS-275 may achieve its 
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antiproliferative effect through increased expression of p21 and TGF-beta type II receptor 
and may also promote differentiation in some cells as indicated by induction of the 
maturation marker gelsolin.125, 228, 231  
Analysis of p53 and p21 (WAF1/CIP1) by Western blot indicated that when 
sensitive cell lines were exposed to MS-275, the accumulation of p21 was directly 
proportional to the cell line sensitivity and was independent of p53 levels. MS-275 also 
showed properties similar to the HDAC inhibitors sodium butyrate and trichostatin-A 
since it causes growth arrest with altered cell cycle distribution. Such modulation results 
in decreased S-Phase fraction, with concomitant induction of the actin-modulating 
protein, gelsolin, in PC3M cells.  To identify differential mechanism of HDAC inhibitors 
to target the same genes, a cDNA microarray analysis was used to generate global gene 
expression profiles in prostate carcinoma (PC3M) cells in response to TSA and MS-275. 
These studies demonstrated that MS-275 has its own unique targets and HDAC binding 
site affinity. MS-275 was observed to have exposure time-dependent antitumor activities 
in 11 cell lines. The IC50 (concentration at which 50% growth inhibition occurs) for MS-
275 was 2.0-4.8 µM (1.5-3.6 ng/ml) in human leukemia cell lines. Exposure to MS-275 at 
concentrations of 0.3 and 1 µM resulted in accumulation of hyperacetylated  histones in 
tumor cell cultures. The levels of acetylation were identical in different cell lines (K562, 
HL-60, A2780, KB-3-1 and HCT-15).124, 125  
MS-275 induced increased transcription of p21WAF1/Cip1 and gelsolin, both of 
which are considered tumor suppressors. Accumulation of p21WAF1/Cip1 in tumor cells 
with lower antiproliferative IC50 values (Table 1.4) tended to be faster and greater than in 
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tumor cells with higher IC50 values, while induction of gelsolin did not appear to 
correlate with the antiproliferative sensitivity of cells to MS-275. 125 However, when cells 
were inoculated in mice, there was decreased tumorigenicity due to overexpression of 
gelsolin, and hence investigators believe that gelsolin may function as a tumor suppressor 
in-vivo but not in-vitro. 232 
 
Table 1.4 In-vitro antiproliferative sensitivity of human tumor cell lines to MS-
275 
 
Cell line Tumor type IC50 (µM) 
A2780 human ovarian cancer 0.0415 
Calu-3 Human lung cancer 0.195 
HL-60 Human leukemia 0.212 
K562 Human leukemia 0.589 
St-4 Human gastric cancer 0.820 
HT-29 Human colorectal cancer 1.29 
KB-3-1 Human oral cancer 1.46 
Capan-1 Human pancreatic cancer 1.70 
HCT-15 Human colorectal cancer 4.71 
 
Data from MS-275 Investigator’s Brochure 
 
1.10.4 In-vivo activity 
 MS-275 has been tested on human tumor xenograft models prepared by 
subcutaneously injecting suspension of cancer cell lines into nude mice. Mice were then 
treated orally with daily doses (12.3, 24.5, or 49 mg/kg/day) of MS-275 on a 5 day/week 
dosing schedule repeated for 4 weeks. Compared with untreated and 5-FU-treated control 
groups, an anti-tumor activity of MS-275 was observed against the following carcinoma 
mouse models: 4-IST and St-4 Gastric, KB-3-1 epidermoid, Ca-pan-1 pancreatic, HT-29 
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colon, A2780 ovarian, and Calu-3 lung. The activity of MS-275 was superior to that 
observed with 5-FU in most cases. In-vivo efficacy was also examined in xenografts with 
human myeloma, RPMI-8226. SCID mice bearing subcutaneous RPMI-8226 xenografts 
were treated with MS-275 orally on a 5 day/week schedule repeated for 3 weeks at doses 
of 20, 30, and 45 mg/kg/day. The hollow-fiber assay indicated that MS-275 therapy was 
relatively ineffective after a short (~ 4 day) exposure, and these findings have lead 
investigators to further test a longer treatment regimen. Extended in-vivo studies of MS-
275 showed good efficacy compared to irinotecan in the colon carcinoma model or 
paclitaxel in the lung carcinoma model. The best antitumor activity of MS-275 in human 
tumor xenografts was observed on a 4-week long oral, once daily schedule.105 
 
1.11 Pharmacological and toxicological studies 
 Preclinical pharmacokinetic studies of MS-275 were performed in mice, rats, and 
dogs (data on file, Schering AG).  In rodents, MS-275 was administered intravenously 
and orally in order to characterize the plasma concentration-time profiles and to 
determine bioavailability.  Studies in dogs were more extensive and included assessment 
of oral bioavailability in fasted and fed animals; investigation of the effects of gastric pH 
on the absorption of MS-275; comparison of the pharmacokinetics of two different 
crystal forms of the compound; and evaluation of oral absorption following 
administration of MS-275 in tablets prepared for clinical use. 
 
1.11.1 Pharmacokinetics in mice and rats 
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 In mice, after a single intravenous bolus dose of 49 mg/kg, MS-275 achieved peak 
level (10 min) of 110 µM in plasma, followed by a biphasic decline with distribution and 
elimination half-lives of 0.16 hr and 1.3 hr, respectively. After oral gavage of 49 mg/kg, 
peak plasma levels of 67 µM were observed at 10 minutes. Elimination was monophasic, 
with a half-life of 1.1 hr.  Calculation of AUC values of oral and intravenous 
administration yielded an estimated oral bioavailability of 81%. In rats, after a single 
intravenous bolus dose of 24.5 mg/kg, MS-275 achieved peak level (10 min) of 24.5 µM 
in plasma, followed by a biphasic decline with distribution and elimination half-lives of 
0.31 hr and 2.1 hr, respectively.  After oral gavage at 24.5 mg/kg, peak plasma levels of 
14.9 µM were observed at 10 minutes.  Elimination was monophasic, with a half-life of 
1.7 hr.  Calculation of AUC values of oral and intravenous administration yielded an 
estimated oral bioavailability of 75%. Initially, for quantification of MS-275 in mouse, 
rat and dog plasma, a reversed phase HPLC assay with UV detection at 230 nm was 
developed using an internal standard (4,4’-diaminobenzanilide) using solid phase 
extraction. Calibration curves were linear for MS-275 concentrations from 0.01 to 50 
µM.  
1.11.2 Pharmacokinetics in Dogs 
 Following administration of MS-275 to fasting dogs, the plasma concentration in 
each individual varied considerably (data on file, Schering AG).  The standard deviations 
for Cmax, AUC, and bioavailability were relatively large (>50%) in the fasting group.  
However, the elimination was monophasic with a half-life of ~1 hr, similar to that 
observed after intravenous administration, so the variability was believed related to 
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individual differences in absorption. It was further postulated that these differences might 
be related to the effect of gastric pH on the solubility of MS-275. When gastric pH was 
lowered by prior administration of pentagastrin, the mean bioavailability was increased 
(from mean value of 30% to 55%), and the overall variability of the plasma 
concentration-time curves and derived pharmacokinetic parameters was reduced (Table 
1.5). When animals were fed prior to MS-275 administration, mean Cmax, and AUC0-max 
values were similar to those obtained in the fasting state, but the variability was 
considerably lower. The fed condition resulted in approximately 50% lower Cmax and 
AUC0-max values compared with fasted + pentagastrin, but both interventions reduced the 
observed variability of MS-275 absorption. Food intake also appeared to delay Tmax by 
approximately 20 min. Studies have demonstrated that MS-275 is reasonably well 
absorbed following oral administration to dogs (bioavailability 28-55%), but that 
absorption is substantially dependent on gastric pH and/or food intake. Sequential 
administration of MS-275 tablets observed higher Cmax and AUC values than that of the 
powdered form. These results indicated that MS-275 tablets have higher bioavailability.  
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Table 1.5 Mean plasma pharmacokinetic parameters for oral administration of 
MS-275 (1.5 mg/kg = 30 mg/m2) in beagle dogs 
 
Study  
group 
Cmax  
(µg/ml), 
(µM) 
Tmax 
(h) 
t1/2
(h) 
AUC0-max
(µg*h/ml) 
F 
(%) 
IV 2.35 ± 0.28, (6.24 ± 0.73) - 
0.17 ± 0.07 (α) 
0.96 ± 0.19 (β) 2.01 ± 0.23 - 
Oral (fasted) 0.43 ± 0.32, (1.14 ± 0.85) 
0.45 ± 
0.21 0.90 ± 0.14 0.61 ± 0.49 30 ± 22 
Oral  
(fasted + 
Pentagastrin) 
0.87 ± 0.33, 
(2.31 ± 0.88) 
0.50 ± 
0.18 0.91 ± 0.10 1.11 ± 0.24 55 ± 9 
Oral (fed) 0.40 ± 0.14, (1.06 ± 0.37) 
0.81 ± 
0.24 0.64 ± 0.08 0.56 ± 0.09 27 ± 3 
 
Data is from MS-275 investigator’s brochure. All values are mean ± SD. Pentagastrin 
was administered intramuscular (10 µg/kg) 15 mins prior to MS-275 dosing. 
 
 
Oral absorption of MS-275 tablets was evaluated in four male beagle dogs by 
administering a total dose of 20 mg: 4 x 5mg tablets or 2 x 10mg tablets orally with 20 ml 
water. There were no significant differences in PK parameters between two combinations 
(Table 1.6). AUC and Cmax values (after correction for dose/body weight differences) 
were 1.45-2.29 fold and 0.83 to 3.29-fold higher, respectively, when administered as 
tablet compared to bulk powder. Hence, there was higher bioavailability in dogs for 
tablets indicating suitability for use clinical use.   
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Table 1.6 Mean plasma pharmacokinetic parameters for oral administration of 
MS-275 tablets at two different schedules in dogs 
 
Dose 
regimen  
Cmax 
(µg/ml), (µM) 
Tmax 
(h) 
T1/2
(h) 
AUC0-max
(µg*h/ml) 
4 x 5mg  
tablets 0.75 ± 0.17, (2.00 ± 0.45) 0.75 ± 0.20 0.73 ± 0.99 1.10 ± 0.11 
2 x 10mg  
tablets 0.64 ± 0.30, (1.70 ± 0.80) 0.69 ± 0.13 0.64 ± 0.03 0.94 ± 0.43 
 
Data from MS-275 Investigator’s Brochure 
 
 
1.11.3 In-vitro and in-vivo toxicity 
 Murine and human bone marrow progenitor cells (CFUGM) were continuously 
exposed in-vitro to 0.001, 0.1, 1, 10 and 100 µM concentrations of MS-275.  The IC90 
values calculated from the second order regression analysis were 24, 5.8, and 15.1 µM 
for murine, canine, and human CFUGM.  The dog CFUGM appeared to be more sensitive 
to the toxic effects of MS-275 than either human or mouse cells. The in-vivo MTD was 
40 mg/kg/day when 240 mg/m2 of MS-275 was given to rats on a daily basis for 5 days 
(24). The MTD of MS-275 was 15 mg/kg/day (90 mg/m2/day) and 3 mg/kg/day (18 mg/ 
m2/day) for 14 and 28 days, respectively in mice. Bone marrow toxicity appeared to be a 
dose-limiting factor in the rat. The MTD of MS-275 given orally to dogs for 5 days was 2 
mg/kg/day (40 mg/m2/day).  The MTD of MS-275 was less than 0.7 mg/kg/day (14 
mg/m2/day).  Bone marrow and gastrointestinal toxicity also appeared to be DLT in dogs. 
Therefore, the maximally tolerated dose of MS-275 given orally once a day for 28 days in 
dogs was >0.3 mg/kg/day (6 mg/ m2/day) (data on file, Schering AG). 
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Based on these promising pre-clinical data, several early phase clinical trials were 
initiated mainly to identify MTD, dose-limiting toxicities and a dosing regimen for 
further efficacy studies.  
 
 
Hypothesis and Objectives 
The hypotheses were tested and the objectives of the study were as follows: 
1) Hypotheses 
1. MS-275 will be well tolerated in the clinic when given orally at the proposed 
doses. 
2. MS-275 will have quantifiable effects on the in-vivo biomarkers of anti-
proliferation and apoptosis in the tumor cells. 
3. The in-vitro and ex-vivo plasma protein binding will be extensive and linear in the 
clinically achievable concentration range. 
4. Metabolism by transporters and phase II enzymes will be the major metabolic 
pathway for MS-275. 
5. MS-275 will exhibit linear pharmacokinetics and single-dose pharmacokinetics 
will be useful in predicting steady state concentrations. 
6. The relevant pharmacokinetic parameters of MS-275 absorption and disposition 
will be calculated, which may possibly explain inter-individual variability. 
2) Objectives 
1. To develop and validate an LC/MS assay that will quantitate MS-275 in human 
plasma or other matrix such as human liver microsomes. 
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2. To characterize the pharmacokinetics of oral MS-275 in plasma of patients with 
solid tumors and lymphomas. 
3. To make pharmacodynamic correlations, if any, with the in-vivo anti-proliferative 
and apoptotic markers of biological effect and/toxicity. 
4. To assess the in-vitro plasma protein binding of MS-275. 
5. To characterize in-vitro the metabolic fate of MS-275. 
 
 
 CHAPTER 2 
 
Detection and Quantitation of MS-275, a Histone Deacetylase Inhibitor, in Human 
Plasma, Liver Microsomes and Urine by High-Performance Liquid 
Chromatography-Electrospray Mass Spectrometry 
 
2.1 Introduction 
A validated analytical method is required for measuring the plasma concentrations 
of MS-275 in patients receiving the drug. Hence, a rapid method was developed for the 
quantitative determination of MS-275, in human plasma. The method was also applied 
and slightly modified to quantify concentration of MS-275 in different matrices, namely, 
urine and human liver microsomes. For the plasma matrix, calibration curves were 
constructed in the range of 1 to 100 ng/ml, and were analyzed using a weight factor 
proportional to the nominal concentration. Sample pretreatment involved a one-step 
protein precipitation with acetonitrile of 0.1-ml samples. The analysis was performed on 
a column (75 × 4.6 mm I.D.) packed with 3.5-µm Phenyl-SB material, using methanol – 
10 mM ammonium formate (55:45, vol/vol) as the mobile phase. The column effluent 
was monitored by an UV detector at wavelength of 205nm and mass spectrometry with 
positive electrospray ionization. The values for precision and accuracy were always ≤ 
5.58% and < 11.4% relative error, respectively. This validated method was then 
successfully applied to examine the pharmacokinetics of MS-275 in cancer patients.  
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2.2 Experimental details 
2.2.1 Chemicals and materials 
MS-275 (batch number: 81300002; HPLC purity, 99.82%) was supplied as a 
crystalline white powder by Schering AG (Berlin, Germany). HPLC-grade methanol and 
acetonitrile were obtained from J.T. Baker (Phillipsburg, NJ, USA). Ammonium formate 
and formic acid were purchased from Sigma (St. Louis, MO, USA). Deionized water was 
generated with a Hydro-Reverse Osmosis system (Durham, NC, USA) connected to a 
Milli-Q UV Plus purifying system (Malbourough, MA, USA). Drug-free heparinized 
human plasma was obtained from the National Institutes of Health Clinical Center Blood 
Bank (Bethesda, MD, USA). 
 
2.2.2 Equipment and instrumentation 
The experiments were carried out with a HP1100 system (Agilent Technology, 
Palo Alto, CA, USA). The system consisted of a G1312A binary pump, a mobile phase 
vacuum degassing unit, a G1329A autosampler, a temperature-controlled column 
compartment, and a HP1100 single-quadrupole mass-spectrometric (MS) detector 
equipped with an electrospray source. The autosampler seat and needle sets consisted of a 
polyether-ether-ketone-based needle seat and assembly, and a Tefzel seal (Agilent 
Technology) was used in the injector valve to avoid carry-over. Data were acquired and 
integrated by the ChemStation software run on a HP Vectra 150/PC with a Windows NT 
operating system. The stationary phase was composed of Phenyl-SB material (Agilent 
Technology) packed in a stainless steel column (75 × 4.6 mm I.D. with 3.5 µm particle 
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size), and a Phenyl-SB guard column (12.5 × 4.6 mm I.D. with 5 µm particle size) 
attached to a column-inlet filter (3 mm × 0.5 µm; Varian, Walnut Creek, CA, USA). 
PEEK tubing of 0.127 mm I.D. (Upchurch Scientific, Oak Harbor, WA, USA) was used 
to connect the column to the pump and the MS detector with minimal tubing length to 
avoid an excessive post-column volume. 
 
2.2.3 Chromatographic and MS conditions 
Chromatographic separations were achieved using a mobile phase consisting of 
methanol and 10 mM ammonium formate (pH 3, adjusted with formic acid) (55:45, 
vol/vol), with a flow rate set at 0.8 ml/min. The analytical column was kept at ambient 
temperature. The column effluent was connected to an electrospray ionization MS 
interface without splitting. The MS detector was operated in the positive ion mode, with 
single ion monitoring at a fragmentor setting of 65 V and a multiplier gain of 2. Nitrogen 
was used as the nebulizer gas at a pressure of 55 PSI and as drying gas at a flow rate of 
13 l/min and a temperature of 350°C. The capillary voltage was set at 2200 V, and 
selected-ion monitoring was accomplished at m/z 377 for the protonated molecular ion of 
MS-275. Monitoring was performed using a dwell time of 578 ms and was monitored in 
the high-resolution mode. Simultaneously, UV detection was done at 230 nm and 280 nm 
to detect possible metabolites in clinical samples. After data acquisition, the selected-ion 
monitoring chromatograms were integrated using the HP ChemStation software and used 
for quantitation.  
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2.2.4 Preparation of standards 
Stock solutions were prepared in triplicate by accurately weighting, after 
correction for purity, an appropriate amount of MS-275 and dissolving in methanol. The 
final concentration of the stock solutions was 1 mg/ml, and these were stored at -20oC. 
Working standard solutions were prepared over a range of 0.02 to 40 µg/ml by serial 
dilution of the stock solution with methanol, and then stored at -80oC. Plasma calibration 
standards of 1, 5, 10, 20, 50 and 100 ng/ml were prepared fresh as needed by mixing 30 
µl working standard solution with 570 µl blank human plasma. Quality control (QC) 
samples were prepared from an independent stock solution at concentrations of 3, 40, and 
80 ng/ml by dilution of the working stock solution with blank human plasma. These QC 
samples were subdivided into 0.1-ml aliquots, and stored at –80oC. Standard and QC 
solutions were prepared as shown in Table 2.1 and Table 2.2 respectively. 
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Table 2.1 Preparation of standards  
 QC Concentration Mixture 
A 1mg/ml 10mg/10ml(MeOH) 
B 40µg/ml 1ml of A solution/25ml(MeOH) 
C 10µg/ml 1ml of B solution + 3ml of MeOH 
D 2µg/ml 1ml of C solution + 4ml of MeOH 
E 0.2µg/ml 0.5ml of D solution + 4.5ml of MeOH 
 
 
 
 
 
 
 
Working standards  Spiking solution 
Spiking solution 
(µl) 
MeOH 
(µl) 
F 2000 C 200 800 
G 1000 C 100 900 
H 400 D 200 800 
I 200 D 100 900 
G 100 D 50 950 
K 20 E 100 900 
 
 
 
 
 
 
 
 
 
 
 
Standard  
solutions 
Spiking  
solution 
Spiking solution 
(µl) Plasma (µl) 
100 F 30 570 
50 G 30 570 
20 H 30 570 
10 I 30 570 
5 G 30 570 
1 K 30 570 
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Table 2.2 Preparation of quality controls 
 
 
QC Concentration Mixture 
I 1mg/ml 10mg/10ml(MeOH) 
II 40µg/ml 1ml of I solution/25ml(MeOH) 
III 8µg/ml 1ml of II solution + 4ml of MeOH 
 
 
Working  
QC solutions 
Spiking 
solution 
Spiking 
solution (µl) 
MeOH 
(µl) 
IV 1600 III 200 800 
V 800 III 100 900 
VI 60 V 75 925 
 
QC  
solutions 
Spiking  
solution 
Spiking solution 
(µl) 
Plasma 
(µl) 
80 IV 200 3800 
40 V 200 3800 
3 VI 200 3800 
 
 
2.2.5 Sample preparation 
Standards, QCs samples, and patient samples were allowed to thaw at room 
temperature. A 0.1-ml aliquot of each was transferred to a 1.5-ml Eppendorf tube 
(Hamburg, Germany) and 500 µl of acetonitrile were added to precipitate plasma 
proteins. The mixture was vortex-mixed for 30 seconds, and then centrifuged for 5 
minutes at 13,000 rpm. A volume of 500 µl of the clear supernatant was transferred to a 
glass tube and evaporated to dryness under desiccated air in a water bath at 45oC in a 
Zymark TurboVap LV (Hopkinton, MA, USA). The residue was reconstituted in 200 µl 
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of a mixture of methanol and water (50:50, vol/vol), followed by vortex-mixing. A 50-µl 
volume of the reconstituted sample was injected into the chromatographic system. 
 
2.2.6 Validation characteristics 
To evaluate the specificity of the analytical procedure, blank human plasma 
samples obtained from 6 different individuals were extracted and analyzed for the 
presence of interfering endogenous substances. In addition, plasma samples containing 
mixtures of several commonly administered drugs were tested for potential 
chromatographic interference with MS-275. 
 Calibration curves were constructed by plotting the peak area of the analyte 
versus the nominal concentration (x) of the calibration standards. The regression 
parameters of slope, intercept and correlation coefficient were calculated by a weighted 
(1/x2) least-squares linear regression analysis. The linearity was evaluated by comparing 
the correlation coefficient (r2), residuals and errors between theoretical and back 
calculated concentrations of calibration standard samples.  
The accuracy and precision were assessed by analyzing QC samples prepared at 3 
different concentrations equally distributed over the tested range (i.e., spiked at 3, 40, and 
80 ng/ml) in 6 replicates on 3 different days. The accuracy of the assay was evaluated by 
the percentage deviation (DEV) from the theoretical concentration (TC) using the 
formula: 
DEV = 100% × (mean back calculated concentration – TC) / TC 
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Within- and between-assay precision were obtained by one-way analysis of 
variance (ANOVA) testing, and reported as relative standard deviation for each QC 
concentration. The extraction recovery for MS-275 in human plasma was determined at 3 
concentration levels in triplicate using samples spiked to contain 3, 40, and 80 ng/ml, 
using comparison with samples prepared in 50% (vol/vol) methanol in water injected 
without extraction. 
The stability of MS-275 in human plasma was assessed during three freeze-thaw 
cycles and at room temperature for up to 24 hours. Four aliquots of QC samples of three 
different concentrations were thawed at room temperature, and kept at this temperature 
for 0, 12, and 24 hours, and immediately analyzed. For the freeze-thaw stability study, 
QC samples at three different concentrations in quadruplicate, and stored at -80oC for 24 
hours. Next, the samples were thawed at room temperature, and were refrozen for 12 
hours under the same conditions. The freeze-thaw cycle was repeated two more times, 
and then analyzed on the third cycle.  
 
2.2.7 Clinical experiment 
To demonstrate the applicability of the final analytical procedure, samples were 
obtained from a cancer patient, who participated in the ongoing multi-dose Phase I 
clinical trial with MS-275 tablets as single-agent therapy. The drug was administered 
orally with a meal at a dose of 10 mg/m2. The current experiment was approved by the 
local Institutional Review Board, and the patient signed informed consent before study 
entry for the blood sampling procedure. A total of 11 blood samples (7 ml each) were 
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obtained and collected in 10-ml glass tubes containing heparin as an anticoagulant. These 
samples were obtained before drug administration and at approximately 0.5, 1, 2, 6, 12, 
24, 36, 48, 60 and 72 hours after drug administration. Specimens were immediately 
centrifuged at 3,000 g for 5 minutes to separate the plasma supernatant, which was stored 
at -70°C until the time of analysis. Plasma concentration-time data of MS-275 were 
analyzed by noncompartmental methods using the software package WinNonlin v4.0 
(Pharsight Corp., Mountain View, CA) using equal weighting. 
 
2.3 Results and discussion 
2.3.1 Chromatography 
The mass spectrum of MS-275 showed a protonated molecular ion (MH+) at m/z 
377, in accordance with the NTP chemical repository database, a sodium adduct at m/z 
399 (MH+ + Na), and a prominent fragment ion peak at m/z 359 (MH+ – H2O) (Figure 
2.1).  
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Figure 2.1 Liquid chromatographic-electrospray mass spectrum of MS-275 
 
Sample pretreatment was initially performed by a solvent extraction (e.g., using 
ethyl acetate) or by solid phase-extraction (e.g., using C18 micro-extraction columns). 
However, these procedures resulted in poor extraction recovery, particularly at the upper 
limit of the expected concentration range (i.e., around 100 ng/ml). This is likely the result 
of the hydrophilic nature of MS-275, which is highly soluble in water (approximately 20 
mg/ml at 20°C in acidic buffers). Among various alternative procedures tested, MS-275 
was eventually efficiently extracted with adequate elimination of endogenous interfering 
compounds using a single protein precipitation step with acetonitrile. In the final 
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procedure, only a small fraction of the sample after extraction was injected (i.e., 50 µl of 
200 µL used for reconstitution) on the column to maintain high efficiency and resolution, 
and assay sensitivity was thus compromised. Although increased injection volumes could 
achieve higher response factors, overloading of the small column resulted in asymmetric 
sample bands. The presence of 10 mM ammonium formate (pH 3) in the reconstitution 
mixture was found to induce a distorted separation artifact, which resulted in unstable 
response factors over time following repeat injections of extracted patient samples (not 
shown). In the final procedure, therefore, reconstitution of samples was performed with a 
mixture of methanol and water (50:50, vol/vol). Out of various chemicals that were 
tested, 4, 4’-diaminebenzanilide was initially selected for use as internal standard. But, 
we were unable to use 4, 4’-diaminebenzanilide due to incidences of variability in 
extraction when plasma from different sources was used. 
 
2.3.2 Validation characteristics 
Figure 2.2 displays chromatograms of an extract of blank human plasma sample 
(A), and an extract of a plasma sample spiked with MS-275 at a concentration of 1.0 
ng/ml (LLOQ) (B). The mean retention time for MS-275 during the method validation 
was 4.3 minutes, and the overall chromatographic run time was established at 8 minutes.  
Several different drugs were tested for potential interference with MS-275 (Table 
2.3), and none of these drugs was found to give an interfering peak during the analysis 
around the retention time of MS-275. Plasma samples were acquired from patients who 
were currently taking these medications. 
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Figure 2.2 Typical chromatogram of reversed-phase liquid chromatographic 
analysis of a blank human plasma sample (A), and a human plasma sample spiked 
with MS-275 at a concentration of 1 ng/ml (B). The labeled chromatographic peak 
indicates MS-275 (I). 
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Table 2.3   Interference analysis of various commonly administered drugs 
 
Amlodipine mesylate Glucosamine sulfate Palmidronate disodium 
Atenolol Hydromorphone Phenytoin 
Ciprofloxacin Hydroxyzine Pseudephedrine 
Clotrimazole Ketoconazole Pyridoxine hydrochloride 
Cyanocobalamine Levofloxacin Raloxifene 
Dexamethasone Levothyroxine Ranitidine 
Diazepam Loperamide Rofecoxib 
Diphenhydramine Metronidazole Sertraline hydrochloride 
Docusate sodium Morphine sulfate Verapamil 
Epoetin alpha Omeprazole Warfarin 
Fluticasone propionate Ondansetron Zolpidem tartarate 
Folic acid Oxycodone  
 
The assay for MS-275 analysis in plasma was found to be linear over the range of 
1.0 to 100 ng/ml, applying the peak area in combination with a weighting factor of 1/x2, 
as indicated by the mean linear-regression correlation coefficient of 0.998 (n = 3). A 
comparative evaluation of accuracy between unweighted and 1/x2 weighted analysis is 
provided in Figure 2.3. 
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The horizontal dotted lines indicate the acceptable ± 15% deviation range 
Figure 2.3  Comparison of accuracy (percent deviation from nominal) for 
unweighted versus 1/x2 weighted analysis of MS-275 in human plasma at 3 different 
concentrations  
  
In blank human plasma spiked with MS-275 at 1.0 ng/ml, the mean percentage 
deviation from the nominal concentration and the within-run variability were both less 
than 20% 233. Based on these results, the lower limit of quantitation for MS-275 in human 
plasma was determined to be 1.0 ng/ml, using 0.1-ml sample volumes. The limit of 
detection was determined to be 0.5 ng/ml but due to lack of reproducibility and high 
within-run variability, the lower limit of quantitation was confirmed to be at 1 ng/ml. 
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Validation data of the analytical method in terms of accuracy (percent deviation) 
and precision are shown in Table 2.4. The mean (± SE) equation was: Y = 7388 (±335) * 
X - 2091 (±571). At the upper limit of quantitation (i.e., 100 ng/ml), the mean percentage 
deviation and the within-run variability were less than 15%. The method was shown to be 
accurate, with an average accuracy at the three tested concentrations within ± 7% of 
nominal values, and precise with a within-run and between-run variability of less than 
3.75%. The mean overall extraction recovery, determined at three different 
concentrations, was 37.9% (standard effect, 0.126%). A non-parametric Kruskal-Wallis 
one-way ANOVA indicated a minor concentration-dependence (p = 0.027), as 
determined by a Tukey-Kramer multiple comparison test for all pairwise differences 
between the means (Table 2.5).  
 
Table 2.4   Validation summary for the analysis of MS-275 in spiked human 
plasma samples 
Parameter Nominal concentration (ng/ml) 
 3 40 80 
Accuracy    
Mean observed (ng/ml) 2.95 37.2 79.8 
Deviation (%; n = 18) -1.69 -6.92 -0.26 
Precision    
Intraday (%; n = 6) 4.58 1.13 1.56 
Interday (%; n = 18) 3.75 3.31 2.56 
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Table 2.5 Recovery of MS-275 in human plasma (data expressed as 
chromatographic peak area of MS-275) 
Nominal 
(ng/ml) 
Plasma peak 
area 
Methanol peak 
area 
Relative 
recovery (%) 
3 76984 181773 41.7 
3 76783 187090  
3 77369 185003  
40 1152760 3269960 34.8 
40 1133914 3248894  
40 1123663 3279752  
80 2419225 6517666 37.0 
80 2433135 6522078  
80 2401394 6560018  
 
 
However, this effect is presumably due to normal analytical variability rather than 
reflecting a concentration-dependent extraction recovery. An improvement in recovery 
could be accomplished by using increased volumes of acetonitrile for primary isolation, 
followed by a repeat of the entire extraction procedure. However, in view of the relative 
consistency in the generated data, and the rapidity and ease of use, all experiments were 
performed using a one-step protein precipitation. Repeated freeze-thawing cycles had no 
influence on the stability. In addition, plasma samples spiked with MS-275 and stored for 
variable time periods at ambient temperature were also stable (Table 2.6 and Figure 2.4). 
On the basis of the generated validation parameters, the method was considered 
acceptable for the analysis of plasma samples in support of clinical pharmacokinetic 
studies. 233 
 
 67
Table 2.6 Short-term temperature stability of MS-275 in plasma 
Time (h) Nominal (ng/ml) 
Recovered 
mean ± SD 
(ng/ml) 
Deviation (%) 
0 3 3.00 ± 0.07 -0.08 
0 40 40.5 ± 0.73 1.29 
0 80 81.5 ± 0.86 1.83 
12 3 2.55 ± 0.05 -15.0 
12 40 39.9 ± 0.53 -0.33 
12 80 78.0 ± 2.77 -2.50 
24 3 2.71 ± 0.08 -9.75 
24 40 39.8 ± 1.89 -0.47 
24 80 78.9 ± 0.71 -1.37 
 
Figure 2.4 Short-term temperature stability of MS-275 in plasma 
 
 
 
2.3.3 Clinical application of analytical method 
The described analytical method was applied to a pharmacokinetic pilot study of 
MS-275 given orally to a single cancer patient. The observed concentration-time profile 
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of MS-275 is shown in Figure 5. The time to peak concentration occurred before the first 
sampling time point, and hence the initial absorption phase of MS-275 was not observed 
in this patient. The peak concentration of MS-275 was 41.7 ng/ml, and the area under the 
concentration-time curve amounted to 400 ng⋅h/ml, with an apparent oral clearance value 
of approximately 42 l/h/m2. Ultraviolet detection was also carried out on all samples, but 
no additional peaks that might represent metabolites of MS-275 were detected. 
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Figure 2.5 Plasma concentration-time profile of MS-275 in a patient with cancer 
after a single oral administration of the drug at a dose of 10 mg/m2
 
2.4 Conclusion 
In conclusion, the method presented for the determination of MS-275 in human 
plasma is specific, accurate and precise, and is selective and sensitive enough to be used 
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in clinical trials. The method permits the analysis of patient samples with low 
concentrations of MS-275, and is currently being used in various Phase I clinical trials in 
patients with hematological malignancies or solid tumors to further investigate the 
clinical pharmacologic profile of this agent.
 CHAPTER 3 
In-vitro and In-vivo Characterization of Plasma Protein Binding Profile of MS-275 
 
3.1 Introduction 
 A preliminary pharmacokinetic evaluation of MS-275 given orally to cancer 
patients indicated that the terminal half-life of MS-275 in plasma (approximately 50 
hours) is substantially longer than that observed in laboratory animals (approximately 1 
hour). The basis for this long half-life in humans, at least as a speculation, is possibly 
related to enterohepatic recirculation processes. However, a variety of other factors may 
influence the prolonged circulation of MS-275 in humans, including binding of the 
compound to plasma proteins. Indeed, drugs with high affinity for plasma proteins often 
demonstrate a relatively slow distribution and elimination of drug from the central 
compartment, which may prolong the apparent half-life 234. The purpose of this study was 
to characterize the binding properties of MS-275 to human plasma and individual 
proteins using a novel microequilibrium dialysis method, and to evaluate potential 
interspecies differences in binding affinity that might help explain the apparent 
pharmacokinetic discrepancy between humans and laboratory animals. 
3.2 Materials and methods 
3.2.1 Chemicals and reagents 
 MS-275 (batch number: 81300002; chromatographic purity, 99.82%) and [G-3H] 
MS-275 (specific activity, 1543.6 MBq/mg, 17.5 MBq/ml) were kindly supplied by 
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Schering AG (Berlin, Germany). The final concentration of MS-275 in the radiolabelled 
vial was determined to be 11.3µg/ml (29.1 µM). HPLC-grade methanol and acetonitrile 
were obtained from J. T. Baker (Phillipsburg, NJ, USA). Ammonium formate and formic 
acid were purchased from Sigma (St. Louis, MO, USA). Deionized water was generated 
with a Hydro-Reverse Osmosis system (Durham, NC, USA) connected to a Milli-Q UV 
Plus purifying system (Marlborough, MA, USA). Bio-Safe II scintillation fluid was 
obtained from Research Products International (Mount Prospect, IL, USA). Purified 
human proteins, including albumin, α1-acid glycoprotein (AAG), α- , β-, and γ-globulin, 
fibrinogen, and lipoproteins, as well as mouse, rat, rabbit, dog, and pig plasma were 
obtained from Sigma. Other chemicals were of reagent grade or better. Pure protein 
solutions at respective physiological concentrations in healthy individuals were prepared 
in 0.01 M phosphate buffer (pH 7.4). The stock solutions of all test substances were made 
in dimethylsulfoxide. Human blood was obtained from healthy volunteers or cancer 
patients receiving MS-275, and the plasma fraction was separated by centrifugation (3000 
× g for 5 min at 37 °C), and used within 1 hour after collection. Frozen, drug-free 
heparinized human plasma was obtained from the National Institutes of Health Clinical 
Center Blood Bank (Bethesda, MD, USA). 
 
3.2.2 Development and validation of dialysis method 
 Initially this method was developed to characterize protein binding of docetaxel 
and several parameters were optimized as shown below (Table 3.1). Most of these 
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selected parameters were then incorporated in optimization of a standardized method for 
characterizing protein binding of several other drugs including MS-275. 
 
Table 3.1 Details of the parameter optimization for micro-equilibrium dialysis 
method 
 
Parameters Tested values Selected values 
Molecular weight cut-off of 
plate membranes 5kDa, 10kDa 5kDa 
Reaction time (to reach 
equilibrium) range 
0.5, 1, 2, 3, 4, 6, 8, 16, 24, 48 
h 5 hour 
Wait time after mixing and 
before counting 1’, 5’, 30’, 1h, 24h 5’ 
Scintillation counting time 1’, 20’ 1’ 
Spiking effects of [3H] drug Plasma chamber, PBS chamber Plasma 
Volume of dialysate used for 
counting 
1/4th, 1/3rd, 1/2 and 3/4th of 
reaction volume 1/2 
Total volume of reaction for 
plasma and PBS 200 µl, 250 µl , 300 µl 250 µl 
Effect of cold drug on 
changes in fu using [3H] drug 10, 100, 1000, 10000 ng/ml No effect 
Quenching in plasma on 
scintillation counting 2h, 4h, 6h, 8h, 24h, 48h 
No effect till 
8h 
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Figure 3.1  Layout of equilibrium dialysis method 
 
 For MS-275, equilibrium dialysis was performed on a plate rotator (Model # 74-
2334, Harvard Apparatus, Holliston, MA, USA) at 37°C in a humidified atmosphere of 
5% CO2 using 96-wells micro-dialysis plates (Harvard Apparatus) 235. The dialysis 
compartments in each well are separated by a regenerated cellulose membrane with a 5-
kDa cut-off. Experiments were carried out with 250-µl aliquots of plasma containing a 
 Dialysis plate rotator
Plasma (245 µl) + Hot drug in EtOH (5 µl) 
PBS Buffer (250 µl)
96-well dialysis plate 
Fraction unbound (fu) = 100 * (PBS – Blank) / (Plasma – Blank) 
Count (125µl aliquots) for [3H] using scintillation counter 
After equilibrium 
(5 hours at 37 °C)
  UH + UC + BC + BH UH + UC + BC + BH 
UH + UC 
UH=unbound hot drug 
UC=unbound cold drug 
BC= bound cold drug 
BH= bound hot drug 
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tracer amount of [G-3H] MS-275 against an equal volume of 0.01 M phosphate buffer (pH 
7.4). Drug concentrations in 125 µl-aliquots of both compartments were measured by 
liquid scintillation counting for 1 minute following the addition of Bio-Safe II 
scintillation fluid on a Model LS6000IC counter (Beckman Instruments, Inc., Columbia, 
MD). 
 To evaluate the specificity of this procedure and check for displacement effect of 
other drugs on protein binding of MS-275, blank human plasma was spiked with 19 
different commonly administered drugs at a concentration of 1 µg/ml and was analyzed 
for changes in the fraction unbound drug (fu). The accuracy and precision were assessed 
by analyzing quadruplicate samples prepared from 5 different plasma sources in 
quintuplicate on 5 separate occasions. Within- and between-assay precision estimates 
were obtained by one-way analysis of variance, and reported as relative standard 
deviation. The impact of stability of MS-275 protein binding in human plasma was 
assessed during a freeze-thaw cycle at room temperature after 24 hours.  
 
3.2.3 In-vitro binding experiments 
 Preliminary experiments indicated that volume shifts during the dialysis period 
were negligible (< 10%), and hence the results were used directly without applying a 
correction factor. The time course of equilibrium was assessed in quadruplicate at 15 and 
30 minutes, and at 1, 2, 3, 4, 5, 6, 22, 24 and 28 hours after start of the experiment. Since 
fu measurements were to be made on patient samples that contained variable amounts of 
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drug, fu was also determined in plasma samples over the anticipated clinically relevant 
concentration range of MS-275 (i.e., 0, 1, 5, 10, 50, 100 and 500 ng/ml). 
 
3.2.4 Estimation of binding parameters 
 The drug concentration ratio in the buffer and plasma or protein solution after 
dialysis was calculated for each paired observation, and was taken as an estimate of the 
unbound drug fraction (fu). The bound drug fraction (fbd) was calculated as fbd = (1 – fu) × 
100%. 
Modified Scatchard plots were constructed using the bound drug concentration 
(Cbd) and the unbound drug concentration (Cu), and initial estimates of binding 
parameters were obtained using an automated-model selection procedure implemented in 
the Siphar v4.0 software package (InnaPhase, Philadelphia, PA, USA). For human 
albumin and AAG, the observed data were described by equations for saturable [Cbd = 
mΣI=1 (niP × Ki × Cu) / (1 + Ki × Cu)] and non-saturable binding [Cbd = (nK) × Cu]. In 
these equations, Cbd and Cu are expressed as molar concentrations, m is the number of 
binding site classes, n the number of saturable binding sites per mole of protein in the i-th 
class (1, 2, or 3), P the molar concentration of protein binding, K the association constant, 
and nK the contribution constant of nonspecific, non-saturable binding on one site (per 
molar concentration of protein). Binding parameters were calculated by an iterative 
nonlinear regression analysis using the Powell minimization algorithm and weighted least 
squares with a weight equal to 1/y. The models were evaluated by the Akaike Information 
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Criterion, weighted sum of squared deviations and the coefficient of variation for each 
parameter estimate. 
 
3.2.5 Patients and treatment 
 Blood samples were available from 5 patients, who were enrolled onto a Phase I 
clinical study with MS-275 as single-agent therapy 236. Individual drug doses were 
normalized to body-surface area, and were administered orally as capsules (Schering AG) 
with food at a dose of 10 mg/m2. Trial design, inclusion and exclusion criteria, 
premedication regimens, and detailed clinical profiles are documented elsewhere. The 
clinical protocol was approved by the National Cancer Institute review board (Bethesda, 
MD, USA), and all patients provided written informed consent before entering the study. 
From each patient, serial plasma samples were obtained during the first course of 
treatment at the following time points: (i) immediately before drug administration (pre-
dose), and (ii) at 0.5, 1, 2, 6, 12, 24, 48, 60, 72, and 84 hours after the first drug 
administration. All blood samples were immediately placed in an ice-water bath, 
centrifuged within 30 minutes of collection at 1000 × g for 10 min at 4°C, and were 
stored at or below –70 °C until analysis (see below). 
 
3.2.6 Measurement of total drug concentrations 
 Total MS-275 concentrations were determined using previously validated 
analytical method based on liquid chromatography coupled with mass spectrometric 
detection 237. Chromatography was carried out with a HP1100 system (Agilent 
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Technology, Palo Alto, CA, USA). Data were acquired and integrated by the 
ChemStation software run on a HP Vectra 150/PC with a Windows NT operating system. 
Calibration curves ranged from 1 to 100 ng/ml, and were analyzed using a weight factor 
proportional to the nominal concentration. Sample pretreatment involved a one-step 
protein precipitation with acetonitrile of 0.1-ml samples. The analysis was performed on 
a stainless steel column (75 × 4.6 mm I.D.) packed with 3.5-µm Phenyl-SB material 
(Agilent Technology), using methanol – 10 mM ammonium formate (pH=3) (55:45, 
vol/vol) as the mobile phase. The lowest limit of quantitation was 1 ng/ml and the values 
for precision and accuracy were always ≤ 5.58% and < 11.4% relative error, respectively. 
The method was successfully applied to examine the pharmacokinetics of MS-275 in 
cancer patients. 
 
3.2.7 Measurement of unbound drug concentrations 
 The fraction unbound (fu) MS-275 in each individual patient plasma sample was 
determined using equilibrium dialysis, and samples were analyzed for total radioactivity 
(i.e., [G-3H] MS-275) by liquid-scintillation counting as described above. The unbound 
drug concentrations (Cu) were calculated from the fraction unbound drug (fu) and the total 
drug concentration in plasma (Cp) (i.e., the total of unbound and protein bound), as Cu = 
fu × Cp. 
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3.2.8 Pharmacokinetic analysis 
 Estimates of pharmacokinetic parameters for total and unbound MS-275 in 
plasma were derived from individual concentration-time data sets by noncompartmental 
analysis using the software package WinNonlin v4.0 (Pharsight Corporation, Mountain 
View, CA, USA). The area under the plasma concentration-time curve (AUC) was 
calculated using the linear trapezoidal method from time zero to the time of the final 
quantifiable concentration (AUC [tf]). The AUC was extrapolated to infinity by dividing 
the last measured concentration by the rate constant of the terminal phase (k), determined 
by log-linear regression analysis. The apparent oral clearance of MS-275 (CL/F) was 
calculated by dividing the administered dose by the observed AUC [inf], and the terminal 
half-life was calculated as ln2 / k. 
 
3.2.9 Statistical considerations 
 All experiments were performed in triplicate on at least 3 separate occasions, and 
statistical analyses were carried out using NCSS v2001 (J. L. Hintze, Kaysville, UT, 
USA). The effects of MS-275 concentration, concomitant drugs, and protein source on 
drug binding were estimated by a one-way ANOVA, and if overall p < 0.05, then 
followed by the Tukey-Kramer post-hoc test. All data are presented as mean values ± 
standard deviation (SD), unless stated otherwise, and for all tests the a priori cutoff for 
statistical significance was taken at p-value < 0.05. 
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3.3 Results  
3.3.1 Validation of dialysis method for MS-275 
 Preliminary experiments revealed that the time to equilibrium was attained around 
5 hours (Figure 3.2). All data were fitted to a sigmoidal maximum effect (Emax) model 
based on modified Hill equation, as follows: E = Eo + Emax * [(KPγ)/(KPγ + KP50γ)]. In 
this equation, Eo is the minimum reduction possible, fixed at a value of 0, Emax is the 
maximum response, fixed at 100, KP is the pharmacokinetic parameter of interest, KP50 
is the value of parameter predicted to result in half of the maximum response, and γ is the 
Hill constant describing the sigmoidicity of the curve. It was confirmed in all equilibrium 
dialysis experiments that the total drug recovery from the fractions was equal to the 
amount of [G-3H]MS-275 added to the plasma samples (mean recovery, 98%; P > 0.05 
versus hypothesized mean of initial value = 100%). The mean relative SD of all sample 
values was less than 10%, assuring high discriminatory power in the detection of changes 
in MS-275 fu in patient samples. With the final method, the within-run and between-run 
variability were always less than 6.4% and 9.8%, respectively. 
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Data are presented as individual observations (symbols) and a predicted model fit 
according to a modified Hill function (R2 = 0.930) (solid lines) with 95% prediction 
intervals (dotted lines). 
 
Figure 3.2  Time course to reach equilibrium for determining optimal fraction 
unbound MS-275  
 
Fresh plasma from 5 different sources was analyzed for fu in triplicate, and then 
the same samples were frozen and thawed at room temperature on the next day and 
immediately analyzed to determine fu. The mean fu values were 0.188 and 0.206, 
respectively, before and after the freeze-thaw cycle (P > 0.05), suggesting no significant 
influence. In separate experiments using the LC-MS assay, the chemical stability of MS-
275 during the dialysis was confirmed by analysis of plasma samples spiked with 100 
ng/mL of MS-275 in dialysis plates after incubation for 5 hours at 37 °C. 
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3.3.2 In-vitro binding interactions with MS-275 
 MS-275 was found to bind moderately to human plasma (mean, 81.2 ± 3.2%), 
with a free drug fraction of 0.188 ± 0.008.  There was no significant source difference in 
fu when plasma was used from different healthy individuals (mean fu, 0.185; p = 0.0938). 
The fu obtained in previously frozen plasma from healthy volunteers was found to be 
slightly higher than that observed in the plasma from six cancer patient (mean fu, 0.188 
versus 0.168; p = 0.113).  
At clinically relevant concentrations of MS-275 (1 to 500 ng/ml), the binding was 
concentration independent (P > 0.05), indicating a low-affinity, possibly non-specific and 
non-saturable process. MS-275 binding to physiological levels of albumin (3.5 – 4.5 
g/dL; fu, 0.27 ± 0.042) and AAG (0.04 – 0.1 g/dL; fu, 0.19 ± 0.0037) was similar, drug-
concentration independent (p = 0.53 and p = 0.80, respectively), and similar to the 
binding to patient plasma (Figure 3.3). When albumin and AAG were combined in the 
same buffer, the mean fu was 0.146 ± 0.0010, suggesting that albumin and AAG 
contribute to the majority of binding of MS-275 in human plasma. Regression modeling 
based on plots of bound concentration vs. unbound concentration revealed that the weak 
binding to albumin and AAG was non-saturable on a single site in the concentration 
range studied, with the bound concentration linearly related to unbound drug (R2 > 0.99). 
Binding affinity to AAG, as described by the slope, was about 4.7-fold higher than that of 
albumin, with association constants for non-saturable binding (nK) of 0.0247 ± 0.0003 
µM-1 and 0.116 ± 0.020 µM-1 for albumin and AAG, respectively. Subsequent 
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experiments indicated that MS-275 also had weak binding affinity for globulins (α, β, γ), 
fibrinogen, and high and low-density lipoproteins (Fig 3.3).  
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Data are presented as mean values (bars) ± SD (error bars). AAG, α1-acid glycoprotein 
(0.04 – 0.1 g/dL); LDL, low-density lipoprotein (0.06 – 0.13 g/dL); HDL, high-density 
lipoprotein (0.04 – 0.14 g/dL); Fibrinogen (3 – 4 g/dL); α, β-globulins (0.3 – 0.9 g/dL); γ-
globulin (0.7 - 1.5 g/dL); All, combined mixture of all tested proteins. 
 
Figure 3.3  Binding of MS-275 to human plasma proteins.  
 
3.3.3 Displacement interactions on binding sites 
 A slightly increased fu was observed in the presence of ibuprofen (fu, 0.236 ± 
0.001) and metoclopramide (fu, 0.270 ± 0.042), suggesting a weak displacement from 
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protein-binding sites (p = 0.00012, one-way ANOVA) (Table 3.2). The other tested drugs 
did not significantly alter the protein binding of MS-275.  
 
Table 3.2  Effect of potentially co-administered drugs on plasma binding of MS-
275 
 
Fraction unbound 
MS-275 Drug name 
(1 µg/ml) Mean SD 
% change vs. control 
(p-value*) 
Acetylsalicylic acid 0.187 0.0163 +6.58 ± 5.35 (NS) 
Alendronate 0.159 0.0124 -9.33 ± 4.06 (NS) 
5-Azacytidine 0.178 0.0163 +1.40 ± 5.36 (NS) 
Caffeine 0.221 0.0185 +25.8 ± 6.07 (NS) 
Celecoxib 0.162 0.0447 -22.4 ± 14.7 (NS) 
Cyclosporin A 0.178 0.0087 -0.389 ± 2.87 (NS) 
Dexamethasone 0.182 0.0327 +14.1 ± 10.7 (NS) 
Docetaxel 0.168 0.0099 -4.16 ± 3.26 (NS) 
Erythromycin 0.164 0.0113 -6.48 ± 3.72 (NS) 
Fludarabine 0.163 0.0095 -7.10 ± 3.13 (NS) 
Hydrocortisone 0.170 0.0038 -3.18 ± 1.24 (NS) 
Ibuprofen 0.236 0.0013 +34.6 ± 0.443 (0.00162) 
Ketoconazole 0.173 0.0075 -1.83 ± 2.47 (NS) 
Metoclopramide 0.247 0.0243 +40.8 ± 8.00 (0.00327) 
Midazolam 0.174 0.0082 -0.808 ± 2.70 (NS) 
Nifedipine 0.178 0.0139 +1.19 ± 4.57 (NS) 
Paclitaxel 0.168 0.0083 -7.11 ± 2.74 (NS) 
Ritonavir 0.177 0.0010 +0.817 ± 0.00 (NS) 
UCN-01 0.169 0.0035 -3.94 ± 1.14 (NS) 
 
*NS= not significant 
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3.3.4 Interspecies differences in MS-275 binding 
 MS-275 demonstrated a striking interspecies difference in plasma protein binding 
(p= 0.00846, one-way ANOVA) (Figure 3.4); compared to human plasma, the binding of 
MS-275 was significantly reduced in the mouse (fu, 0.378 ± 0.101), rat (fu, 0.393 ± 
0.0070), rabbit (fu, 0.375 ± 0.0416), dog (fu, 0.436 ± 0.0159), and pig plasma (fu, 0.439 ± 
0.0116).  
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Data are presented as mean values (bars) ± SD (error bars), and the star (*) indicates p < 
0.05 versus human plasma 
 
Figure 3.4  Interspecies comparison of MS-275 binding to plasma   
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3.3.5 Clinical pharmacokinetics of unbound MS-275 
 The developed equilibrium dialysis method was applied to prospectively define 
the concentration-time profiles of total and unbound MS-275 in 5 patients with cancer 
receiving single-agent MS-275, which was administered orally at a dose of 10 mg/m2. 
The mean plasma concentration-time profiles for total and unbound MS-275 are shown in 
Fig 3.5A. A summary of the pharmacokinetic parameters for total and unbound MS-275 
is provided in Table 3.3. Moderate inter-individual variability in unbound MS-275 
pharmacokinetic parameters was noted at the 10 mg/m2 dose level, with a coefficient of 
variation for the apparent oral clearance of 36%. In-vivo, there were no significant 
changes in extent of MS-275 binding with 79.7 ± 5.9% (n = 56) drug bound based on 
data obtained at individual sampling time-points (Fig 3.5B). 
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Table 3.3  Summary of total and unbound pharmacokinetic parameters* 
 
Parameter Total MS-275 Unbound MS-275 
Cmax (ng/ml) 50.6 ± 64.6 (9.41 – 163) 7.25 ± 7.18 (1.75 – 19.1) 
Tmax (h) 1.0 (0.50 – 2.0) 1.0 (0.50 – 2.0) 
AUC (ng·h/ml) 476 ± 155 (360 – 747) 96.6 ± 41.7 (56.2 – 167) 
CL/F (l/h/m2) 22.4 ± 5.43 (13.4 – 27.8) 117 ± 42.1 (59.8 – 178) 
T1/2 (h) 46.4 ± 12.6 (27.7 – 60.3) 52.4 ± 18.8 (30.3 – 80.5) 
AUC ratio Cu/Cp N/A 0.20 ± 0.042 (0.14 – 0.25) 
 
* Data were obtained from 5 patients receiving MS-275 orally at a dose of 10 mg/m2, and 
are presented in the table as mean values ± SD with range in parentheses, except for 
Tmax (median) 
Abbreviations: Cmax, peak plasma concentration; Tmax, time to peak concentration; 
AUC, area under the plasma concentration-time curve; CL/F, apparent oral clearance; 
T1/2, half-life of the terminal phase; Cu, unbound drug concentration; Cp, total drug 
concentration in plasma. 
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Data are presented as mean values (symbols) ± SD (error bars), and were obtained from 5 
patients with cancer treated with MS-275 given orally at a dose of 10 mg/m2. 
 
Figure 3.5  Concentration-time profiles of total MS-275 (ng/ml) (closed circle) 
and unbound MS-275 (ng/ml) (open circle) in plasma (panel A) and the fraction 
unbound MS-275 in plasma versus time profiles (panel B).  
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3.4 Discussion 
 In the present study we have described the in-vitro and ex vivo plasma protein 
binding of MS-275, an investigational histone-deacetylase inhibitor. The binding of MS-
275 to human plasma was approximately 81% and independent of drug concentration 
over the presumed clinically relevant range. When binding studies were extended to 
individual plasma proteins, it was found that AAG and human serum albumin contributed 
to about an equal extent to drug binding, with an association constant for nonspecific, 
nonsaturable binding of 0.116 µM-1 and 0.0247 µM-1 for AAG and albumin, respectively. 
There was a slight increase in value of fu obtained from healthy volunteer plasma 
compared to plasma from six cancer patients. Even though this difference was not 
statistically significant, the decrease in overall fu may be due to the plasma protein level 
changes that occur in cancer patients, including decreased albumin 238 and increased 
AAG 239. 
In cancer patients, AAG concentrations vary approximately 5-fold between 
patients, and these variations may contribute to differences in protein binding and 
systemic drug clearance.240 Albumin levels are lower in most cancer patient population 
due to adverse effects from chemotherapeutic regimen. AAG has been identified as a 
significant predictor of clearance of certain drugs (e.g. docetaxel), with high AAG levels 
being associated with reduced clearance. 241 Plasma binding of certain drugs may be 
further influenced by the presence of its formulation vehicles, such that there is an 
increase in its unbound fraction.242 This time-dependent change in unbound fraction may 
result in unwanted toxicity if there is a correlation between exposure to unbound drug and 
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dose-limiting toxicities. In case of MS-275, because it is only moderately bound, there 
will be minor influence of plasma protein binding on pharmacokinetic profile.  
 Since treatment with MS-275 commonly involves numerous other drugs, 
interactions of bound MS-275 by these agents might occur, particularly in view of the 
relatively weak associations with its main binding proteins, AAG and albumin. The effect 
of 19 potentially co-administered drugs with MS-275 on its binding to plasma was 
performed with the maximum reported clinical concentrations of these drugs. It was 
found that only ibuprofen and metoclopramide at relevant clinical concentrations, 
significantly increased fu of MS-275.  Previous investigations have shown that albumin is 
the major binding protein in plasma for ibuprofen 243. Furthermore, statistically 
significant interactions involving displacement of drugs from binding sites on albumin by 
ibuprofen have been described for various drugs 244. However, based on theoretical 
considerations outlined in detail elsewhere 245, it is unlikely that changes in the protein 
binding of MS-275 as a result of co-administration of ibuprofen in-vivo will significantly 
influence the systemic exposure to MS-275. Nonetheless, since preliminary data seem to 
indicate that MS-275 might have a rather narrow therapeutic concentration range 236, the 
combined use of MS-275 with high doses of ibuprofen should be carefully monitored. 
The increase in fu in the presence of metoclopramide is less well understood. The main 
binding protein for metoclopramide in human plasma is AAG 246, but its affinity is less 
than that of UCN-01 247, which does not substantially interfere with the binding 
properties of MS-275. Given the structural similarities of metoclopramide and MS-275, it 
is possible that the observed interaction involves competition for the same site on an as 
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yet unidentified plasma protein. The other tested agents had no substantial influence on 
the binding of MS-275, even at relatively high concentrations, and are thus unlikely to 
modulate the pharmacokinetic profile of MS-275 in-vivo. 
 The present study demonstrated a striking species-dependence of plasma protein 
binding of MS-275. There was a remarkable two-fold difference in plasma protein 
binding of MS-275 to human plasma as compared to plasma from a variety of other 
species that are commonly used for pre-clinical studies.  The reasons for the large 
differences in binding of MS-275 between the test species are currently unknown, 
although one possibility is species-dependent binding of MS-275 to AAG, as has been 
described previously for various xenobiotic ligands 248, including the staurosporine 
analogue UCN-01 247. Regardless of the underlying mechanism, this species dependent 
binding of MS-275 should be taken in consideration when attempting to extrapolate data 
obtained in tumor-bearing animals to the clinical situation. Because only unbound drug is 
involved in distribution and systemic elimination 234, the differential binding of MS-275 
might explain, at least in part, the relatively slow apparent oral clearance and the long 
terminal half-life of observed in humans (~50 hours) 236, in comparison with the 
laboratory animals (mice 1.1 h, rats 2.1 h, dogs <1 h) (Schering AG, data on file).  
 There was moderate inter-individual variability in unbound MS-275 
pharmacokinetic parameters at the dose level tested, with a relatively lower variability for 
the apparent oral clearance, which suggests that the inter-individual variation in plasma 
protein binding of MS-275 is relatively small in metabolically normal individuals. 
Consistent with the in-vitro data, almost 80% of drug was bound within the circulation 
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without any trend over time. Therefore, protein binding does not seem to be an important 
factor in pharmacokinetic monitoring for MS-275 in cancer patients, and that the more 
easily measured total MS-275 concentrations provide a consistent and accurate reflection 
of the unbound concentrations with relatively lower interpatient variability (i.e., the 
binding is concentration independent and reversible). 
  
3.5 Conclusions 
 In conclusion, a reliable and reproducible equilibrium dialysis method for the 
determination of the fraction unbound MS-275 in plasma was developed and validated. 
MS-275 was found to bind with a moderate degree of affinity to several human plasma 
proteins, including AAG and albumin. This clearly signifies the importance to account 
for differences in the fraction unbound drug when attempting to extrapolate data obtained 
in in-vitro model systems in protein-free media to the clinical situation. The plasma 
binding of MS-275 was also found to be significantly species-dependent. Indeed, whereas 
in humans the major fraction of the administered drug is sequestered by AAG and 
albumin, thereby restricting the unbound concentration and affecting distribution and 
elimination pathways, in the other test species binding of MS-275 to plasma proteins was 
relatively insignificant. This not only provides a mechanistic explanation for the observed 
species differences in pharmacokinetic parameters of MS-275 noted previously, but also 
suggests that interspecies relationships between drug exposure measures and 
pharmacodynamic outcome of treatment should be based on unbound MS-275 
concentrations.
 
 
CHAPTER 4 
 
 
In-vitro Characterization of Absorption and Elimination Pathways of MS-275 
 
4.1 Introduction 
Interindividual variability in MS-275 pharmacokinetics, toxicity and response is 
extensive, and largely unexplained. We hypothesized that this is due to affinity of MS-
275 for an uptake transporter that indirectly regulates elimination pathways. Here, we 
studied accumulation of [3H] MS-275 in Xenopus laevis oocytes injected with cRNA of 
the liver-specific organic anion transporting polypeptide (OATP) family members 
OATP1B1 (OATP2) or OATP1B3 (OATP8).   
Based on our data from similar experiments with paclitaxel, it was found that 
paclitaxel transport by OATP1B1 expressing oocytes was not significantly different from 
that of controls, whereas uptake by OATP1B3 was 3.25-fold higher (P<0.0001). 
OATP1B3-mediated paclitaxel transport was saturable (Michaelis-Menten constant, 6.79 
µM), time-dependent, and highly sensitive to chemical inhibition. Furthermore, uptake 
was inhibited by the formulation excipient Cremophor EL (74.4% inhibition, P<0.0001, 
concentration = 10 µl/ml = 15 v/v), cyclosporin A (25.2%, P=0.005), glycyrrhizic acid 
(24.6%, P=0.012), and hyperforin (28.4%, P=0.003) at their clinically relevant 
concentrations. These data indicated that OATP1B3 is a key regulator of hepatic uptake, 
and suggested that this transporter has a role in the variable response to paclitaxel 
treatment.    
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Similar to paclitaxel, substantial interindividual differences in MS-275 
pharmacokinetics, toxicity and response have been observed. However, the reasons for 
this variability are not well understood, but can be hypothesized to be due to disposition 
profile of MS-275. MS-275 is a novel compound under clinical development, and 
currently there are no published data in literature about metabolic pathways. The initial 
hypothesis is that MS-275 will be a substrate to hepatic CYP450 enzymes that play a role 
in metabolism and elimination of approximately 70% of drugs. It is increasingly 
recognized that drug disposition is highly dependent on the interplay between drug 
metabolizing enzymes and transporters 249.  There is a possibility that MS-275 is a 
substrate of the efflux transporters such as ABCB1 (P-glycoprotein) and/or ABCG2 
(MDR1), and the mechanisms by which MS-275 may be taken up into hepatocytes also 
remain unknown.  
Members of the organic anion transporting polypeptide (OATP) family mediate 
the cellular uptake of a large number of structurally diverse endogenous compounds and 
xenobiotics 250, 251.  The expression of OATP1B1 (formerly OATP2, OATP-C or LST-1) 
and OATP1B3 (formerly OATP8 or LST-2) is restricted to the basolateral membrane of 
hepatocytes 252, 253.  Consequently, these transporters facilitate the hepatocellular 
accumulation of compounds prior to metabolism and biliary secretion, and thus are likely 
to play an important role in governing drug disposition. Genetic polymorphisms in 
several members of the OATP family have been described 251, and there is accumulating 
evidence that these can result in interindividual variability in the pharmacokinetics of 
certain substrate drugs 254-256.   
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 Hepatic phase I metabolic studies were performed using incubations with human 
liver microsomes, Tris Buffer, MgCl2 and NADPH generating system. Both heat-
inactivated microsomes and microsomes without NADPH generating system were used 
as negative controls. Incubations were terminated with the addition of acetonitrile and the 
supernatant was removed and evaporated to dryness and reconstituted samples were 
analyzed using the validated LC-MS assay.  
Hepatic phase II metabolism for glucuronidation was also studied using an 
incubation of human liver microsomes with MS-275 (at different concentrations) along 
with UDPGA, magnesium chloride, 1-4 saccharolactone, alamethicin and Tris buffer. 
The urinary excretion data, if available, will be used to determine the ‘total’ MS-275 
excreted in urine and the glucuronidated MS-275 which will be obtained by subtracting 
the amount of ‘parent’ compound from the ‘total’ MS-275 amount. 
Based on the data available from the clinical trial on patients taking MS-275 on a 
biweekly schedule, a more-than proportional increase in mean or median peak 
concentrations (Cmax) with increasing dose, particularly at higher dose level was noticed 
(Appendix Figures 4.5 and 4.6). This may, in part, be due to the lower cohort size (n=3 
patients) at these dose levels which may have increased the observed variability. 
Alternatively, there is a possibility that MS-275 may be a substrate for gastrointestinal 
efflux transporters such as P-glycoprotein (P-gp, ABCB1) or multi-drug resistance 
proteins such as ABCG2 (MDR1), commonly present in intestinal membranes. If MS-
275 were a substrate, then at higher dose levels, it may be saturate these transporters and 
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hence peak concentrations measured in plasma compartment would increase more than 
proportional with dose.  
ABCB1 (P-gp) as well as ABCG2 are the most prominent efflux transporters in 
the human intestine.257 It is widely recognized that most compounds that are substrates of 
P-gp are also known to be metabolized by CYP3A4 (except for digoxin, fexofenadine, 
and possibly topotecan).258-260 We have shown that MS-275 is not metabolized by 
CYP3A4 (from phase I experiments) and hence MS-275 may not be a substrate or an 
inhibitor of this transporter. This, of course, does not rule out possible role of other 
intestinal uptake and absorption transporters. Also, based on the new Biopharmaceutics 
Drug Disposition Classification System, MS-275 can be considered to fall under Class 3 
compounds (high solubility, low permeability) and thus, absorptive transporter effects 
may predominate as compared to efflux transporter effects.261 Also, the amount of drug 
administered as a single dose may not be high enough to saturate such transporters. To 
confirm the hypothesis of such substrate specificity, cellular accumulation experiments 
were performed using cell-lines transfected with genes that will specifically express P-gp 
or ABCG2.  
 
4.2 Materials and methods 
4.2.1 In-vitro uptake studies 
Uptake of MS-275 was studied using Xenopus laevis oocytes specifically 
expressing human liver organic anion transporting proteins (OATPs). Xenopus laevis 
oocytes injected with water, OATP1B1 or OATP1B3 cRNA were purchased from BD 
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Biosciences (Woburn, MA). Studies were performed in sodium buffer containing 10 mM 
HEPES/Tris, 100 mM NaCl, 1 mM MgCl2, 2 mM KCl and 1 mM CaCl2, adjusted to pH 
7.4 (BD Biosciences).  [3H]Paclitaxel (5 Ci/mmol), which was used as a positive control 
was obtained from Moravek Biochemicals Inc., (Brea, CA).  The oocytes were washed 
and 8 to 12 were incubated at room temperature in 100 µL buffer containing 1µM of [G-
3H] MS-275 (Schering AG, Germany; purity, >99%) and 20 nM paclitaxel (final ethanol 
concentration 1%).  After 90 minutes, the oocytes were washed four times with 3 ml of 
ice-cold buffer.  The oocytes were then placed in individual scintillation vials and lysed 
by the addition of 150 µL 10% SDS (BD Biosciences) and agitation for 10 minutes.  
Following the addition of 5 ml scintillation fluid, radioactivity was measured using a LS 
6000IC scintillation counter (Beckman Coulter, Inc. Fullerton, CA).  Data represent the 
mean uptake and are presented as percent of control with error bars showing standard 
deviation.  A two-tailed unpaired Student’s t test was used to compare means.  The 
uptake of [G-3H] MS-275 and [3H] paclitaxel is expressed as a percentage relative to 
uptake in the water-injected controls. 
 
4.2.2 In-vitro phase I hepatic metabolism studies 
Cytochrome P450-mediated metabolism of MS-275 was evaluated using human 
liver microsomes obtained from Xenotech (Lenexa, KS). Experiments were performed 
using 1 mg/ml of protein with incubations at 37°C in a Tris-HCl buffer (100 mM, pH 7.4) 
containing magnesium chloride (4 mM), and an NADPH-generating system consisting of 
500 µL of NADP+ (10 mM), 30 µL of glucose-6-phosphate dehydrogenase (1300 U/mL), 
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1000 µL of  D-glucuose-6-phosphate (0.1 M), 870 µL of distilled water, and 100 µL of 
magnesium chloride (1 M). Heat-inactivated microsomes and microsomal incubations in 
the absence of the NADPH-generating system were used as negative controls (Table 4.1 
A & B).  
 
Table 4.1 Reaction mixture and details for hepatic phase I metabolism using 
human liver microsomes 
(A) 
 
Name Buffer (µl) 
Enzyme
(µl) 
NADPH
(µl) 
Drug 
(µl) 
Control 
(µl) 
Sample 
(µl) 
Tris Buffer + 
MgCl2 (24:1) 
50 0 0 0 50 50 
Enzyme 0 25 0 0 25 25 
Drug 0 0 0 5 5 5 
NADPH GS 0 0 100 0 0 100 
Water 450 475 400 495 420 320 
Total 500 500 500 500 500 500 
 
 (B) 
 
Name Original Conc. Final Conc. 
Tris buffer 1 M 100 mM 
MgCl2 (24:1) 1 M 4 mM 
Enzyme 20 mg/ml 1 mg/ml 
Drug 5 mg/ml (13.25 mM) 
0.05 mg/ml 
(132.5 µM) 
NADPH GS 10 mM 2 mM 
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Incubations were terminated with the addition of (twice the reaction volume) 
acetonitrile. After centrifuging the reaction mixture, the supernatant was removed and 
evaporated to dryness under desiccated air at 40°C in a Zymark Turbo Vap LV 
evaporator (Hopkinton, MA). Samples were reconstituted in mobile phase and analyzed 
by liquid chromatography-mass spectrometry as described previously 237. Peak areas 
were quantified to determine loss of the parent compound. The assay was also modified 
by changing mobile phase and enabling UV detection at 205nm and 230nm for 
identification and quantitation of potential metabolite peaks. 2-methoxyestradiol (2ME2), 
an analogue of estradiol, which has been shown to be metabolized in hepatic microsomal 
system, was used as a positive control. Once the metabolite/s is/are detected, isozyme 
identification would be done using individual CYP450 enzymes to identify the specific 
enzymes subtypes involved in metabolism.  
 
4.2.3 In-vitro hepatic phase II metabolism studies 
Hepatic phase II metabolism for glucuronidation was studied by a two-fold 
approach; measuring decrease in parent peak (and formation of metabolites) using 
UDPGA and by measuring increase in parent peak after enzyme digestion using B-
glucuronidase. First, glucuronidation was studied by measuring a decrease in parent peak 
area related to concentration of MS-275, using human liver microsomes and UDPGA. 
For identification of potential metabolites, the analytical method was modified to use 
gradient elution and also detect peaks at UV wavelengths of 205nm and 230nm. Similar 
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experimental conditions as described for phase I studies were used for characterizing 
phase II metabolic pathway of MS-275. Pooled human liver microsomes were used as a 
source of uridyl glucuronyl transferases (UGTs) and uridine diphosphate glucuronic acid 
(UDPGA) was added to the reaction mixture as a cofactor. Alamethicin, which acts as a 
detergent to make the cellular membrane porous for better transport of cofactors as well 
as 1-4 saccharolactone, which diminishes β-glucuronidase activity were added (Table 
4.2). As a positive control, the phase II conjugation of 2-methoxyestradiol was assessed 
to verify glucuronidation activity.  
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Table 4.2 Reaction mixture and details for hepatic phase II metabolism using 
human liver microsomes 
(A) 
 
Name Matrix(µl) 
Drug 
(µl) 
Control
(µl) 
Sample 
(µl) 
Tris Buffer + 
MgCl2 (24:1) 
50 0 50 50 
Enzyme 25 0 25 25 
Drug 0 5 5 5 
UDPGA 0 0 0 25 
Alamethicin 12.5 0 0 12.5 
Saccharolactone 25 0 25 25 
Water 385.8 495 380.5 355.5 
Total 500 500 500 500 
 
 
 
(B) 
 
Name Original Conc. Final Conc. 
Tris buffer 1 M 100 mM 
MgCl2 (24:1) 1 M 4 mM 
Enzyme 20 mg/ml 1 mg/ml 
Drug 5 mg/ml  (13.25 mM) 
0.05 mg/ml 
(132.5 µM) 
Alamethicin 2 mg/ml 50 µg/ml 
Saccharolactone 100 mM 5 mM 
UDPGA 100 mM 5 mM 
 
 
 
With the second approach, 0.1 ml plasma samples from three patients at time-
points where peak concentration were observed earlier, were treated with 200 units β-
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glucuronidase enzyme for 2 hours at 37 0C. The main stock of β-glucuronidase (105,000 
units/ml) was diluted such that a working stock with 200 units/20 µl can be used for the 
experiments. The increase in peak area of parent compound was measured using UV and 
LC-MS detections. The amount of glucuronidation can then be quantified by taking a 
ratio of increase in total MS-275 concentration and the parent concentration.  
All incubations were terminated with the addition of acetonitrile. After 
centrifuging the reaction mixture, the supernatant was removed and evaporated to dryness 
under desiccated air at 40°C in a Zymark Turbo Vap LV evaporator (Hopkinton, MA). 
Samples were reconstituted in mobile phase and analyzed by liquid chromatography-
mass spectrometry as described previously.237 The ultraviolet (UV) spectrum at 205 nm 
was also recorded in order to further evaluate the presence of potential metabolites. 
Moreover, the chromatographic run-time was extended to 20 minutes, and a gradient 
elution was used in order to allow for slow eluting potential metabolites to be detected. 
 
4.2.4 Preliminary urinary excretion information 
In an effort to identify potential in-vivo glucuronidated metabolites in urine and 
the role of renal elimination, MS-275 concentration was measured in three patient urine 
samples, who received 2 mg/m2 dose of MS-275. Calibration samples containing MS-275 
were prepared by addition of aliquots of the working solutions to drug-free human urine. 
Calibration standards were prepared within the concentration range of 1 ng/mL to 1 
µg/mL. The urine matrix had less interferences compared to plasma and the LC-MS 
method as described in Chapter 2 was modified and used for analysis.  
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Urine analysis for MS-275 was performed in three patients (24-hour urine, known 
volume), and fraction excreted unchanged in urine was estimated. Also, urine samples 
were digested with ß-glucuronidase (similar experimental conditions and conc. of 
enzyme as used for plasma experiments, see Chapter 2) and final concentrations were 
compared to look for an increase in parent compound concentration.  
 
4.2.5 Cellular accumulation experiments to determine substrate specificity to efflux 
transporters 
Human embryonic kidney (HEK-293) cells were transfected with either the empty 
vector (PC) (control), ABCG2 expressing (R2) or P-gp expressing (MDR-19) gene and 
were cultured and harvested and made available to us (courtesy of  Dr. Bates, NCI). In 
preparing the cell monolayers, 2 mL of a cell suspension containing at least 1 x 106 cells 
in EMEM with 10% FCS was seeded in six-well tissue culture plates. 90% confluent 
cells were used for the experiment. On the day of experiment, cells were washed once 
with Hank’s balanced salt solution (HBSS) (containing 10 mM HEPES buffer, pH 7.4), 
which is called transport buffer. 2 mL of transport buffer containing trace [G-3H]MS-275 
(0.5 µCi/ml) at a final concentrations of 30 nM and 300 nM (clinically relevant range) 
were added to each well. [G-3H]Docetaxel was used as a positive control.262, 263 The cells 
were incubated in drug containing transport medium for 2 h, after which the reaction was 
terminated by removing the medium and rinsed twice with 5 mL ice-cold transport 
buffer. Cells were lysed in 0.5 mL of 1 N NaOH, neutralized with 0.25 mL of 2 N HCl, 
and transferred to scintillation vials. 5 mL of scintillation cocktail was added to each vial, 
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and the total radioactivity was measured by liquid scintillation counter. All samples were 
done in triplicate. The cellular accumulation of radiolabelled drug was determined and 
amount of cellular uptake is presented as % change of control. A decrease in amount 
taken up would suggest active efflux transporter activity and substrate specificity.  
In a separate experiment under similar conditions, cells were divided based on 
volume (approximately 500000/vial) and then treated with equal amount of radiolabelled 
drug in transport buffer. The cells were lysed as described above and were counted and 
results expressed as % change of control. 
 
4.3 Results 
4.3.1 General experimental optimizations 
Preliminary experiments focused on determining the need to use an NADPH-
generating system using glucose-6-phosphate (G6P) and glucose-6-phosphate 
dehydrogenase (G6PDH) using nicotine adenine dinucleotide phosphate (NADP+) as a 
cofactor versus simply using readily available NADPH (Sigma). The results were 
confirmed to be better when the generating system was used and hence for all phase I 
metabolism experiments, the NADPH generating system was prepared fresh for use 
(Table 4.3). 
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Table 4.3 Preparation of NADPH-generating system 
 
Name Mixture (µl) 
Original 
Conc. Stock solution 
NADP+ 500 10 mM 7.65 mg/ml 
G6PDH 30 100 units 32 mg/ml 
G6P 1000 100 mM 34 mg/ml 
MgCl2 100 1 M 95.2 mg/ml 
Water 900   
Total 2530   
 
 
Initial experiments focused on optimization of various parameters. Ideal substrate 
concentration for MS-275 was selected at 132.5 µM (= 50 µg/ml) after testing 5.3, 10.6, 
15.9, 21.2, 26.5, 53, 106, 159, 212 and 265 µM. For MS-275, 1 mg/ml converts to 
approximately 2.65 mM. Incubation time was selected to be 90 minutes after testing 0, 
15, 30, 45, 60, 75, 90 and 120 minutes. Human liver microsome enzyme concentration 
was selected to be at 1 mg/ml after testing for 0.5, 1 and 2 mg/ml. NADPH concentration 
was selected to be at 2 mM after testing 0.5, 1 and 2 mM. These set of conditions were 
kept constant for most other experiments. 
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4.3.2 In-vitro uptake and transport  
 Accumulation of [G-3H] MS-275 by oocytes expressing OATP1B1 or OATP1B3 
was not significantly different from that by water-injected controls (p = 0.82). Water-
injected oocytes were used as a control for non-specific uptake and binding of MS-275 
and paclitaxel. The uptake of [G-3H] MS-275 and [G-3H] paclitaxel by oocytes injected 
with OATP1B1 cRNA was measured and was found to be not significantly different from 
that by water injected oocytes. However, OATP1B3 expressing oocytes accumulated [G-
3H] paclitaxel 3.25-fold over controls (p < 0.0001, unpaired Student’s t test), but not [G-
3H] MS-275 (Figure 4.1). This suggests that MS-275 is not a (high-affinity) substrate for 
the two main liver-specific isoforms of the family of organic anion transporting 
polypeptides, and is not supportive of active, transporter-mediated uptake of MS-275 into 
hepatocytes.  
 
 106
 
Paclitaxel MS-275 
400.00 
300.00 Uptake  
200.00 
(% control) 
100.00 
0.00 
OATP1B3 Water-injected OATP1B1
 
Figure 4.1 Uptake of radiolabelled MS-275 and paclitaxel into OATP expressing 
oocytes 
 
4.3.3 In-vitro phase I metabolism 
There was no apparent loss in parent compound concentration after incubations of 
MS-275 with human liver microsomes under the various conditions applied when 
assessed by LC-MS detection (Figure 4.2). The UV spectra of reaction mixture incubated 
with MS-275 at various concentrations in the clinically relevant range also did not show 
any evidence of oxidated metabolite(s) of MS-275 (Figure 4.3). These experiments were 
repeated several times in order to discount experimental errors. These results are 
consistent with the notion that hepatic phase I metabolism is a minor pathway of 
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elimination for MS-275, and likely does not contribute substantially to explaining inter-
individual pharmacokinetic variability of MS-275. 
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Figure 4.2 LC-MS chromatogram for phase I hepatic metabolism comparing 
control and sample 
 108
UV comparison of control and sample
-1500
-1000
-500
0
500
1000
1500
0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0
Time (min)
A
bu
nd
an
ce
Control
Sample
 
Figure 4.3 UV chromatogram for phase I hepatic metabolism comparing control 
and sample 
 
4.3.4 In-vitro hepatic phase II metabolism 
There was no apparent loss in parent compound concentration after incubations of 
MS-275 with human liver microsomes under the various conditions applied when 
assessed by UV and LC-MS detection. When patient plasma samples were digested with 
β-glucuronidase enzyme, there was no increase in parent peak area or total MS-275 
concentration. This indicated that glucuronidation mediated by UDP 
glucuronosyltransferase mediated conjugation is not a preferred elimination pathway 
either. A potential drawback of using such an approach is that sensitivity of the assay 
may limit detecting very low levels glucuronidase-free MS-275 and that lower % change 
in peak concentrations may not be quantified accurately. These results taken together do 
not contribute substantially in explaining interindividual pharmacokinetic variability of 
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MS-275 and hence, additional experiments using cDNA expressed drug metabolizing 
enzymes were not considered. 
 
4.3.5 Preliminary urinary excretion data 
Table 4.4 Preliminary data from urine analysis from 3 patients taking MS-275 
on 2 mg/m2 dose level  
Patient 
Urine 
Matrix 
volume 
(µl) 
β-
glucuronid
ase (µl) 
Final 
reaction 
volume 
MS-275 
Conc. 
(ng/ml) 
Volume 
(ml) 
(after 24h) 
Amount 
excreted  
(µg) 
1 100 0 100 12.0 1820 21.92 
2 100 0 100 8.8 2250 19.66 
3 100 0 100 20.5 1150 23.56 
DU1* 80 20 100 9.5   
DU2* 80 20 100 10.5   
DU3* 80 20 100 18.1   
 
 * Digested urine samples from individual patients 
 
As shown in Table 4.4, the results indicate that approximately 21.7 (±1.9) µg 
(overall mean) is excreted in urine. All patients (U) were at dose level 2 mg/m2, who 
received an actual dose of 4 mg. Hence, approximately 0.5% of drug is excreted 
unchanged in urine. This suggests that renal elimination may not be a major pathway of 
elimination and/or MS-275 has poor oral bioavailability. Also, the ß-glucuronidase 
treated urine samples did not show any significant increase in parent MS-275 
concentration, suggesting lack of presence of glucuronidated metabolites in urine.  
 
4.3.6 Substrate specificity for efflux transporters 
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Figure 4.4 Substrate specificity of MS-275 to efflux transporters P-gp and 
ABCG2 
 
Although there was some level of affinity seen for P-gp, expressed by lower % 
control uptake relative to P-gp-negative control, the difference was not statistically 
significant (p=0.23). There was higher variability at lower concentration for both P-gp 
and ABCG2 expressing cells treated with MS-275. At both the tested concentrations of 
30nM and 300nM, MS-275 cannot be confirmed to be a substrate for neither P-gp nor 
ABCG2 efflux transporters. Under the same experimental conditions, docetaxel showed 
almost 3-fold stronger affinity towards P-gp compared to MS-275. These results were 
confirmed by both approaches described above. In conclusion, the variability in peak 
concentrations observed at higher dose levels cannot be correlated to inhibition of efflux 
proteins. 
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Even though the in-vitro transporter experiments incorporate the currently 
available strategy, there are potential pitfalls of using such approach for in-vivo 
predictions. For example, the concentrations selected in these experiments were based on 
a low and a high of the peak plasma concentration observed in humans. However, the 
differences in concentration of the drug in the gut to those used in in-vitro experiments 
may pose hinderences with accurately identifying extent of inhibition of the transporter. 
Also, the number and amount of transporter activity based on phenotypic differences in 
individuals varies and thus transporter efficiencies will be different. Although limited in a 
sense, these experiments provide some initial insight into substrate specificities of MS-
275, but further experiments remain to be done in order to confirm these observations. 
 
4.4 Discussion 
The various processes mediating drug absorption and elimination, either through 
metabolic breakdown or active transepithelial secretion, are likely to impact substantially 
on variability in drug handling between individuals. For some drugs, strategies to 
individualize administration schedules based on patient differences in enzyme or protein 
expression or by co-administration of specific agents modulating side effects are being 
explored, which may ultimately lead to more selective chemotherapeutic use of those 
agents. The OATPs mediate the cellular uptake of a large number of structurally diverse 
endogenous compounds and xenobiotics 251. Expression of two members of this family, 
namely OATP1B1 (formerly OATP-C, OATP2, or LST-1) and OATP1B3 (formerly 
OATP8, or LST-2) is restricted to the liver; due to their localization on the basolateral 
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membrane of hepatocytes, these proteins are likely to indirectly influence the hepatic 
metabolism and outward-directed transport of a wide variety of substrates 264. Based on 
the peculiar concentration-time profile of MS-275 in humans 215, which is characterized 
by a peak concentration observed within 0.5 to 2 hours after drug intake, and which is 
followed by a very rapid decay in circulating concentrations, we speculated that MS-275 
may be taken up actively into hepatocytes after gastrointestinal absorption and 
subsequently eliminated through hepatobiliary routes. In contrast, the in-vitro studies 
performed using Xenopus laevis oocytes expressing either OATP1B1 or OATP1B3 as a 
model system did not demonstrate any significant affinity of MS-275 for the liver-
specific OATPs.  
Cytochrome P450-mediated metabolism was also found not to be a major 
elimination pathway for MS-275, as evaluated using human liver microsomal 
preparations. This is not entirely surprising in view of prior work on similar agents that 
contain a benzamide moiety 265. It is of note that the metabolism studies are somewhat 
limited by the fact that the rate of disappearance of the parent compound was assessed 
rather than the more analytically sensitive rate of formation of an unknown metabolite. 
However, it is unlikely that cytochrome P450-mediated oxidation is clinically relevant 
since no changes in the UV chromatogram were noted and hence, the primary pathways 
of elimination for MS-275 remain to be elucidated.  
Based on above analysis, it cannot be entirely ruled out that MS-275 is sensitive 
to esterase-mediated cleavage and/or is conjugated by phase II enzymes. Indeed, 
consideration of the chemical structure of the drug suggests the potential for glucuronic 
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acid type of conjugation. Furthermore, the plasma concentration-time profile of MS-275 
in several patients indicated the presence of a secondary peak, which is suggestive of 
enterohepatic circulation of the drug. Enterohepatic circulation is most commonly 
associated with the hydrolysis of drug secreted in the bile as a glucuronide conjugate by 
enzymatic activity originating from gastrointestinal microflora, followed by reabsorption 
of the liberated parent compound in the lower gastrointestinal tract. In contrast, no 
evidence for formation of glucuronic-acid conjugates of MS-275 was noted in our in-
vitro experiments. The lack of any identifiable metabolite in these in-vitro studies does 
not necessarily mean that there are none in-vivo. However, under the experimental 
conditions applied, the contribution of metabolism to overall drug elimination is likely to 
be sufficiently small to conclude that this process does not cause a substantial 
interindividual difference in MS-275 pharmacokinetics. 
4.5 Conclusion 
In conclusion, these findings indicate that MS-275 is not a substrate for 
OATP1B1 and OATP1B3, and that inhibition of uptake by this transporter will not result 
in a clinically important, previously unrecognized type of pharmacokinetic interaction. 
Furthermore, hepatic phase I or phase II pathways do not seem to be relevant elimination 
routes for MS-275. The variability in MS-275 absorption noticed at higher dose levels is 
not an effect of inhibition of efflux transporters like P-gp or ABCG2. Future studies 
should focus on identifying possibilities of protease or esterase mediated cleavage of MS-
275.  
 CHAPTER 5 
 
Phase I Clinical Trial of Oral MS-275, in Patients with Advanced and Refractory 
Solid Tumors or Lymphoma 
 
5.1 Introduction 
 Based on the promising preclinical data, a phase 1 trial of MS-275 was initially 
designed to use a daily schedule.  This is an open label, single arm, and dose escalation, 
phase 1 study in advanced solid tumor and lymphoma patients.   
Primary objectives of this phase I trial are: 
1) To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) in 
humans of MS-275 orally, initially given daily, once every two weeks, and subsequently 
on a once weekly schedule. 
2) On the weekly schedule, to compare two formulations, one uncoated given in 
conjunction with a meal, and an uncoated formulation administered in the fasted state, 
with respect to toleration and preliminary pharmacology 
3) To characterize the profile of adverse events, including changes in clinical chemistry 
and laboratory parameters. 
3) To study the pharmacology and pharmacokinetics of MS-275. 
4) To use the understanding of MS-275 pharmacology emerging from different schedules 
as a basis for designing possibly more frequent dose administration regimens. 
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Secondary objectives of this phase I trial are: 
1) To look for evidence of antineoplastic activity in MS-275. 
2) To measure the level of acetylation of histones H3 and H4 in peripheral blood 
mononuclear cells before and after MS-275 treatment. 
3) To assess acetylation and specific gene expression in tumors, where readily accessible 
(skin or nodal metastasis). 
a) Acetylation of histones H3 and H4 
b) p21WAF1/CIP1 and gelsolin gene expression by real-time RT-PCR 
This is an open labeled single armed Phase I study of MS-275.  As described 
before, MS-275 treatment produced DLT to the bone marrow (leucopenia and 
thrombocytopenia) and to the gastrointestinal systems in mice, rats, and dogs.  Dose 
limiting toxicities were revealed early in the conduct of the daily schedule. Therefore, we 
focused our attention on a q14 day schedule without change of objectives. 
 
5.2 Patients and Methods 
5.2.1 Patient inclusion and exclusion criteria 
 Patients were eligible for this trial if they met the following criteria: Patients must 
have (1) a pathologically confirmed malignancy that is metastatic or unresectable, and for 
which standard curative or palliative measures do not exist or would likely not be 
effective; (2) an ECOG performance status <2, with no recent (within 2 months) weight 
loss of >10% of average body weight; (3) Life expectancy greater than 3 months; (4) age 
> 18 years;  (5) leukocytes >3000/µl, absolute neutrophil count >1500/µl, platelets 
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>100,000/µl, creatinine within normal limits or measured creatinine clearance > 60 
ml/min/1.73m2, total bilirubin <1.5 x upper limit of normal, AST /ALT  <2.5 x upper 
limit of normal, adequate oral intake and serum albumin > 75% of lower limit normal; 
and (6) is able to give written consent,  is willing to self administer and document the 
doses of MS 275 as needed, and is able to return to NCI for follow-up.   
The following patients were excluded from the study: (1) those who had received 
prior anticancer therapy (chemotherapy, radiotherapy, vaccines and hormone therapy 
with the exception of GnRH agonists) within 4 weeks of study entry (6 weeks for 
nitrosoureas or mitomycin C, 8 weeks for UCN-01), or those who have not recovered 
from adverse events (reduced to grade 2 or less) due to agents administered more than 4 
weeks earlier; (2) with known brain metastases; (3) history of allergic reactions attributed 
to compounds of similar chemical or biologic composition to MS-275; (4) uncontrolled 
intercurrent illness; (5) pregnant or lactating women; (6) men and women of reproductive 
potential without adequate contraception; (7) known HIV; (8) gastrointestinal conditions 
that might predispose for drug intolerability or poor drug absorption; and (9) major 
surgery within 21 days of study entry, intercurrent radiation, chemotherapy, 
immunotherapy or hormonal therapy (except for GnRH agonists).   
 This trial has been conducted under an IRB approved protocol of a NCI sponsored 
IND.  The protocol design and conduct has followed all applicable regulations, guidance 
and local policies. 
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5.2.2 Dosage and dose escalation scheme 
 The initial human dosing design was a daily oral schedule for 28 days with an 
intended 14 day recovery period, constituting a 42 day cycle. The drug was administered 
with food, owing to preliminary evidence from animal studies of enhanced bioavailability 
in the fed state at a starting dose of 2 mg/m2 (1/10th rat MTD) and an accelerated dose 
escalation scheme was planned at increments of 100% with single patient per dose level. 
266 Due to unforeseen toxicities observed, the subsequent dosing schedule was changed to 
once orally every 2 weeks (q14 day schedule), constituting an approximately 14 day 
course. The drug administration and starting dose were the same as for the daily schedule, 
with a dose escalation increment of 2 mg/m2, using a modified Fibonacci dose escalation 
scheme (3-6 patient cohorts). No intra-patient dose escalation was undertaken.   
 DLT was defined as 1st course adverse events > grade 3 non-hematologic or > 
grade 4 hematologic toxicity. The MTD was defined as one dose level below the dose at 
which > 2/6 patients experience DLT. Dose reduction by one dose level was applied in 
the q14 day schedule for the occurrence of either grade 3 non-hematological toxicity, 
grade 4 hematological toxicity and persistent (> 2 weeks) grade 2 non-hematological 
toxicity or per the investigator’s assessment. There was no limitation for the number of 
dose reductions allowed.  For dose reduction at dose level 1, 25%, 50%, and 75% 
decrease of starting does was the order of reduction. 
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5.2.3 Safety and efficacy measures 
 At study entry, a history, physical examination, laboratory studies (complete 
blood count, electrolytes, creatinine, BUN, total and direct bilirubin, ALT, AST, alkaline 
phosphatase, uric acid, prothrombin time, partial thromboplastin time, and urinalysis),  
CT scan, CXR and ECG were performed. Clinical assessments including a physical 
examination and adverse event evaluation were conducted at each follow up. Adverse 
events were graded by the NCI Common Toxicity Criteria, version 2.0. The CT scan and 
staging were performed every 6 weeks for the q14 day schedule. Disease specific staging 
techniques, such as bone marrow aspirate and biopsy, flow cytometry, cutaneous lesion 
photography or bone scan, were used as indicated.  Responses were evaluated by the 
RECIST criteria 267 for solid tumors and the Cheson criteria 268 for lymphoma. Due to the 
daily schedule experience, MUGA scans were obtained on the q14 day schedule at base 
line, prior to course 2 and at each re-staging, in addition to ECG.  Laboratory studies 
(CBC with differential, chemistry 20, PT and PTT) were performed at day 1, 3, 5, and 7 
and then repeated weekly for the q14 day schedule. Twenty-four hour urine clearance, 
albumin, protein, uric acid and electrolytes were performed for q14 day schedule at 
baseline, and on days 3 and 13. 
 
5.2.4 Pharmacokinetic studies 
 For pharmacokinetic analysis, 6 ml blood samples were taken on day 1 via an 
intravenous cannula inserted in the forearm prior to administration, at 2, 6, 12, 24, 36, 48, 
60, 72, 84, and 96 hours post-dosing.  Following initial pharmacokinetic evaluation of 
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data obtained from patients treated on the first 2 dose levels, the sampling protocol was 
amended to also include blood collection at 30 minutes and 1 hour. On the first day of 
pharmacokinetic sampling, patients were administered standardized meals immediately 
prior to drug administration. Blood samples were collected in sodium heparin tubes and 
were immediately centrifuged at 3000 g for 10 minutes at 4oC, after which plasma was 
divided into 2 aliquots of at least 1 ml and frozen at –70oC until the time of analysis.  
Plasma samples were assayed by the specific and sensitive high-performance liquid 
chromatographic assay with mass-spectrometric detection. 237  The lower limit of 
quantitation of this assay is 1 ng/mL, with values for precision and accuracy of < 5.58 
and <11.4% relative error, respectively. 
 Estimates of pharmacokinetic parameters for MS-275 were derived from 
individual concentration-time data sets by non-compartmental analysis using the software 
package WinNonlin v4.0 (Pharsight Corporation, Mountain View, CA). The peak plasma 
concentrations and the time to peak concentrations were the observed values. The area 
under the plasma concentration versus time curve (AUC) was calculated using the linear 
trapezoidal method from time zero to the time of the final quantifiable concentration 
(AUC [tf]). The AUC was then extrapolated to infinity (AUC [inf]) by dividing the last 
measured concentration by the rate constant of the terminal phase (k), which was 
determined by linear-regression analysis of the final 3 or 4 time points of the log-linear 
concentration-time plot. The apparent oral clearance of MS-275 (CL/F) was calculated by 
dividing the administered dose by the observed AUC [inf] and the terminal half-life (T1/2) 
was calculated by dividing 0.693 by k. 
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5.2.5 Statistical analysis 
 All pharmacokinetic data are presented as mean + SD except where otherwise 
indicated. Dose proportionality for MS-275 was assessed using a power model (i.e., AUC 
= α x doseβ) where an ideal proportional model corresponds to β = 1 (i.e., to a model of 
the form AUC = α x dose) and with the proportionality constant (α).  Deviations of β 
from 1 correspond to deviations from ideal dose proportionality. Interindividual 
differences in pharmacokinetic parameters were assessed by the coefficient of variation 
(CV), expressed as the ratio of the standard deviation to the observed mean (SD/M). The 
apparent oral clearance and the terminal half-life were analyzed as a function of the MS-
275 dose level using the Kruskal-Wallis’ one-way analysis of ranks, followed by the 
Dunn’s multiple comparison test for identifying statistically significantly different 
groups. Variability in parameter estimates for MS-275 between cohorts of patients that 
did or did not experience DLT was evaluated by a one-sided Mann-Whitney U test for 
differences in medians after testing for normality and heteroscedacsticity. A one way 
ANOVA was performed to compare mean values using two sided Dunnett’s test. 
Statistical calculations were performed using the Number Cruncher Statistical System 
2001 series (NCSS; J. L. Hintze, Kaysville, UT). The cut-off for statistical significance 
was considered at p < 0.05. 
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5.2.6 Pharmacodynamic analysis  
 Immunocytochemical analysis of acetylated histone H3 was performed on 
peripheral blood mononuclear cells (PBMCs) and data was provided to us for further 
analysis. PBMCs were isolated from whole blood by centrifugation on Ficoll-Paque Plus 
(Amersham, Little Chalfont, UK), pelleted onto glass slides by cytocentrifugation, fixed 
in 95% ethanol/5% glacial acetic acid for 1 min at room temperature, permeabilized with 
0.2% Triton X-100 for 10 min at room temperature and nonspecific binding sites were 
blocked by incubating the cells with 1% bovine serum albumin in phosphate-buffered 
saline (PBS) for 1 hr at 4°C.  Slides were incubated with polyclonal anti-acetylated 
histone H3 antibody (Upstate Biotechnology, Lake Placid, N.Y.) for 1 hr at 4°C. Each 
was washed two times for 2 min with PBS, then incubated at 4°C for 1 hr with Cy3-
conjugated goat anti-rabbit immunoglobulin (Molecular Probes, Eugene, OR), and 
washed again with PBS. Finally, the slides were incubated with 4,6-diamidoino-2-
phenylindole (DAPI, Sigma) for 10 min at room temperature, rinsed quickly with water, 
air-dried, mounted using SlowFade (Molecular Probes), and imaged using a Zeiss 
Axiophot microscope interfaced with a CCD camera (Optronics Engineering, Goleta, 
CA).  Positive controls were prepared by exposing healthy donor PBMC to MS-275 in-
vitro.  For this analysis, buffy coats,  provided anonymously as a byproduct of whole 
blood donations from paid healthy volunteer donors through an IRB approved protocol, 
were centrifuged on Ficoll-Paque Plus, mononuclear cells were depleted of monocytes by 
adherence to plastic for 2 hr at 37°C and incubated with MS-275 in-vitro for various 
times and at varying drug concentrations. Cells were then processed for histone 
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hyperacetylation in the same manner as the patient samples.  Images of PBMC stained for 
acetylated histone H3 were imported into the Openlab image analysis program 
(Improvision, Coventry, UK), and of histone acetylation levels were assessed using the 
Openlab quantification software.   
 
5.3 Results 
5.3.1 General 
  The first subject was enrolled on April 5, 2001 and enrollment on the daily 
schedule finished after two patients and twenty-nine patients enrolled on the q14 day 
schedule until July 29, 2003. Of the total 31 enrolled patients, 30 patients received MS-
275 and were evaluable for toxicity.  One patient with melanoma was withdrawn before 
receiving treatment, because she developed bowel obstruction secondary to disease 
progression, requiring immediate surgical intervention.  All patients had received prior 
therapy, 90% had surgical resection of the tumor, 97% had prior chemotherapy, 50% had 
radiotherapy and 50 % had immunotherapy.  Patient demographics are summarized in 
Table 5.1. Patients were heavily pre-treated with a median of three prior therapies.   
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Table 5.1 Patient demographics 
 
Patient characteristics 
Number of patients, 
Mean or 
Median (range) 
Total 31 
Age (years) 57 (36-76) 
Sex, male/female 19 / 12 
ECOG performance status 1 (0-2) 
0 7 
1 21 
2 3 
Tumor type  
Melanoma 6 
Renal cell carcinoma 6 
NSCLC 4 
Sarcoma 4 
Breast 2 
Colorectal 2 
Lymphoma 2 
Cervix 1 
Mesothelioma 1 
Prostate 1 
Small bowel 1 
Thyroid 1 
Number of prior 
chemotherapy 3 (0-20) 
0 1 
1 6 
2 10 
≥ 3 14 
Number of prior 
radiotherapy  
0 16 
1 9 
2 4 
≥ 3 2 
Number of prior 
immunotherapy  
0 16 
1 9 
2 6 
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5.3.2 Dose escalation and dose-limiting toxicity in daily and q14 day schedule 
 The dose escalation experience for both the MS-275 daily and the q14 day 
schedules are summarized in Table 5.2.   
Daily schedule:  Two male patients were enrolled in the daily x 28 schedule at 
dose level of 2 mg/m2.  Both experienced DLT before the completion of the first cycle.   
DLTs observed were abdominal/epigastric pain in one patient, and cardiac arrhythmia 
(SVT), elevated AST/ALT, hypotension, hypoalbuminemia, and hypophosphatemia in 
the second patient.  All adverse events resolved within 2-3 weeks.  Preliminary PK data 
from our initial 2 patients suggested that MS-275 had a substantially longer half-life in 
humans than initially predicted from the animal models.  This may explain the unforeseen 
toxicity observed in these two patients during the daily MS-275 schedule.  Assessment of 
histone H3 and H4 acetylation indicated HDAC inhibition occurred after one dose of 
MS-275.  To ensure study patients’ safety, we amended the dosing schedule to q14 days 
instead of pursuing the MTD on a reduced dose on daily schedule.   
 Q14 day schedule: A total of 28 patients have been treated on the q14 day 
schedule.  As summarized in Table 5.2, the first patients with first course DLTs 
considered to be related to MS-275, anorexia, nausea and vomiting, were observed at 
dose level 3, or 6 mg/m2.  After 5 patients tolerated dose level 4 without DLT, dose 
escalation was continued up to level 5, or 10 mg/m2. One patient experienced similar 
DLTs at level 5 as had been seen at level 3.  At dose level 6 (12 mg/m2), two patients 
experienced similar DLTs (Table 5.2).  Therefore, the DLTs of MS-275 on a q14 day 
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schedule were recognized to include anorexia, nausea, vomiting and fatigue. We thus 
determined the MTD and RP2D of MS-275 for a q14 day schedule to be 10 mg/m2.    
  First course adverse events observed, either probably or possibly related or 
unrelated to the MS-275 (based on the investigators assessment) are summarized in Table 
5.3.  There were no grade 4 adverse events probably or possibly related to MS-275 
observed during the first course. The only first course grade 4 adverse event (dyspnea) 
observed during the study, which occurred at dose level 6 (12 mg/m2), was considered 
unrelated to the MS-275 and likely due to progression of metastatic mesothelioma. 
MS275-induced fatigue, anorexia, nausea, and vomiting were observed as early as dose 
level 1 (2 mg/m2), but were all tolerable. With dose escalation, intensity of these 
toxicities gradually increased.  Other less frequent possible toxicities included taste 
change, headache, diarrhea, flatulence, bloating and reflux symptoms. Hematologic 
toxicities, such as thrombocytopenia and neutropenia became more apparent at these 
higher dose levels (Table 5.3).  Anemia was frequently noticed during the first course and 
was thought to be induced by the frequent PK and laboratory sampling and not related to 
MS-275. 
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Table 5.2 Schedule, dose level and dose administration of MS-275 
 
 
Dose level 
and 
schedule 
Dose 
(mg/m2) 
Enrolled 
patient 
No. 
Total number 
of courses 
(treated 
patients) 
No. of patients 
with 1st course 
DLT 
DLTs 
 
QD x 28/42 
day 1 
 
2 
 
2 
 
2* 
 
2 
 
See text
Q 14 days 
1 
2 
3 
4 
5 
6 
 
2 
4 
6 
8 
10 
12 
 
3 
3 
6 
5 
6 
5 
 
22 (4) 
16 (4) 
51 (8) 
22 (9) 
30 (8) 
16 (5) 
 
0 
0 
1 
0 
1 
2 
 
0 
0 
3** 
0 
3** 
7*** 
 
* Due to dose limiting toxicity, the treatment was terminated before the completion of the 
first course for both patients. 
** Anorexia, nausea, and vomiting  
*** Anorexia, nausea, vomiting, and fatigue 
 
 
Table 5.3 Summary of first-course adverse events probably or possibly related 
to MS-275 at all dose levels (N=28) 
 
Adverse 
Events 
All 
grades 
(%) 
Grade 
3 (%) Adverse Events 
All 
grades 
(%) 
Grade 
3 (%) 
Cardiovascular Hematological 
Sinus 
Tachycardia 1 (3) 0 Anemia 8 (29) 0 
Gastrointestinal Leucopenia 6 (21) 0 
Anorexia 10 (36) 4 Lymphopenia 5 (18) 0 
Constipation 2 (7) 0 Neutropenia 7 (25) 0 
Diarrhea 2 (7) 0 Thrombocytopenia 10 (36) 0 
Dyspepsia 6 (21) 0 Laboratory 
Flatulence 3 (11) 0 Alk Phos 1 (4) 0 
GI Other 2 (7) 0 Bilirubin 4 (14) 0 
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Nausea 18 (64) 4 Creatinine 2 (7) 0 
Stomatitis 1 (4) 0 Hyperglycemia 3 (11) 0 
Vomiting 11 (39) 4 Hypermagnesemia 2 (7) 0 
General Hypoalbuminemia 18 (64) 0 
Allergic 
Reaction 1 (4) 0 Hypocalcaemia 6 (21) 0 
Dehydration 3 (11) 0 Hypokalemia 1 (4) 0 
Depression 1 (4) 0 Hyponatremia 7 (25) 0 
Fatigue 15 (54) 1 Urinary electrolyte wasting 3 (11) 0 
Fever 1 (4) 0 Neurology 
Headache 14 (50) 0 Neuro-Sensory deficits 2 (7) 0 
Infection 
without 
Neutropenia 
2 (7) 0 Tremors 1 (4) 0 
Libido 1 (4) 0 Pain 
Middle Ear 
Infection 1 (4) 0 Abdominal pain 2 (7) 0 
Muscle 
Weakness 1 (4) 0 Chest pain 2 (7) 0 
Myalgia 1 (4) 0 Pain Other 1 (4) 0 
Nail changes 1 (4) 0 Pleuretic Pain 1 (4) 0 
Sweating 1 (4) 0 Respiratory 
Taste 
Disturbance 8 (29) 0 Cough 1 (4) 0 
- - - Rhinitis 1 (4) 0 
 
Among possible drug-related biochemical abnormalities observed during the first-
course hypoalbuminemia was observed most frequently, but it did not reach DLT on the 
q14 day schedule. Twenty-four hour urine analysis indicated there is no renal wasting of 
albumin, protein or electrolytes after MS-275 administration.  No obvious gastrointestinal 
loss of albumin was observed clinically.  The hypothesis that MS-275 may trigger 
inflammatory response, leading to decrease of albumin was examined by evaluating 
several patients’ fibrinogen, C-reactive protein, and ferritin level at baseline and after 
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receiving MS-275.  These inflammatory factors were only slightly elevated. The level of 
ACTH, Cortisol, Progestin and Estrogen was accessed on patients, who entered higher 
dose level of MS-275 (8, 10 and 12 mg/m2), at the time of 0 and 24 hour of the first dose 
administered and no changes of these hormones were found.  However, the level of pre-
albumin was decreased after MS-275 administration, which suggests the possibility of 
production decline.   
 A total of 157 courses of MS-275 were administered on the q14 day schedule 
(Table 5.2).  To assess potential adverse events during MS-275 chronic dosing, we 
noticed that with each course, some cumulating adverse events caused treatment 
interruption.  For example, some grade 1-2 AEs occurred during early courses and 
occasionally progressed to higher grades during later courses, requiring reduction in dose 
or dosing frequency. The dose reductions were frequent on dose levels higher than 8 
mg/m2, as noted in Figure 5.1 and Table 5.4 (A).  
 
 
 
 
 
Table 5.4 Dose reductions and summary of second course adverse events 
 
(A) Number of patients who received dose reduction after course 1 
 
Number of 
patients 
2 
mg/m2 
4 
mg/m2
6 
mg/m2
8 
mg/m2 
10 
mg/m2 
12 
mg/m2 
Total 
Course 1 3 3 6 5 6 5 28 
Course 2 3 3 5 4 5 3 23 
> Course 2 
dose reduction 2 0 2 2 3 3 12 
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(B) Frequent (≥ 10%) Adverse Events Observed during ≥ Course 2, probably or 
possibly related to MS-275 (N = 23) 
 
Adverse 
events 
All Grade 
(%) 
Grade 
3 
Grade
4 Adverse events 
All  
Grade  
(%) 
Grade 
3 
Grade 
4 
Cardiovascular Hematology 
LVEF 3 (13) 0 0 Anemia 6 (26) 0 0 
Gastrointestinal Leucopenia 8 (35) 2 1 
Abdominal 
Pain 5 (22) 0 0 Lymphopenia 4 (17) 0 0 
Anorexia 13 (56) 1 0 Neutropenia 17 (74) 3 1 
Constipation 3 (13) 0 0 Thrombocytopenia 14 (61) 1 0 
Diarrhea 8 (35) 3 0 Laboratory 
Dyspepsia 6 (26) 0 0 Alk Phos 3 (13) 0 0 
Flatulence 3 (13) 0 0 Creatinine elevation 3 (13) 0 0 
Nausea 19 (83) 4 0 Hypercalcemia 4 (17) 0 0 
Stomatitis 3 (13) 0 0 Hyperglycemia 5 (22) 0 0 
Vomiting 7 (30) 1 0 Hypernatremia 1 (4) 0 0 
General Hypoalbuminemia 11 (48) 1 0 
Arthalgia 4 (17) 0 0 Hypocalcemia 10 (43) 1 0 
Chest Pain 4 (17) 0 0 Hypomagnesemia 6 (26) 0 0 
Dehydration 5 (22) 0 0 Hyponatremia 8 (35) 2 0 
Edema 4 (17) 0 0 Hypophosphatemia 6 (26) 4 0 
Fatigue 23 (100) 3 0 SGPT (Alt) 3 (13) 0 0 
Fever 5 (22) 0 0 Neuromuscular    
Headache 12 (52) 0 0 Muscle Weakness 3 (13) 0 0 
Myalgia 7 (30) 0 0 Neuro-Sensory 3 (13) 0 0 
Taste 
Disturbance 10 (43) 0 0 Respiratory 
Urine 
retention 2 (9) 0 0 Dyspnea 4 (22) 0 0 
 
   
Frequent, cumulative drug-related AEs observed at or beyond course 2 were: 
anorexia, nausea, hypoalbuminemia, fatigue, headache, diarrhea, neutropenia, 
thrombocytopenia, leucopenia, and hypophosphatemia.  Table 5.4 (B) summarizes all 
grade, grade 3, and grade 4 adverse events, occurring with a frequency of >10%during 
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the second course and beyond.  Incidences of dose reduction after the second and 
subsequent courses of MS-275 are shown in Figure 5.1 and Table 5.4a.  When MS-275 
used on a q14 day schedule, the lowest (2 – 4 mg/m2) doses are well tolerated, with ≤ 
33% of patients going onto dose reduction, while in the 6 – 10 mg/m2 dose range ≥ 50% 
of patients ultimately required dose reduction.  One patient with metastatic NSCLC, who 
had stable disease at the first re-staging, withdrew himself from the study on the 7th day 
of course 4 and selected to receive standard chemotherapy (docetaxel 50 mg/m2 q 
3week).  This patient developed a grade 4 neutropenia and leucopenia 8 days after 
receiving docetaxel, which was 16 days after the course 4 MS-275 dose. Taken together, 
the data of Table 5.4 and Figure 5.1 suggest that while 10 mg/m2 every 14 days was the 
formal MTD  according to the definition of the protocol, in practice titration of the 
tolerated dose to lower doses may be necessary during chronic or more frequent dosing.    
 Symptomatic cardiac adverse events were not observed in patients who received 
q14 day MS-275.  There were 184 ECGs performed among 28 patients per protocol 
design.  There were no ECG adverse events observed on q14 day schedule.  The ECG 
intervals (HR, PR, QRS and QTc) only varied slightly at some follow up time points after 
baseline, but were of no statistical or clinical significance (data not shown).  There were 
no ST–T wave changes from the baseline. MUGA (multiple gated acquisitions) scans 
were collected as per protocol design for all patients on the q14 day schedule. A total of 
91 MUGA scans were performed and at baseline the mean LVEF in all 28 patients was 
58.2% + 1.62.  Twenty-six of twenty-eight patients had both baseline MUGA and at least 
one follow up MUGA.  At follow up, mean LVEF were 58.7% + 1.08 in 26 patients. 
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There were no statistically significant LVEF changes detected by the paired t-test in all 
26 patients treated on q14 day schedule (p = 0.526) or per each dose level (p = 0.106 for 
2 mg/m2, p = 0.350 for 4 mg/m2, p = 0.133 for 6 mg/m2, p = 0.951 for 8 mg/m2, 0.201 for 
10 mg/m2, and p = 0.834 for 12 mg/m2). 
 With respect to the possibility of MS-275- induced immunosuppression, 
lymphopenia was observed through out the MS-275 courses.  However, only three 
instances of HSV- positive stomatitis were apparent in patients receiving greater than one 
course.  A CTCL patient who had stable disease for over 4 months experienced one 
episode of herpes zoster recurrence in conjunction with clinical worsening of a skin 
bacterial infection. 
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Each line represents a single patient started at his or her enrolled dose level and 
subsequent dose modification. 
 
Figure 5.1 Dose reductions in patients on q14 day schedule at each dose level.   
 
5.3.3 Responses 
 The treatment duration for each patient on the q14 day schedule is depicted in 
Figure 5.2. No CR or PR was observed on q14 day schedule.  We observed 15 cases of 
stable disease with durations of 62 to 309 days.  One patient with cervical cancer, treated 
at 12 mg/m2 for the first course, 10 mg/m2 for the second course, 8 mg/m2 for the third 
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course and continued on 6 mg/m2 every 3 weeks after the fourth course, sustained a 10 
month period of stable disease.  Another patient with NSCLC received the first course at 
10 mg/m2 and had two dose reductions to 6 mg/m2, sustained a 9 month stable disease.  
Two melanoma patients initially treated at 8 mg/m2 and continued on 6 mg/m2, had 5 and 
4 months stable disease. 
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Figure 5.2 Treatment duration of patients receiving MS-275 on once every 14 
days schedule   
 
5.3.4 Pharmacokinetics  
 Pharmacokinetic studies were performed in 28 patients and complete 
concentration-time profiles were available for 27. The plasma concentration versus time 
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profiles of MS-275 were very similar for most patients studied, with mean curves 
obtained at each of the tested MS-275 dose levels (Figure 5.3).  The mean non-
compartmental pharmacokinetic parameters of MS-275 after doses ranging from 2 to 12 
mg/m2 are summarized in Table 5.5.  Substantial interpatient variability in 
pharmacokinetic parameters was apparent at any dose level (CV for AUC, up to 53%).  A 
similar degree in variability between patients was evident in the apparent oral clearance 
(CV = 38.8%), thereby influencing the actual systemic exposure to MS-275 during drug 
treatment.  Furthermore, absorption of the drug was highly variable and yet the median 
peak plasma concentrations were reached 2 hours after drug intake.  In 4 patients, the 
apparent gastro-intestinal uptake of MS-275 was very slow with peak plasma 
concentrations observed at 24 hours (n = 2), 48 hours (n = 1), and even 60 hours (n = 1) 
post dosing.  In contrast, for 7 patients, peak plasma concentrations were observed 
already at the first sampling time point of 0.5 hours, suggesting very rapid absorption and 
a possible underestimation of the true extent of drug uptake in these individuals. 
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Table 5.5  Summary of MS-275 pharmacokinetic parameters using non-
compartmental analysis 
 
Dose 
(mg/m2) 
No. of 
patients 
(n) 
Cmax 
(ng/ml) 
AUC 
(ng*h/ml) 
CL/F  
(L/h/ m2) 
t1/2  
(h) 
Tmax 
(h) 
2 3 1.7  (0.2) 
196.3 
(104.5) 
13.8 
(10.3) 
80 
(49) 
6  
(2-24) 
4 3 4.8  (1.1) 
391.7 
 (150.7) 
11.3  
(4.6) 
51 
 (13) 
6  
(2-36) 
6 6 9.6  (4.6) 
492.8 
(177.8) 
13.1  
(3.4) 
53 
 (21) 
2  
(2-60) 
8 5 15.5  (11.7) 
357.7 
(38.1) 
22.6  
(2.7) 
40 
 (15) 
2  
(0.5-24) 
10 6 45.1  (59.3) 
528.9 
(170.6) 
20.5  
5.9) 
52 
 (11) 
1.5  
(0.5-2) 
12 4 131.6 (128.3) 
680.2 
(262.0) 
19.9  
(8.1) 
45  
(7) 
0.5  
(0.5-2) 
Grand Mean (SD) 17.4   (6.8)* 
52  
    (22)**  
Grand Median (Range)   2 (0.5-60) 
 
All values expressed as Mean (SD) except Tmax is in Median (Range) 
*p-value for Kruskall-Wallis test (p = 0.071) 
** p-value for Kruskall-Wallis test (p = 0.652) 
 
 
Disappearance of MS-275 from the plasma compartment was characterized by 
elimination in an apparent bi-exponential fashion, with an overall very slow apparent oral 
clearance of 17.4 + 6.8 L/h/m2.  The estimated apparent terminal disposition half-life was 
relatively consistent in all patients, exhibiting a mean value of 51.7 + 21.6 hours (CV = 
42%). As a result of the slow clearance, extended persistence of MS-275 was apparent, 
with detectable levels of the compound even 5 days after initial treatment in 19 of 27 
patients.   
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Data obtained from 31 cancer patients treated with MS-275 at dose levels ranging from 
2.0 to 12 mg/m2.  Data from patients treated at the same dose levels were grouped and are 
presented as mean values (symbol) + SE (error bar). The legend indicates each of the 
dose levels used. 
 
 
Figure 5.3 Concentration-time profiles of MS-275 administered orally grouped 
by dose levels 
The peak plasma concentrations as well as the AUCs increased in near proportion 
with the doses of MS-275 (Figure 5.4).  The power model analysis indicated that the 
model poorly described the data, and that estimates of the parameter β was 0.517 + 0.172 
(r2 = 0.323), while linear-regression analysis indicated near dose proportionality (r2 = 
0.556).  The mean apparent oral clearance of MS-275 was not significantly dependent on 
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drug dose (p = 0.071), and the estimated terminal half-life was dose independent (p = 
0.652) as well.  A preliminary analysis of pharmacokinetic-pharmacodynamic 
relationships for MS-275 suggests that drug exposure is significantly higher in patients 
experiencing DLTs compared with patients that had no DLT (mean AUC, 517 + 276 
ng*h/mL, n = 4;  versus 280 + 121 ng*h/mL, n = 23 p = 0.048) (Figure 5.5). 
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Thirty-one cancer patients were treated with MS-275 at dose levels ranging 2.0 to 12 
mg/m2.  Each symbol represents data from an individual patient.  Horizontal lines 
indicate the mean value for each dose group. 
 
Figure 5.4 Effect of MS-275 dose on the area under the plasma concentration 
versus time curve (AUC)  
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Each symbol represents data from an individual patient. 
Figure 5.5 Comparative AUC of MS-275 from patients with and without dose-
limiting toxicity (DLT).   
 
5.3.5 Analysis of PBMC histone H3 acetylation 
 In-vitro incubation of healthy donor PBMCs with MS-275 induced 
hyperacetylation of histone H3 (Figure 5.6A, upper panel).  Increased histone H3 
acetylation could be seen in a concentration-dependent manner, as low as 30 nM MS-275 
(data provided from collaborator).  Patient PBMCs were collected pre-dosing and at 
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several time points post-dosing.  Histone H3 hyperacetylation is shown for two patients at 
the 10 mg/m2 level, one at 24 hr and one at 48 hr post treatment  (Figure 5.6A, middle 
and lower panels).  The level of histone hyperacetylation was quantified by image 
analysis software and displayed in graphical form for two series of patients.  Figure 5.6B 
shows histone H3 acetylation in 7 patients treated at the 2 mg/m2 level.  Four of these 
patients never displayed H3 acetylation fluorescence above a two fold elevation from 
baseline, but three displayed greater than two fold elevation between 24 and 48 hr after 
their first dose of drug, and were showing evidence of deceased fluorescence staining by 
greater than 48 hr after drug. Figure 5.6C shows the histone H3 hyperacetylation 
response in a group of patients at the 10 mg/m2 level.  All of the patients treated at this 
dose level responded with differing intensities and kinetic profile. In the limited sample 
size studied in this protocol, there was no significant (p < 0.05; Number Cruncher 
Statistical System 2001 Series) correlation between the AUC, AUC/dose, CL/F, Cmax, 
Cmax/dose and the normalized change in histone H3 acetylation at 24 hr after the initial 
dose (Table 5.6). However, these  data emphasize that histone acetylation is apparent at 
doses well below 10 mg/m2 , raising the possibility that an optimal biological effect in 
causing histone acetylation may be achievable at less than the MTD defined by clinical 
toxicity. 
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(A) Histone H3 hyperacetylation in response to MS-275 exposure in healthy donor 
PBMCs incubated in-vitro with 1 µM MS-275 for 20 hrs (upper panel).  Shown in the 
middle and lower panels are PBMCs from two patients treated with 10 mg/m2 MS-275.  
(B) Line graph of the mean fluorescence intensity of histone H3 acetylation in a group of 
patients treated at 2 mg/m2 MS-275.  (C) Line graph of the mean fluorescence intensity of 
histone H3 acetylation in a group of patients treated with 10 mg/m2 MS-275. 
 
Figure 5.6 Histone H3 hyper-acetylation in response to MS-275 treatment   
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Table 5.6 Correlation between PK parameters and % change in H3 acetylation 
after 24 hours 
 
 
PK parameter p-value R-square 
Cmax 0.8110 0.0054 
Dose (mg) 0.7936 0.0035 
Dose (mg/m2) 0.7815 0.0035 
Cmax/dose 0.8712 0.0025 
AUC 0.7182 0.0123 
AUC/dose 0.4513 0.0525 
CL/F 0.6976 0.0143 
 
Figures 5.34, 5.35, 5.36, 5.37 and 5.38 in the appendix depict actual plots. 
 
 
5.4 Discussion 
 Different HDAC family members may target different promoters in controlling 
gene expression.  Some of the transcriptional repressors recruit heterochromatin-like 
complexes that cause gene silencing mediated via specific repression pathways.  These 
appear to involve HDAC and heterochromatin proteins that convert the gene region into a 
heterochromatic environment.269  Non-histone proteins, including the activators p53 and 
GATA-1, and the general transcription factors, TFIIE and TFIIF, have also been reported 
to be acetylated by histone and acetyltransferases. This suggests that HDACs may 
regulate gene expression by deacetylation of non-histone proteins. 270-272 Very recently 
evidence has been gathered to show that even cell structural elements such as tubulin and 
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heat shock protein (hsp) 90 also can be acetylated after exposure to certain classes of 
HDAC inhibitors. Therefore a significant portion of anti-tumor and differentiating effect 
may arise through these additional mechanisms.  HDACs may also participate in cell 
course regulation, since Rb/E2F mediated transcriptional repression involves recruitment 
of HDAC1 or HDAC2 by Rb. 273, 274  Therefore, the inhibitors of HDAC present an 
exciting, novel approach to the treatment of solid tumors, many of which are refractory to 
current therapies. Recent studies have emphasized that HDIs may be augmented in their 
gene-regulatory effects by co-administration with DNA methyltransferase inhibitors, and 
therefore understanding the pharmacologic profile of HDIs as single agents is a prelude 
to constructing regimens that would maximize ability to modulate gene expression. 44  
 We conducted studies with MS-275 on two different dosing schedules. Initial 
experience with the MS-275 daily schedule revealed that the schedule with greatest 
antitumor activity predicted from animal studies was intolerable for humans. The human 
pharmacokinetic data suggested that MS-275 might have approximately 50 times longer 
half-life in humans relative to mice, rats and dogs.  The implementation of the q14 day 
schedule allowed detailed assessment of human MS-275 adverse events and the 1st 
determination of the MS-275 pharmacokinetic and pharmacodynamic profile in humans.  
The q14 day schedule was relatively tolerable. The MTD was determined to be 10 
mg/m2.  DLTs include generalized fatigue and gastrointestinal symptoms of nausea, 
vomiting, and anorexia.  Similarly, frequent gastrointestinal adverse events related to 
MS-275 are dominant with gastrointestinal symptoms and also fatigue.  
Myelosuppression became apparent among cumulative adverse events related to MS-275.  
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Unlike the daily schedule, the q14 day schedule had neither symptomatic nor diagnostic 
cardiac adverse events observed.  Compared to the published phase 1 studies of other 
histone deacetylase inhibitors such as SAHA IV q21days, depsipeptide (FK228), 
phenylbutyrate 120-hour IV and daily oral, neither grade 4 toxicity was observed on the 
MS-275 q14 day schedule, nor grade 2 or higher cardiac toxicity. 53, 119, 208, 210, 212, 275  On 
the other hand, frequent nausea, vomiting, and dyspepsia were a complication of 
depsipeptide, phenylbutyrate by the oral route, suggesting that the development of an oral 
HDAC inhibitor may prove to be a challenge. The grade 3 toxicities observed were all 
reversible. The tolerable adverse event profile observed in q14 day schedule encouraged 
the possibility that MS-275 might be a potentially well-tolerated chemotherapeutic agent. 
However, the q14 day schedule may not maintain a constant inhibition of HDAC activity. 
Therefore, based on our pharmacokinetic analysis a weekly dosing schedule is presently 
being tested for tolerability and possible tumor response. 
The plasma concentration versus time profile of MS-275 after oral administration, 
and the subsequent long half-life justify the need for extended sampling, in this case up to 
96 hours, coupled with sensitive analytical procedures for the accurate estimation of 
pharmacokinetic parameters. MS-275 was previously shown to be highly active in 
various animal models when administered orally.  Most importantly, the recommended 
dose for further clinical studies using the current q 14 day oral dosing regimen provides 
peak plasma concentrations on average exceeding 75 ng/mL. This is above 
concentrations required in-vitro and in-vivo to induce significant growth inhibition in 
many models for various primary human tumors. 125, 126 
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In the present study, MS-275 displays an apparent linear, dose-independent 
pharmacokinetic behavior over the dose range studied (2 - 12 mg/m2). Overall, drug 
absorption was relatively rapid and, in some patients, the time to peak concentration was 
observed as early as 30 minutes, suggesting that MS-275 might undergo rapid gastric 
absorption prior to reaching the small intestine.  The disappearance of MS-275 was 
characterized by a bi-exponential decline with a terminal half-life in plasma of 
approximately 50 hours, which is substantially longer than that observed for MS-275 in 
laboratory animals (Schering AG, data on file). The basis for this long half-life in humans 
may be related to enterohepatic recirculation processes; this is indicated by the 
appearance of a second MS-275 peak around 24-48 hours after initial drug intake in 
several patients.  Furthermore, in one patient, the time to peak concentration was only 
observed at 60 hours, which is substantially longer than the normal gastrointestinal transit 
time.  Any hypothetical recirculation is thus likely to mask the true disposition half-life of 
the free drug, as has been observed previously with many other agents. 276 In addition to 
enterohepatic recirculation, other factors which may influence the prolonged circulation 
of MS-275 could include binding of the compound to plasma proteins like human serum 
albumin and α1-acid glycoprotein. However, we have found that MS-275 is only 
approximately 80% protein bound, and did not find any greater binding affinity to 
albumin than to other proteins. Therefore, there should be no significant clinical impact 
of protein binding on clearance.  It has been well established that for drugs with extensive 
protein binding, prolonged sampling may demonstrate a relatively slow redistribution of 
drug into plasma and thus prolong the apparent half-life.  It is also noteworthy that for 
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drugs undergoing enterohepatic recirculation, ingestion of food may impact plasma drug 
concentrations due to emptying of the gall bladder. However, although its potential 
impact on kinetics were not investigated here, the times that the patients under study took 
any food were noted and it thus unlikely that this alone explains the individual 
pharmacokinetic profiles. 
 The observed variability in the pharmacokinetic behavior of MS-275, with an 
interpatient variability in the apparent oral clearance of about 40%, is typical for cancer 
drugs administered orally. 277 As indicated, however, over the total dose range studied, 
the AUC of MS-275 demonstrated an apparent dose-independent behavior.  Interestingly, 
body-surface area correction did not reduce the interpatient variability in the oral 
clearance (38.8% versus 39.5%), suggesting that body-surface area is not a significant 
predictor of MS-275 pharmacokinetics and that flat-dosing regimens might be applied in 
future studies without compromising overall safety profile. 
 H3 acetylation in PBMCs provided a surrogate measure of HDAC inhibition after 
MS-275 administration. While encouraging evidence of H3 acetylation was observed 
during this trial, it is clearly not an indicator of tumor response.  Our data demonstrate 
interpatient variability in the magnitude and kinetics of histone H3 hyperacetylation.  
Although MS-275 can induce histone H3 hyperacetylation in PBMCs in-vivo, it is not 
clear whether histone H3 hyperacetylation is the most biologically relevant endpoint, nor 
is it known to what extent PBMCs reflect the MS-275 response in tumor cells in-vivo.  
These are critical questions which should continue to be examined in relation to MS-275 
and other clinically-relevant histone deacetylase inhibitors.    
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 In conclusion, our data indicate that MS-275 can be given safely on a once every 
14 day schedule, but not on a daily schedule in the dose range explored.  The DLTs were 
fatigue and gastrointestinal toxicities, including anorexia, nausea, vomiting. The 
recommended MS-275 q14 day dose for phase II studies is 10 mg/m2.  It is clear that for 
MS-275 used on a q14 day schedule, the low to median dose range of 2-4 mg/m2 is well 
tolerated among patients.  Although objective responses were not observed, 15 patients 
had stable disease while on q14 day schedule. An evaluation of pharmacokinetic-
pharmacodynamic relations indicated a significant association between exposure to MS-
275 and the occurrence of DLT.  Evidence of drug target effect in a surrogate tissue, 
PBMCs, was observed.  The relatively long half-life of MS-275 suggests that more 
frequent administration of low dose MS-275, but less frequent than daily administration, 
may be superior to the q14 day schedule. In addition, the actual influence of ingestion by 
humans in the fed or fasted state needs to be clarified and will be addressed in future 
studies. Further analysis of the absorption and disposition of MS-275 in individual 
patients with cancer, with respect to the current pharmacodynamic findings of HDAC 
inhibition, should be of great importance to identify the role of the various biological 
factors that may influence the compound's pharmacokinetic profile and pharmacological 
actions, as well as effects of other drug administered concomitantly.  Therefore, further 
studies using a weekly schedule supported by these pharmacokinetic data are ongoing. 
 CHAPTER 6 
 
Factors Affecting the Pharmacokinetic Profile of MS-275, in Patients with Cancer 
 
6.1. Introduction 
 Data from a Phase I clinical trial with MS-275 administered orally revealed 
significant inter-individual pharmacokinetic variability, with the apparent oral clearance 
ranging approximately 4.3 fold between different patients, and with a coefficient of 
variation of 39%.278 Although such high degree of variability is not unusual for 
anticancer drugs administered orally, it is an important issue to be addressed in relation to 
further development and optimization of dosing strategies for MS-275. This is 
particularly significant for MS-275, as variability in its oral exposure has been identified 
as an important determinant contributing to variability in toxicity.278 Specifically, a 
preliminary analysis of pharmacokinetic-pharmacodynamic relationships for MS-275 
suggests that drug exposure is significantly higher in the four patients experiencing dose-
limiting toxicities compared to 23 patients that had no dose-limiting toxicity [mean (± 
SD) dose-normalized area under the curve, 517 ± 276 ng•h/mL versus 280 ± 121 
ng•h/mL; p = .048].278 Here, we evaluated potential sources of this pharmacokinetic 
variability by performing an exploratory analysis aimed at identifying predictors of drug 
exposure in-vivo. 
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6.2. Patients and methods 
6.2.1 Patient Population 
Records collected as part of two Phase I clinical trials with oral MS-275 
performed at the National Cancer Institute (Trial I) and University of Maryland/Johns 
Hopkins University (Trial II) were examined prospectively. All patients had 
pathologically confirmed metastatic or unresectable malignant solid tumor or lymphoma 
(Trial I) or hematologic malignancy, predominantly acute myeloid leukemias (Trial II) 
for which standard curative or palliative measures did not exist or would likely be 
ineffective. All patients had adequate hematopoietic (absolute neutrophil count ≥1.5 × 
109/liter; platelet count ≥100 × 109/liter, leucocytes ≥ 3 × 109/liter), hepatic and renal 
function at the time of entry in Trial I. Inclusion also required an Eastern Cooperative 
Oncology Group performance status of ≤2, age of ≥18 years, and a life expectancy of ≥3 
months. All patients with complete information, consisting of sex, age, disease, height, 
weight, and first dose pharmacokinetic data, were included in the current analysis. 
Administration of all other concomitant drugs was avoided in order to reduce potential 
interactions. All patients showed willingness to self-administer and document doses of 
MS-275, and provided written informed consent for the pharmacologic analysis. The 
study protocols were approved by the respective local institutional review boards. 
 
6.2.2 Drug Administration 
MS-275 was provided by Schering AG (Berlin, Germany) as 1-, 5-, and 10-mg 
uncoated tablets. The drug was administered orally once a day at nominal dose levels 
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ranging between 2 to 12 mg/m2 (Trial I) or 4 to10 mg/m2 (Trial II) with dose increments 
of 2 mg/m2 between subsequently evaluated dose levels. Tables in the appendix describe 
the dose administered, demographics, type of tumors, etc. for patients on both trials. 
 
6.2.3 Pharmacokinetic Analysis 
For pharmacokinetic analysis, 6-mL blood samples were collected in tubes 
containing sodium heparin prior to drug administration and at approximately 0.5, 1, 2, 6, 
12, 24, 36, 48, 60, 72, 84, and 96 hours post-dose. The samples were immediately 
centrifuged at 3000 g for 10 minutes at 4° C, after which plasma was separated and then 
frozen at –70° C until the time of analysis.  Plasma samples were assayed by high-
performance liquid chromatography with mass-spectrometric detection, as described 
previously in Chapter 2. 
 Estimates of pharmacokinetic parameters for MS-275 were derived from 
individual concentration-time data sets by non-compartmental analysis using the software 
package WinNonlin v4.0 (Pharsight Corp., Mountain View, CA). The apparent oral 
clearance of MS-275 (CL/F) was calculated by dividing the administered nominal dose 
(mg/m2) by the observed area under the plasma concentration versus time curve 
extrapolated to infinity (AUC). The percent contribution of the area extrapolated to 
calculate AUC was, on average (± SD), 32 ± 16%. Due to ethical constraints and in view 
of patient comfort, we could not extend the sampling time point beyond 96 hours. The 
CL/F of MS-275 in units of L/h was calculated by dividing the actual dose administered 
(in mg) by the observed AUC values. The CL/F in units of L/h/m2 was calculated by 
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dividing the absolute clearance of MS-275 by a patient’s individual body-surface area 
(BSA). A preliminary analysis indicated that the CL/F of MS-275 was not significantly 
dependent on drug dose, either in Trial I (p = 0.232, one-way analysis of variance test) or 
in Trial II (p = 0.211), suggesting that MS-275 displays a linear, dose-independent 
pharmacokinetic behavior over the studied dose range (2.0 to 12 mg/m2). Therefore, the 
values of CL/F from patients treated on both trials at the various dose levels were 
combined without any further correction.  
The various body size measures, including BSA (in m2), lean body mass (LBM; 
in kg), ideal body weight (IBW; in kg), adjusted ideal body weight (AIBW; in kg; this 
parameter is often referred to as adjusted body weight or ABW in clinical practice), and 
body mass index (BMI in kg/m2), were calculated using the following equations, with 
height expressed in meters and weight in kg 279-282: 
BSA = 0.007184 × weight 0.425 × height 0.725       (eq. 1) 
LBM (men) = 1.10 × weight – 120 × (weight/ (height × 100))2    (eq. 2) 
LBM (women) = 1.07 × weight – 148 × (weight/[height × 100])2    (eq. 3) 
IBW (men) = 50 + 0.91 × ([height × 100] –152)      (eq. 4) 
IBW (women) = 45 + 0.91 × ([height × 100] –152)     (eq. 5) 
AIBW = IBW + 0.25 × (weight – IBW)      (eq. 6) 
BMI = weight / (height)2        (eq. 7) 
BSA was also calculated using Mosteller’s equation, √[(height × weight) / 36], 
which is also commonly used in clinical practice.280 A preliminary analysis indicated that 
BSA values calculated using both equations were very similar; the mean ratio of BSA 
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calculated using one or the other method was 1.00 (range, 0.99 to 1.02; p = 0.99, unpaired 
Student’s t-test), confirming the equivalence of both methods for the present 
pharmacokinetic analysis. All subsequent analyses were performed using individual BSA 
values as calculated using eq. 1. Patients were also classified into four BSA-groups: BSA 
<1.50 m2, BSA between 1.51 and 1.70 m2, BSA between 1.71 and 2.0 m2, and BSA >2.0 
m2, respectively, and analyzed for differences in the observed CL/F as well as variability 
in CL/F. 
 
6.2.4 Statistical analysis 
All pharmacokinetic parameters are reported as mean values ± SD, unless stated 
otherwise. Inter-individual variability in parameters was evaluated by the coefficient of 
variation (%CV). Univariate linear-regression analysis was performed to evaluate 
potential relationships between MS-275 clearance and each of the studied body-size 
measures, sex, tumor type, and age. After testing for normality in parameter value 
distribution, absolute oral clearance (dependent variable) was plotted versus BSA, LBM, 
IBW, AIBW, BMI, weight, and height, respectively (independent variables). Adjusted r2 
and p-values were calculated and | r | values were used as a measurement for extent of 
correlation. The following categorization was applied for values for | r |, such that | r | > 
0.70 indicates a strong association; 0.50 < | r | < 0.70 indicates moderately strong; 0.30 < | 
r | < 0.50 indicates weak to moderately strong, and | r | < 0.30 indicates a weak 
correlation. Differences in the %CV among BSA groups were determined by a modified-
Levene equal-variance test. One-way analysis of variance (ANOVA) was used to 
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compare difference in body-size normalized CL/F values among different size categories 
and dose levels, followed by a post-hoc analysis using Dunnett’s two-sided multiple-
comparison test to determine group differences. All statistical calculations were 
performed using the NCSS package version 2001 (J. L. Hintze, Kaysville, UT). All p-
values were two-sided and not adjusted for multiple comparisons. 
 
6.3. Results 
6.3.1 Patient population 
 The entire population studied consisted of 64 patients, of whom 36 were males 
and 28 females. A summary of patient demographic variables is provided in Table 6.1. 
The median age of patients was 57 years (range, 22-86 years). The patients received MS-
275 orally on two independent trials (dose range Trial I, 2 to12 mg/m2; dose range Trial 
II, 4 to10 mg/m2). All patients had a pathologically confirmed metastatic or unresectable 
malignant solid tumor including lymphomas (Trial I) or relapsed or refractory acute 
leukemias (Trial II). 
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Table 6.1   Summary of patient demographic characteristics 
Patient characteristic Number of patients Mean (range) 
Total number of patients 64 
Age, years 58a (22-86) 
Sex, male/female 36:28 
Height, m 1.69a (1.30-1.85) 
Weight, kg 77a (49-125) 
BSA, m2 (eq. 1) 1.88a (1.47-2.35) 
LBM, kg (eq. 2, 3) 55ª (28-76) 
IBW, kg (eq. 4, 5) 63a (25-80) 
AIBW, kg (eq. 6) 55a (32-84) 
BMI (eq. 7) 27a (18-49) 
Primary tumor site  
Bone marrow (hematologic) 25 
Adrenal gland 1 
Breast 3 
Colorectal 6 
Cervix 1 
Oro-pharyngeal 1 
Kidney 6 
Liver 1 
Lung 4 
Head and neck 1 
Lymph gland 3 
Prostate 1 
Sarcoma 3 
Skin (melanoma) 8 
MS-275 dose (mg/m2)  
2 5 
4 15 
6 16 
8 16 
10 8 
12 4 
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6.3.2 Evaluation of candidate covariates for CL/F of MS-275 
The overall mean CL/F of MS-275 was 38.5 ± 18.7 L/h (range, 11.3 to 95.4 L/h), 
with a %CV of 48.7% (Table 6.2). After correction of CL/F for BSA, a mean value of 
20.7 ± 10.4 L/h/m2 was observed with a similar degree of variability (i.e., 50%). 
Likewise, after adjustment of MS-275 CL/F for individual differences in LBM, IBW, 
AIBW, BMI, weight, or height, the %CV was not reduced (Table 6.2). Using linear-
regression analysis, it was found that the CL/F of MS-275 was not significantly related to 
any of the studied body-size estimates (Figures 6.1, 6.2, 6.3. 6.4 and 6.5). In a univariate 
analysis, including weight, height, sex, age, albumin, bilirubin, serum creatinine and 
tumor type as independent variables, no significant covariates were identified (P-value 
range, 0.06 to 0.99; adjusted r2 range, <0.0001 and 0.082) (Table 6.3 and Figures 6.6, 6.7, 
6.8, 6.11, 6.12, 6.13, 6.14, 6.15).  
 
Table 6.2  Apparent oral clearance of MS-275 as a function of body-size 
measures 
Body size measure CV (%) Mean clearance (Mean ± SD) Units 
None 49 38.5 ± 18.7 L/ h 
BSA 50 20.7 ± 10.4 L/ h/ m2
LBM 53 0.72 ± 0.38 L/ h/ kg 
IBW 54 0.63 ± 0.34 L/ h/ kg 
AIBW 47 0.71 ± 0.33 L/ h/ kg 
BMI 55 1.48 ± 0.82 L/ h/ kg/ m2
Weight 55 0.52 ± 0.28 L/ h/ kg 
Length 49 22.8 ± 11.1 L/ h/ m 
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Table 6.3  Relationship between apparent oral clearance of MS-275 and patient 
characteristics 
 
Variable Significance P  r
2 Correlation 
| r | 
 
Slope 
BSA 0.88 0.0004 0.0199 1.9742 
LBM 0.97 < 0.0001 0.0052 0.0101 
IBW 0.69 0.0026 0.0512 0.0938 
AIBW 0.02 0.0822 0.2867 0.4466 
BMI 0.99 < 0.0001 0.0011 0.0035 
Weight 0.89 0.0003 0.0178 0.0221 
Length 0.75 0.0017 0.0407 8.1929 
Dose (mg) 0.04 0.0688 0.2622 0.9221 
Dose (mg/m2) 0.03 0.0748 0.2734 1.9102 
Gender 0.57 NA* NA* NA* 
Age 0.06 0.0577 0.2402 0.3494 
Tumor type 0.52 NA* NA* NA* 
Albumin 0.26 0.0205 0.1430 -5.0317 
Bilirubin* 0.83 0.0043 0.0656 -18.09 
Creatinine* 0.19 0.0209 0.1446 -6.932 
 
* Data available for n=26 patients on NCI trial 
 
It is noteworthy that AIBW showed a statistically significant (p = 0.02; r2 = 
0.082), albeit weak correlation (| r | = 0.29) with CL/F of MS-275. Although a significant 
correlation between BSA-corrected dose (in mg/m2) and CL/F was observed (p = 0.03), a 
post-hoc analysis indicated that this association was the result of high %CV observed in 
dose groups 6 mg/m2 and 8 mg/m2 without any obvious trends (Figures 6.9 and 6.10). 
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This is presumably an artifact due to the small sample sizes studied per dose group. 
Indeed, a multiple regression analysis did not result in any significant correlation of any 
of the studied covariates with the CL/F of MS-275 (p = 0.22, | r | = 0.25). 
There were also no statistically significant gender differences in CL/F (males, 
39.7 ± 17.4 L/h; females, 36.9 ± 20.5 L/h; p = 0.57), with similar %CV observed between 
sexes. Although minor differences in CL/F variability for the four studied BSA groups 
(i.e., ≤1.50, >1.50 and ≤1.70 m2, >1.70 and ≤2.0 m2, and >2.0 m2) were found, these were 
not significantly different (p = 0.51); the %CV for these groups were 39% (n = 3), 35% 
(n = 8), 52% (n = 39), and 43% (n = 14), respectively. The corresponding mean CL/F 
values in these groups were 49.5 ± 19.1 L/h, 30.8 ± 10.9 L/h, 40.3 ± 20.8 L/h, and 35.5 ± 
15.1 L/h, respectively (p = 0.38). Furthermore, correction with neither BSA nor any other 
body-size estimate could reduce variability (not shown). 
 
6.4 Discussion 
The dose of the majority of investigational agents evaluated in Phase I clinical 
trials is most commonly determined by using BSA as the only independent variable, and 
it has been shown that this approach nevertheless results in large inter-individual 
pharmacokinetic variability 277, 283. Whilst this has been widely recognized for some 
agents, until recently its significance has not been fully appreciated, and it remains 
unstudied for most investigational anticancer drugs as well as those commonly used in 
today’s clinical practice. The purpose of the present report was to assess the apparent oral 
clearance of the novel histone deacetylase inhibitor, MS-275, as a function of commonly 
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used body-size measures in adult cancer patients in an effort to explain the agent’s 
substantial inter-individual pharmacokinetic variability 215. 
As mentioned previously, and despite lacking evidence of its clinical relevance in 
adults, the use of BSA in drug dose calculations is widespread 284-286. The most 
commonly used formula to estimate BSA originates from 1916, and during the last 
decade, several critical notes concerning this BSA-based dosing concept in oncology 
have been published 284, 286-289. Indeed, it has been demonstrated that the clearance of 
most anticancer agents, including epirubicin, topotecan, cisplatin, and busulfan, is not 
related to BSA in adults 281, 290-294. Various alternative body-size measures have been 
proposed in recent years, including ideal body weight, adjusted ideal body weight, body 
mass index, and lean body mass, which might be better predictors of drug clearance, 
although no clear rationale for their use has yet been described for any anticancer drug 
277, 283. 
In the present study we have also evaluated the relationships between the apparent 
oral clearance of MS-275 and several body-size measures in a group of 64 cancer 
patients. The coefficients of variation for the apparent oral clearance of MS-275 
(expressed in L/h) or that expressed relative to BSA (expressed in L/h/m2) when 
including all patients in this study were 49% and 50%, respectively. Thus, similar to most 
other chemotherapeutic agents, it was found that dose-adjustments based on BSA as done 
in both clinical trials did not reduce inter-individual pharmacokinetic variability of MS-
275. In addition, using linear-regression analyses with body-size measures as the 
independent variable, no significant covariate for clearance could be identified. In 
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contrast, some estimates of body size (i.e., lean body mass, ideal body weight, and body-
mass index) were shown to be even worse predictors of the apparent oral of MS-275 than 
BSA. It is noteworthy to point out that, although there was a statistically significant 
influence of adjusted-ideal body weight (AIBW) on the apparent oral clearance of MS-
275, the correlation was weak and the data showed considerable scatter. Specifically, the 
apparent oral clearance of MS-275 increased by only 2.7 L/h per unit of AIBW and 
hence, a 1-kg increase in AIBW was associated with a mere 7.4% increase in apparent 
oral clearance. The interquartile range of AIBW values observed in our patient 
population was 46.0 to 63.8 kg, which suggests that, based on the regression model, a 
majority of treated adults will have a predicted oral CL/F of MS-275 in the range of 34.3 
to 42.3 L/h. This range is clearly of minor relevance against a background of %CV in oral 
clearance. This suggests that dose adjustment of MS-275 for body-size measures is 
unnecessary in adult patients with cancer. As predicted by the regression model, typical 
patients with an AIBW of 32.5 kg and 84.1 kg would have apparent oral clearances of 
MS-275 of 28.3 and 51.4 L/h, respectively. These values are similar to the actually 
observed values of 32.3 and 60.6 L/h, respectively, and translate into an almost 2-fold 
difference in systemic exposure to MS-275 for a given oral dose. Further analysis is 
required to evaluate the clinical significance and the potential implications of this 
observation. 
Albumin, bilirubin, serum creatinine, age and sex also had no significant 
influence on the apparent oral clearance of MS-275, suggesting that alterations of dosing 
regimens may not be required for the elderly. In addition to the processes mentioned, a 
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variety of other factors may influence MS-275 disposition, including binding of the 
compound to plasma proteins. For example, it has been well established that for drugs 
with very high protein binding, prolonged sampling may demonstrate a relatively slow 
redistribution of drug into plasma and thus prolong the apparent half-life and thereby 
change the apparent oral clearance. As shown in Chapter 3, the binding of MS-275 to 
human plasma proteins was concentration-independent, indicating a low affinity, possibly 
non-specific and non-saturable process, with overall a fraction unbound drug of 
approximately 19%.295 Because this degree of binding can be considered relatively 
insignificant, it is likely that protein binding plays a negligible role in the context of the 
present study. This supposition is consistent with the observation in the current analysis 
that interindividual differences in albumin concentrations were not identified as an 
important contributing factor to pharmacokinetic variability of MS-275.  
In order to further resolve the issue of attempting to individualize dosing 
strategies for MS-275, it will be imperative to determine which factors critically 
influence MS-275 absorption, elimination, and clinical outcomes (i.e., toxicity and 
efficacy). For example, as mentioned previously, the absolute oral bioavailability of MS-
275 in humans is unknown, and it is likely that relatively small changes in the amount of 
drug absorbed have an increasingly greater impact on the apparent oral clearance for 
drugs with low bioavailability. Furthermore, there is a current lack of information 
regarding renal elimination pathways of MS-275 and unless renal excretion is negligible, 
which remains to be determined in subsequent investigations, its contribution to 
interpatient variability in the apparent oral clearance of MS-275 cannot be discounted. 
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Regardless, the concept of fixed-dosing rather than BSA-normalized dosing should be an 
area for fruitful clinical pharmacological studies with MS-275. Clearly, implementation 
of such concepts would have significant economic implications. The ability to rationally 
design unit doses has obvious benefits for the pharmaceutical company involved. 
Similarly, the availability of a fixed oral dose preparation without the need for subsequent 
individualization for patients’ body size is in clinical practice more efficient and 
potentially more cost-effective than preparing individualized doses, and would eliminate 
a significant source of error in attempting to obtain precise dosing.296 
 
6.5. Conclusion 
In conclusion, the current pharmacokinetic analysis has eliminated a number of 
candidate covariates from further consideration as important determinants of MS-275 
absorption and disposition. In view of the significant degree of variability in the apparent 
oral clearance of MS-275 and the relatively small range in observed BSA within the 
studied population, MS-275 can be added to the list of anticancer agents where BSA-
based dosing does not appear to be more accurate and may suggest a false sense of 
accuracy. We are currently exploring the possible effects of food and differences in 
formulations of MS-275 that may help explain, in part, the high inter-individual 
pharmacokinetic variability. Better individual predictors of MS-275 pharmacokinetics 
and pharmacodynamics might be available in the future. However, further research into 
the exact relationships between these key factors and pharmacologic endpoints of MS-
275 treatment is necessary before they can be implemented routinely. Unless such 
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predictors are identified, it is recommended to apply flat dosing regimens for MS-275 in 
future clinical trials involving adult cancer patients as the best and most cost effective 
alternative. 
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Figure 6.1  Relationship between apparent oral clearance of MS-275 and body 
surface area (BSA) (n = 64) 
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Figure 6.2 Relationship between apparent oral clearance of MS-275 and lean 
body mass (LBM) (n = 64) 
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Figure 6.3 Relationship between apparent oral clearance of MS-275 and ideal 
body weight (IBW) (n = 64) 
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Figure 6.4 Relationship between apparent oral clearance of MS-275 and adjusted 
ideal body weight (AIBW) (n = 64) 
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Figure 6.5 Relationship between apparent oral clearance of MS-275 and body 
mass index (BMI) (n = 64) 
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CL/F vs Height 
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Figure 6.6 Relationship between apparent oral clearance of MS-275 and height 
(n = 64) 
 
CL/F vs Weight 
100.0 
75.0 
CL/F 
50.0 
25.0 
(L/h) 
0.0 
40.0 65.0 90.0 115.0 140.0 
Weight (kg) 
Figure 6.7 Relationship between apparent oral clearance of MS-275 and weight 
(n = 64) 
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CL/F vs Albumin
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Figure 6.8 Relationship between apparent oral clearance of MS-275 and albumin 
(n = 64) 
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Figure 6.9 Relationship between apparent oral clearance of MS-275 and dose 
(mg) (n = 64) 
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Figure 6.10 Relationship between apparent oral clearance of MS-275 and dose 
(mg/m2) (n = 64) 
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Figure 6.11 Disease type differences and correlation with oral apparent clearance 
of MS-275 (n = 64) 
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Figure 6.12 Gender differences and correlation with apparent oral clearance of 
MS-275 (n = 64) 
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Figure 6.13 Relationship between apparent oral clearance of MS-275 and age (n = 
64) 
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Figure 6.14 Relationship between apparent oral clearance of MS-275 and 
bilirubin levels from patients on NCI trial (n = 27) 
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Figure 6.15 Relationship between apparent oral clearance of MS-275 and serum 
creatinine levels from patients on NCI trial (n = 27) 
 CHAPTER 7 
Summary and Conclusions 
 
MS-275 is a histone deacetylase inhibitor that is currently under clinical development for 
treatment of cancer. The work summarized here primarily focused on the clinical 
pharmacological aspects including pharmacokinetics and pharmacodynamics of MS-275 
in patients with refractory solid tumors, lymphoma or advanced hematological 
malignancies. 
The hypotheses that were tested and the objectives of the study were as follows: 
1) Hypotheses 
1. MS-275 will be well tolerated in the clinic when given orally at the proposed 
doses. 
2. MS-275 will have quantifiable effects on the in-vivo biomarkers of anti-
proliferation and apoptosis in the tumor cells. 
3. The in-vitro and ex-vivo plasma protein binding will be extensive and linear in the 
clinically achievable concentration range. 
4. Metabolism by transporters and phase II enzymes will be the major metabolic 
pathway for MS-275. 
5. MS-275 will exhibit linear pharmacokinetics and single-dose pharmacokinetics 
will be useful in predicting steady state concentrations. 
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6. The relevant pharmacokinetic parameters of MS-275 absorption and disposition 
will be calculated, which may possibly explain inter-individual variability. 
2) Objectives 
1. To develop and validate an LC/MS assay that will quantitate MS-275 in human 
plasma or other matrix such as human liver microsomes. 
2. To characterize the pharmacokinetics of oral MS-275 in plasma of patients with 
solid tumors and lymphomas. 
3. To make pharmacodynamic correlations, if any, with the in-vivo anti-proliferative 
and apoptotic markers of biological effect and/toxicity. 
4. To assess the in-vitro plasma protein binding of MS-275. 
5. To characterize in-vitro the metabolic fate of MS-275. 
 
The best anti-tumor activity of MS-275 in human tumor xenografts was observed 
on a 4-week long oral, once daily schedule. The drug was tolerable with acceptable 
toxicity profile at the highest dose. The drug was dosed based on body weight in 
preclinical species, while in humans the dosing was based on body-surface area. Based 
on in-vitro IC50 data, MS-275 has shown activity in cell-lines at micromolar 
concentration ranges (0.75 - 1.6 µg/ml or 2 - 4.8 µM). The peak concentrations in 
patients after single oral dose administration at the highest dose of 12 mg/m2 were in the 
nanomolar range (29 - 320 ng/ml or 76 -848 nM), which were much lower in-vitro levels 
from preclinical species. The fraction unbound of MS-275 in in-vitro experiments with 
human plasma was found to be 19%. But it was significantly higher in five preclinical 
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species, namely rat, mice, dog, pig and rabbits (range 35 -45%). This difference in drug 
binding may be accounted due to lower proteins in plasma of all preclinical species 
compared to humans, and may in part explain the substantially longer half-life observed 
in humans. Although there was increase in acetylation of histone H3 seen in these 
patients at such low concentrations, the clinical activity cannot be translated into clinical 
efficacy of MS-275. 
Initial experience with the first human dose levels of MS-275 on a once daily for 
28 days schedule revealed that the drug was much less tolerated compared to rodents, 
with dose limiting thrombocytopenia and abdominal pain. Preliminary pharmacology 
studies pointed to a longer half-life in humans than the preclinical species (mouse, rat, 
dogs) (from Investigator’s brochure).  The preliminary PK data suggested that MS-275 
might have a 40- to 50-fold longer half-life in humans. The MTD of MS-275 in rats was 
18 mg/m2/day and in dogs was >6 mg/m2/day for 28 days dosing. A starting dose of 2 
mg/m2/day (about 1/10 of MTD in rats) was determined safe for human subjects as the 
initial dose of MS-275 in the phase I clinical trial administered daily for 28 days with an 
accelerated titration design. However, the initial human experience raised the possibility 
of abdominal pain, liver function and electrolyte abnormalities, and cardiac arrhythmia as 
potential adverse effects of the agent. Therefore, a more conservative dose escalation 
schedule, namely once every two weeks, was pursued with consideration of 
pharmacokinetic and pharmacodynamic endpoints as a basis for recommendation of 
dosing interval.  
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A total of 47 patients have been treated so far on three different administration 
schedules enrolled in the phase I clinical trial of orally administered MS-275. A 
minimum of 3 patients were accrued at each of the dose levels on each treatment arm. 
The daily x 28 schedule could not be pursued due to dose-limiting gastrointestinal 
toxicities in 2/2 patients treated. Hence, the biweekly schedule (q14 day) was evaluated. 
A total of 29 patients were treated, of which 28 were evaluable for toxicity and 27 were 
evaluable for pharmacokinetics. The DLTs on this schedule were grade 3 nausea, 
vomiting, fatigue and headache and the MTD was determined to be 10 mg/m2. Based on 
this, a weekly schedule is currently being evaluated with a starting dose of 6 mg/m2. On 
this schedule, the dose had to be de-escalated and the MTD has been determined to be 2 
mg/m2 and is in the final phase of completion. A food-effect study and a formulation 
effect study will be evaluated next on this weekly schedule. On all treatment schedules, 
single dose pharmacokinetics assessment were done in cycle 1 where blood samples were 
obtained before oral administration of the drug and 0.5, 1, 2, 6, 12, 24, 36, 48, 60, 72, 84 
and 96 hours after drug administration. It was also observed that the group of patients 
who had a higher exposure to MS-275 had significantly higher occurrence of dose-
limiting toxicities.  
A sensitive, specific and rapid liquid chromatographic assay with mass 
spectrometric detection was developed and validated to quantitate MS-275 in plasma as 
well as pooled human liver microsomes. Calibration curves were constructed in the range 
of 1 to 100 ng/ml, and were analyzed using a weight factor proportional to the nominal 
concentration. Sample pretreatment involved a one-step protein precipitation with 
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acetonitrile of 0.1-ml samples. The analysis was performed on a column (75 × 4.6 mm 
I.D.) packed with 3.5-µm Phenyl-SB material, using methanol – 10 mM ammonium 
formate (55:45, vol/vol) as the mobile phase. The column effluent was monitored by 
mass spectrometry with positive electrospray ionization. The values for precision and 
accuracy were always ≤ 5.58% and < 11.4% relative error, respectively. Long term 
stability and freeze thaw stability of MS-275 were also evaluated. This method was 
successfully utilized to examine pharmacokinetics of MS-275 in cancer patients by 
assessing concentrations in various patient plasma samples. Assay characteristics were 
modified by using ultraviolet detection and using gradient elution when using human 
liver microsomal matrix.  
The pharmacokinetic characterization was done for all patients by calculating all 
the non-compartmental parameters such as area under the curve (AUC), half life (t1/2), 
apparent total clearance (Clt/F), apparent pseudo steady state volume of distribution 
(Vdpss/F) and elimination rate constant (ke) using specialized software WinNonlin 
(Pharsight Corp.). It was determined that MS-275 exhibits linear pharmacokinetics as the 
clearance was found to be independent of dose administered. The AUC and Cmax 
increased in near-proportions with increase in dose. The absorption was found to be very 
rapid in most patients with median Tmax of 2 h. The half-life was 50-fold longer than in 
pre-clinical species. Large interpatient variability was hypothesized to be due to variable 
absorption at gastrointestinal pH. To further explore and understand the factors affecting 
such interpatient variability of MS-275 in-vivo, in-vitro plasma protein binding and in-
vitro drug metabolism were evaluated. Potential correlation of pharmacokinetic 
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parameters with in-vivo pharmacodynamic marker, histone acetylation was also 
addressed. Although there was an increase in acetylation of histones seen in PBMCs over 
time after exposure to MS-275, there was no significant correlation found when 
preliminary PK-PD analysis was performed between all relevant PK parameters such as 
exposure, peak concentration and apparent oral clearance with pharmacodynamic 
endpoint, % acetylation of histone H3 and H4 after 24 hours. Based on the 
pharmacokinetic data and adverse events observed from biweekly (q14day) schedule, 
another weekly (q7day) schedule is currently being tested. Preliminary data on the 
weekly schedule with starting dose of 6 mg/m2 had to be de-escalated at further dose 
levels. This is not entirely surprising considering that half-life of MS-275 is 50 to 60 
hours, there may be a 10-15% drug accumulation when dosing on a weekly schedule, 
which may in part be responsible for higher toxicity forcing dose de-escalation. 
One of the early hypothesis for longer half life in humans was that MS-275 is 
extensively bound to plasma proteins, specifically to either albumin or alpha-acid 
glycoprotein. To explore this, we examined the role of protein binding as a possible 
determinant of the pharmacokinetic behavior of MS-275. The distribution of MS-275 in 
plasma was studied in-vitro using equilibrium dialysis and ex vivo in 5 cancer patients 
receiving the drug orally at a dose of 10 mg/m2. The dialysis method uses a tracer amount 
of radiolabelled [G-3H]MS-275 on a 96-well microdialysis plate with a 5-kDa cut-off 
membrane, and requires 250 µL sample. The time to equilibrium was established to be 
within 5 hours, and the mean unbound fraction of MS-275 (fu) over a presumed 
therapeutic concentration range in human plasma was 0.188 ± 0.0075. The binding was 
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found to be concentration-independent, when tested over a clinically relevant 
concentration range, indicating a low affinity, possibly non-specific and non-saturable 
process. MS-275 was found to bind in decreasing order to plasma > α1-acid glycoprotein 
> albumin. When displacement effect was tested among 19 commonly administered 
concomitant drugs, a slightly increased fu was observed in the presence of only ibuprofen 
(fu, 0.236 ± 0.001) and metoclopramide (fu, 0.270 ± 0.042), suggesting weakly 
competitive displacement from protein-binding sites (p < 0.01). Compared to humans, 
significant species specific differences fu was significantly higher in plasma from mouse 
(0.376), rat (0.393), rabbit (0.355), dog (0.436), and pig (0.439) (p < 0.01), which may 
explain, in part, the species-dependent pharmacokinetic profile of MS-275 observed 
previously. When fraction unbound was measured in 5 patient plasma samples, it was 
found that the total plasma concentrations were reflective of unbound concentration of 
MS-275 and that the fraction unbound does not change over time. Overall, MS-275 is 
81% bound to plasma proteins and hence the clinical impact of binding on disposition 
would be minimal. 
In an effort to identify transport and elimination pathways of MS-275, uptake 
studies were performed to identify substrate specificity for two liver-specific isoforms of 
organic anion transporting proteins OATP1B1 and OATP1B3. In-vitro hepatic phase I 
metabolism of MS-275 was evaluated by incubation of MS-275 with pooled human liver 
microsomes using appropriate co-factors like NADPH for CYP-450 enzymes and 
glucuronidation. In-vitro phase II metabolism studies involved using UDPGA as a co-
factor or use of enzyme digestion technique using β-glucuronidase.  
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Accumulation of [G-3H]MS-275 by oocytes expressing OATP1B1 or OATP1B3 was not 
significantly different from water-injected controls (p = 0.82). Furthermore, no 
metabolites could be detected after incubation of MS-275 in human liver microsomes, 
suggesting that hepatic metabolism is a minor pathway of elimination. 
Elimination occurs by excretion and metabolism. Some drugs are excreted 
through bile and the more volatile substances through exhalation. Although, metabolism 
is the major mechanism for elimination of drugs, few drugs are eliminated entirely 
unchanged in urine. We have shown that for MS-275, hepatic phase I metabolic 
transformation is at best a minor pathway of elimination. Also, in related experiments 
with phase II metabolism, hepatic glucuronidation seems to be a minor pathway of 
elimination.  
On the other hand, MS-275 has a substantially long half-life of approximately 52 
hours in humans and we have confirmed that this is not due to extensive plasma protein 
binding. Currently, we believe that MS-275 may undergo enterohepatic recirculation 
(EHC) and may eventually be excreted in bile. Although this hypothesis has not been 
verified in individual experiments, the reason to believe of such a possibility is the 
presence of secondary peaks, observed in majority of patients’ individual concentration-
time profiles. The role of EHC can be identified by correlating the occurrence time of 
secondary peaks with the time of food intake. Unfortunately such information was not 
documented and is not available. Furthermore, there may be a correlation between 
bilirubin as a marker of biliary excretion and drug clearance. Bilirubin levels were 
measured over time and there was no trend observed. Using bilirubin as a covariate, there 
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was no correlation found with apparent oral clearance that may explain the wide inter-
individual variability among patients. In addition, serum creatinine values also did not 
explain the high inter-individual variability and did not show any significant correlation 
with CL/F. 
A correlative covariate analysis between apparent oral clearance and several 
covariates such as various demographic and body size measures was performed in an 
effort to explain the substantial interindividual pharmacokinetic variability of MS-275 in 
cancer patients. In-vivo pharmacokinetic data were obtained from 64 adult patients (36 
male/28 female; median age, 57 years) receiving MS-275 orally (dose range, 2 to 12 
mg/m2) enrolled on two separate phase I clinical trials involving solid tumors, 
lymphomas and hematologic malignancies. The mean (± SD) apparent oral clearance of 
MS-275 was 38.5 ± 18.7 L/h, with a coefficient of variation (%CV) of 48.7%. When 
clearance was adjusted for body-surface area (BSA), the inter-individual variability was 
similar (%CV = 50.1%). In addition, in a linear-regression analysis, except for adjusted 
ideal body weight (p = 0.02, | r | = 0.29), none of the studied measures (BSA, lean-body 
mass, ideal body weight, body-mass index, height, weight, albumin, bilirubin, creatinine, 
age or sex) was a significant covariate (P > 0.13; | r | < 0.11) for oral clearance. This 
analysis eliminated a number of candidate covariates from further consideration as 
important determinants of MS-275 absorption and disposition. Furthermore, MS-275 can 
be added to the list of cancer drugs where BSA-based dosing is not more accurate than 
fixed dosing. 
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 As per the guidelines suggested in the new proposed Biopharmaceutics Drug 
Disposition Classification System and available physicochemical data on MS-275, it can 
be predicted to fall under class 3 i.e. good GI solubility and poor permeability.261 This 
classification system may be useful in predicting routes of elimination, effects of efflux 
and absorptive transporters on oral absorption, when transporter-enzyme interplay will 
yield clinically significant side-effects such as low bioavailability and drug-drug 
interactions, the direction and importance of food effects, and transporter effects on post-
absorption systemic levels following oral and intravenous dosing. BDDCS suggests that 
Class 3 compounds are primarily eliminated unchanged in urine or bile. In preliminary 
data from urine samples of patients taking MS-275, we notice that less than 1% of drug is 
eliminated unchanged in urine. Also, the lower permeability profile may be affecting 
limited access to metabolizing enzymes within the hepatocytes. Based on our in-vitro 
studies with human liver microsomes, we have shown that phase I metabolism is a minor 
pathway of elimination. In light of all these observations, we speculate strongly that 
biliary excretion is a major pathway of elimination for MS-275. 
For Class 3 compounds, sufficient drug will be available in gut lumen due to good 
solubility, but an absorptive transporter may be necessary to overcome the poor 
permeability characteristics of these compounds. However, intestinal apical efflux 
transporters may also be important for the absorption of such compounds when sufficient 
enterocyte penetration is achieved via an uptake transporter. It is also possible that drug 
formulation excipients can affect uptake transporters and modify bioavailability. The 
outcome from the formulation-effect sub-study will shed more light on this issue. Food 
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can also influence drug bioavailability and the rate of availability. There is a speculation 
that high-fat meals may inhibit drug transporters, both influx and efflux. For Class 3 
compounds, high-fat will decrease the extent of bioavailability as shown recently (effect 
of fruit juices on fexofenadine) by decreased uptake due to inhibition of organic anion 
transporting polypeptides. We conducted studies involving liver-specific OATPs, and 
even though we found that MS-275 is neither a substrate for OATP1B1 and OATP1B3 
nor P-gp and ABCG2, effects of other intestinal OATPs cannot be ruled out. Renal 
elimination of may be affected by uptake and efflux transporters and may be important 
where a kidney-specific uptake transporter is involved. Further studies may substantiate 
our findings and shed more light onto the transporter-enzyme interplay related to drug 
absorption and disposition. 
Considering all the results from this project together, there is a lot of potential for 
further exploration of MS-275, specifically to identify enzymes involved in elimination 
and metabolism. Also, as data becomes available from parallel clinical trials elsewhere, a 
more robust covariate analysis can be performed using modeling approaches. The 
outcome from the currently ongoing formulation-effect and food-effect sub-studies would 
be critical in understanding the absorption differences as well as explaining the wide 
interindividual variability of MS-275. Furthermore, it will be worthwhile to perform a 
bioavailability study as and when an IV formulation becomes available.  
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Table 5.7 Summary of non-compartmental pharmacokinetic parameters for all patients on biweekly schedule 
receiving MS-275 orally with food 
 
 
Pat 
# 
Patient 
Initials 
Dose 
(mg/m2)
Dose 
(mg) 
Dose 
Group R-sq  Lambda_z t1/2 (h) 
Tmax 
(h) 
Cmax 
(ng/mL)
Tlast 
(h) 
           
1           HJ 2 4 1 1 0.0281 24.7 2 1.85 24
2          DU 2 4 1 0.9894 0.006 115.5 6 1.85 48
3          BH 2 4 1 1 0.0069 100.4 24 1.45 48
4          BA 4 8 2 0.8129 0.0195 35.5 2 4.01 96
5          LD 4 8 2 0.9596 0.012 57.8 36 6.09 96
6          RR 4 9 2 0.9603 0.0119 58.2 6 4.41 96
7          HR 6 11 3 0.8972 0.0119 58.2 12 4.83 96
8          ML 6 12 3 0.7744 0.0208 33.3 2 11.16 96
9          TJ 6 10 3 0.9821 0.0108 64.2 2 8.1 96
10 SL 6 12 3 0.9243 0.0218 31.8 60 10.49 96 
11          HP 6 11 3 0.2921 0.0155 44.7 2 5.6 96
12           JC 6 11 3 0.434 0.0082 84.5 2 17.36 96
13          WB 8 16 4 0.9086 0.0125 55.4 2 5.33 96
14          PR 8 14 4 0.8837 0.0135 51.3 0.5 19.07 96
15          RP 8 14 4 0.9402 0.0301 23.0 24 4.53 96
16          TB 8 12 4 0.9831 0.0155 44.7 0.5 33.01 96
17          TL 8 16 4 0.7966 0.0287 24.1 2 15.53 96
18          BD 10 20 5 0.8547 0.0115 60.3 0.5 44.85 84
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19          WC 10 21 5 0.6608 0.0105 66.0 2 17.43 96
20          LJ 10 20 5 0.7804 0.0133 52.1 0.5 163.21 96
21          TC 10 16 5 0.8613 0.0176 39.4 1 25.43 84
22 WR 10 20 5 0.9248 0.017 40.8 2 10.07 72 
23          CJ 10 23 5 0.9686 0.0136 51.0 2 9.41 96
24          HJ 12 23 6 0.8089 0.0171 40.5 2 29.19 96
25          CC 12 23 6 0.7613 0.0173 40.1 0.5 96.3 84
26 TD 12 21 6 0.7417 0.0153 45.3 0.5 319.12 96 
27 ED 12 25 6 0.8569 0.0128 54.1 0.5 81.91 96 
           
Median    0.8837 0.0136 50.96 2 10.49 96
Mean    0.8429 0.0155 51.74 7.278 35.244 87.56
SD    0.1663 0.0062 21.52 13.71 67.198 18.48
%CV    19.728 39.695 41.66 188.3 190.67 21.10
Min   0.2921 0.006 23.02 0.5 1.45 24
Max     1 0.0301 115.5 60 319.12 96
 
*Patients #’s 10, 22, 26 and 27 (highlighted boxes) experienced dose limiting toxicities. 
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Table 5.8 Summary of non-compartmental pharmacokinetic parameters for all patients on biweekly schedule 
receiving drug orally with food 
  
Pat 
# 
Patient 
Initials 
Dose 
(mg/m2)
Dose 
(mg)
Dose 
Group
AUC last 
(ng.h/mL)
AUC inf 
(ng.h/mL) 
AUC 
% 
extrap 
Vz/F CL/F (L/h/m2)
          
1          HJ 2 4 1 34.71 78.07 55.54 0.91 25.60
2          DU 2 4 1 69.01 276.18 75.01 1.20 7.20
3          BH 2 4 1 55.14 234.54 76.49 1.24 8.50
4          BA 4 8 2 181.34 244.93 25.96 0.84 16.30
5          LD 4 8 2 355.05 546.06 34.98 0.61 7.30
6          RR 4 9 2 248.37 384.05 35.33 0.88 10.40
7          HR 6 11 3 285.51 426.21 33.01 1.18 14.10
8          ML 6 12 3 331.47 398.31 16.78 0.72 15.10
9          TJ 6 10 3 225.89 353.30 36.06 1.57 17.00
10 SL 6 12 3 634.86 839.45 24.37 0.33 7.10 
11          HP 6 11 3 238.62 425.25 43.89 0.91 14.10
12          JC 6 11 3 283.79 514.34 44.82 1.42 11.70
13          WB 8 16 4 287.99 388.02 25.78 1.65 20.60
14          PR 8 14 4 256.20 352.08 27.23 1.69 22.70
15          RP 8 14 4 259.86 294.11 11.64 0.90 27.20
16          TB 8 12 4 296.78 371.47 20.11 1.39 21.50
17          TL 8 16 4 341.82 382.88 10.72 0.73 20.90
18          BD 10 20 5 239.60 400.39 40.16 2.17 25.00
19          WC 10 21 5 439.20 734.38 40.19 1.29 13.60
20          LJ 10 20 5 544.82 746.87 27.05 1.01 13.40
21          TC 10 16 5 385.20 502.20 23.30 1.13 19.90
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22 WR 10 20 5 243.31 359.53 32.33 1.63 27.80 
23          CJ 10 23 5 310.37 429.81 27.79 1.72 23.30
24          HJ 12 23 6 466.34 592.97 21.35 1.19 20.20
25          CC 12 23 6 305.16 391.17 21.99 1.77 30.70
26 TD 12 21 6 887.62 1016.67 12.69 0.77 11.80 
27 ED 12 25 6 519.57 719.82 27.82 1.30 16.70 
          
Median 287.99     398.31 27.79 1.186 16.70
Mean  323.24 459.37 32.31 1.190 17.40
SD    178.88 204.39 16.38 0.424 6.75
%CV  55.338 44.495 50.69 35.63 38.82
Min    34.71 78.07 10.72 0.329 7.1
Max    887.62 1016.67 76.49 2.171 30.7
 
*Patients #’s 10, 22, 26 and 27 (highlighted boxes) experienced dose limiting toxicities. 
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Table 5.9 Details of pharmacokinetic parameters per dose level 
 
 
Pat 
# 
Dose 
(mg/m2) 
Dose 
Group
Cmax 
(ng/mL)
AUC inf 
(ng.h/mL) Vz/F 
CL/F 
(L/h/m2) Cmax/Dose AUC/Dose t1/2 (h) 
          
1          2 1 1.85 78.07 0.91 25.6 0.93 39.03 24.7
2          2 1 1.85 276.18 1.20 7.2 0.93 138.09 115.5
3          2 1 1.45 234.54 1.24 8.5 0.73 117.27 100.4
          
          Mean 1.72 196.26 1.12 0.01 13.77 0.86 98.13
          SD 0.23 104.45 0.18 0.01 10.27 0.12 52.23
          %CV 13.45 53.22 16.20 74.59 74.59 13.45 53.22
          Min 1.45 78.07 0.91 0.01 7.20 0.73 39.03
          Max 1.85 276.18 1.24 0.03 25.60 0.93 138.09
          
4          4 2 4.01 244.93 0.84 16.3 1.00 61.23 35.5
5          4 2 6.09 546.06 0.61 7.3 1.52 136.52 57.8
6          4 2 4.41 384.05 0.88 10.4 1.10 96.01 58.2
          
          Mean 4.84 391.68 0.77 0.01 11.33 1.21 97.92
          SD 1.10 150.71 0.15 0.00 4.57 0.28 37.68
         %CV 22.82 38.48 18.76 40.34 40.34 22.82 38.48
          Min 4.01 244.93 0.61 0.01 7.30 1.00 61.23
          Max 6.09 546.06 0.88 0.02 16.30 1.52 136.52
          
7          6 3 4.83 426.21 1.18 14.1 0.81 71.04 58.2
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8          6 3 11.16 398.31 0.72 15.1 1.86 66.38 33.3
9          6 3 8.1 353.30 1.57 17.0 1.35 58.88 64.2
10          6 3 10.49 839.45 0.33 7.1 1.75 139.91 31.8
11          6 3 5.6 425.25 0.91 14.1 0.93 70.88 44.7
12          6 3 17.36 514.34 1.42 11.7 2.89 85.72 84.5
          
         Mean 9.59 492.81 1.02 0.01 13.18 1.60 82.13
          SD 4.57 177.77 0.46 0.00 3.44 0.76 29.63
         %CV 47.66 36.07 45.19 26.08 26.08 47.66 36.07
          Min 4.83 353.30 0.33 0.01 7.10 0.81 58.88
         Max 17.36 839.45 1.57 0.02 17.00 2.89 139.91
          
13          8 4 5.33 388.02 1.65 20.6 0.67 48.50 55.4
14          8 4 19.07 352.08 1.69 22.7 2.38 44.01 51.3
15          8 4 4.53 294.11 0.90 27.2 0.57 36.76 23.0
16          8 4 33.01 371.47 1.39 21.5 4.13 46.43 44.7
17          8 4 15.53 382.88 0.73 20.9 1.94 47.86 24.1
          
         Mean 15.49 357.71 1.27 0.02 22.58 1.94 44.71
          SD 11.65 38.14 0.44 0.00 2.70 1.46 4.77
         %CV 75.21 10.66 34.33 11.98 11.98 75.21 10.66
          Min 4.53 294.11 0.73 0.02 20.60 0.57 36.76
         Max 33.01 388.02 1.69 0.03 27.20 4.13 48.50
          
18          10 5 44.85 400.39 2.17 25.00 4.49 40.04 60.3
19          10 5 17.43 734.38 1.29 13.60 1.74 73.44 66.0
20          10 5 163.21 746.87 1.01 13.4 16.32 74.69 52.1
21          10 5 25.43 502.20 1.13 19.9 2.54 50.22 39.4
22          10 5 10.07 359.53 1.63 27.8 1.01 35.95 40.8
23          10 5 9.41 429.81 1.72 23.3 0.94 42.98 51.0
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         Mean 45.07 528.87 1.49 0.02 20.50 4.51 52.89
          SD 59.34 170.57 0.43 0.01 6.00 5.93 17.06
         %CV 131.66 32.25 28.96 29.25 29.25 131.66 32.25
         Min 9.41 359.53 1.01 0.01 13.40 0.94 35.95
         Max 163.21 746.87 2.17 0.03 27.80 16.32 74.69
          
24          12 6 29.19 592.97 1.19 20.2 2.43 49.41 40.5
25          12 6 96.3 391.17 1.77 30.7 8.03 32.60 40.1
26          12 6 319.12 1016.67 0.77 11.8 26.59 84.72 45.3
27          12 6 81.91 719.82 1.30 16.7 6.83 59.99 54.1
          
         Mean 131.63 680.16 1.26 0.02 19.85 10.97 56.68
         SD 128.28 262.00 0.41 0.01 8.01 10.69 21.83
         %CV 97.45 38.52 32.77 40.36 40.36 97.45 38.52
          Min 29.19 391.17 0.77 0.01 11.80 2.43 32.60
        Max 319.12 1016.67 1.77 0.03 30.70 26.59 84.72
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Table 6.4 Patient demographics 
 
 
Pat # Age (yr) 
Dose 
mg/m2
Dose 
mg Sex 
Weight 
kg 
Height 
(m) Albumin    HISTOLOGY Primary Site
1 65 6 10 F 62.5 1.63 4.1 ACUTE MYELOGENOUS LEUKEMIA Bone marrow 
2 54 6 12 M 84.0 1.72 3.2 ACUTE LEUKEMIA Bone marrow 
3 85 6 10 M 56.1 1.70 2.9 ACUTE MYELOGENOUS LEUKEMIA Bone marrow 
4 69 6 12 M 84.4 1.68 2.8 ACUTE MYELOID LEUKEMIA Bone marrow 
5 74 8 16 M 78.0 1.85 3.7 ACUTE MYELOGENOUS  LEUKEMIA Bone marrow 
6 56 10 18 M 63.4 1.78 2.8 ACUTE MYELOGENOUS LEUKEMIA Bone marrow 
7 65 8 15 F 76.4 1.62 3.8 PERSISTENT ACUTE MYELOID LEUKEMIA Bone marrow 
8 57 10 18 M 71.4 1.65 3.8 RESIDUAL ACUTE MYELOID LEUKEMIA Bone marrow 
9 44 6 10 F 82.2 1.30 3.6 ACUTE MYELOGENOUS LEUKEMIA Bone marrow 
10 66 8 16 M 81.9 1.74 3.7 PERSISTENT ACUTE MYELOID LEUKEMIA Bone marrow 
11        36 8 19 F 125.4 1.73 4 ACUTE MYELOGENOUS LEUKEMIA RELAPSE Bone marrow 
12          55 4 8 F 78.3 1.70 2.3 MULTIPLE LYELOMA Bone marrow
13 72 4 6 M 49.9 1.62 2.2 MYELODYSPLASTIC SYNDROME Bone marrow 
14 76 8 12 F 49.1 1.63 2.8 ACUTE MYELOID LEUKEMIA Bone marrow 
15 70 4 9 M 95.2 1.85 3.4 RELAPSED ACUTE  LEUKEMIA Bone marrow 
16 49 6 12 F 94.0 1.58 3.1 RESIDUAL ACUTE LEUKEMIA Bone marrow 
17 45 8 15 M 70.0 1.85 3.0 PERSISTENT ACUTE MYELOID LEUKEMIA Bone marrow 
18 86 8 16 M 77.8 1.79 3.5 RESIDUAL ACUTE LEUKEMIA Bone marrow 
19 56 4 8 F 94.7 1.63 3.1 ACUTE LEUKEMIA Bone marrow 
20        50 8 14 F 60.4 1.70 4.2 RELAPSE ACUTE MYELOGENOUS LEUKEMIA Bone marrow 
21 69 8 14 F 76.0 1.58 3.2 ACUTE LEUKEMIA Bone marrow 
22 49 6 11 M 69.5 1.68 3.8 CML WIH NUMEROUS EARLY PRECURSORS Bone marrow 
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23 72 8 15 M 74.0 1.75 3.5 RELAPSED ACUTE LEUKEMIA Bone marrow 
24 65 8 14 M 64.8 1.66 3.2 RESIDUAL ACUTE MYELOID LEUKEMIA Bone marrow 
25 57 4 8 M 81.8 1.73 3.9 RELAPSED MULTIPLE MYELOMA Bone marrow 
26 35 4 8 F 78.6 1.718 4.2 Adrenal Cortical Carcinoma Adrenocortical Cancer 
27 57 2 4 F 72.4 1.593 3.8 Poorly Diff Adenoca Breast 
28        40 4 6 F 55.2 1.609 2.6 Infiltrating poorly different ductal CA Breast 
29         57 6 11 F 77.4 1.73 3.3 Adenocarcinoma Breast
30 43 12 21 F 64.2 1.668 3.7 mod diff adenoca Cervix 
31 53 12 23 M 75 1.755 3.6 Poorly Diff Adenoca Colon 
32 46 4 7 F 78.2 1.688 3.9 mod diff adenoca Colon 
33 54 10 16 F 53.3 1.607 3.5 mod diff invasive adenoca Colon 
34 83 4 7 F 72.1 1.642 3.3 Poorly to mod diff Adeno Ca Colon 
35 22 2 3 M 55.6 1.732 3.3 Nasopharyngeal Carcinoma Head and Neck 
36 63 2 4 M 84.7 1.841 3.8 Renal Cell Clear Cell Kidney 
37 53 6 11 M 75.3 1.692 3.8 Renal Cell Carcinoma Kidney 
38 35 4 8 M 91.7 1.712 4.0 Renal Cell Carcinoma Kidney 
39 54 6 12 F 93.8 1.711 3.8 Renal Cell CA, Clear cell type. Kidney 
40 46 8 14 F 76.3 1.613 3.0 Renal Cell Clear Cell Kidney 
41 56 6 10 M 58.8 1.576 3.2 Renal Cell Clear Cell Kidney 
42 60 4 8 F 71.9 1.669 4.1 Spindle cell sarcoma, Leromyosarcoma Leiomyosarcoma 
43        68 4 7 F 80.2 1.631 3.8 Adenocarcinoma Liver 
44 56 6 11 M 68.4 1.667 4.3 Poorly different. adenocarcinoma of lung Lung 
45         74 10 20 M 82.1 1.73 3.7 Bronchoalveolar CA Lung
46 61 8 14 M 64.7 1.68 2.7 Squamous Cell Carcino Lung 
47         65 8 12 F 53.2 1.496 3.1 Non Small Cell Lung
48 64 12 23 M 70.3 1.78 3.9 Peripheral T cell lymphoma Lymphoma 
49 51 6 11 F 69.6 1.68 2.9 Cutaneous T-cell Lymphoma Lymphoma 
50         62 2 4 F 103.5 1.579 4.2 Follicular Lymphoma
51          58 10 23 M 114.2 1.784 3.9 Melanoma Melanoma
52 61 6 11 F 78.2 1.568 4.1 Metastatic Malignant Melanoma Melanoma 
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53          70 4 9 M 88.6 1.835 3.7 Melanoma Melanoma
54          56 6 12 F 86.4 1.62 3.9 Melanoma Melanoma
55          56 8 16 M 85 1.71 3.9 Melanoma NOS Melanoma
56         58 10 21 M 95.3 1.763 3.8 Cutaneous Melanoma
57          60 12 25 M 89.7 1.799 3.4 Mesothelioma NOS Mesothelioma
58          77 4 8 M 86.1 1.783 4.3 Poorly Differentiated Oral-Pharyngeal
59         71 8 16 M 79 1.76 4.0 Adenocarcinoma Prostate 
60 28 6 11 F 66.4 1.719 3.6 mod diff adenoca Rectum 
61 55 10 20 M 81.6 1.785 4.5 mod to poorly diff colonic adenoca Rectum 
62         57 10 20 M 86 1.771 3.4 Sarcoma NOS Sarcoma
63          53 2 4 M 110.5 1.73 5 Mycosis Fungoides Skin
64        72 4 8 M 81.8 1.72 3.8 Atypical lymphoid infiltrate consistant Skin 
          
Mean          58 6.6 12.4 77.4 1.69 3.56
SD          13 2.7 5.3 15.0 0.09 0.51
%CV          22 40.7 43.0 19.4 5.55 14.46
Min          22 2.0 3.0 49.1 1.30 2.20
Max          86 12.0 25.0 125.4 1.85 4.50
Median          57 6.0 11.7 77.9 1.70 3.70
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Table 6.5 Patient demographics and adjusted CL/F with body measures 
 
 
 
Pat # 
BSA 
1 
(m2) 
BSA 
2 
(m2) 
Ratio 
BSA 1 / 
BSA 2 
LBM 
(kg) 
IBW 
(kg) 
AIBW 
(kg)  BMI
CL/F 
(L/h) 
CL/F 
(L/h/m2) 
CL/F 
(L/h/kg) 
CL/F 
(L/h/kg) 
CL/F 
(L/h/kg) 
CL/F 
(L/h/kg) 
CL/F 
(L/h/kg) 
CL/F 
(L/h/m) 
             BSA 2 LBM IBW AIBW BMI Weight Length
1               1.68 1.67 0.99 45.01 54.65 56.61 23.64 26.56 15.90 0.59 0.49 0.47 1.12 0.42 16.33
2                2.00 1.97 0.98 63.78 68.20 72.15 28.39 27.41 13.90 0.43 0.40 0.38 0.97 0.33 15.94
3                1.63 1.65 1.01 48.67 66.56 63.95 19.37 48.12 29.19 0.99 0.72 0.75 2.48 0.86 28.27
4                1.99 1.95 0.98 62.70 64.92 69.79 29.76 25.50 13.10 0.41 0.39 0.37 0.86 0.30 15.14
5                2.00 2.02 1.01 64.56 80.39 79.80 22.69 26.03 12.90 0.40 0.32 0.33 1.15 0.33 14.04
6                1.77 1.79 1.01 54.48 73.48 70.96 20.06 51.74 28.87 0.95 0.70 0.73 2.58 0.82 29.10
7                1.85 1.81 0.98 48.83 54.10 59.68 29.11 95.43 52.61 1.95 1.76 1.60 3.28 1.25 58.91
8                1.81 1.79 0.99 56.07 61.83 64.22 26.23 82.37 46.12 1.47 1.33 1.28 3.14 1.15 49.92
9                1.72 1.59 0.93 28.32 24.53 38.94 49.02 38.64 24.29 1.36 1.58 0.99 0.79 0.47 29.84
10                1.99 1.97 0.99 63.50 70.02 72.99 27.05 56.23 28.58 0.89 0.80 0.77 2.08 0.69 32.32
11                2.45 2.35 0.96 56.15 63.84 79.23 42.04 50.83 21.67 0.91 0.80 0.64 1.21 0.41 29.43
12                1.92 1.90 0.99 52.46 61.56 65.75 27.03 24.79 13.05 0.47 0.40 0.38 0.92 0.32 14.56
13                1.50 1.51 1.01 43.48 58.92 56.66 19.06 46.30 30.62 1.06 0.79 0.82 2.43 0.93 28.61
14                1.49 1.51 1.01 39.11 55.01 53.53 18.48 70.00 46.37 1.79 1.27 1.31 3.79 1.43 42.95
15                2.21 2.20 0.99 73.08 80.39 84.10 27.70 60.58 27.58 0.83 0.75 0.72 2.19 0.64 32.68
16                2.03 1.94 0.96 47.86 50.01 61.00 37.89 24.78 12.77 0.52 0.50 0.41 0.65 0.26 15.73
17                1.90 1.92 1.01 59.82 80.03 77.52 20.45 90.51 47.04 1.51 1.13 1.17 4.43 1.29 48.92
18                1.97 1.96 1.00 62.91 74.57 75.38 24.28 38.04 19.36 0.60 0.51 0.50 1.57 0.49 21.25
19                2.07 1.99 0.96 51.13 54.65 64.66 35.82 75.46 37.87 1.48 1.38 1.17 2.11 0.80 46.41
20                1.69 1.70 1.01 45.99 61.56 61.27 20.85 25.24 14.84 0.55 0.41 0.41 1.21 0.42 14.83
21                1.82 1.77 0.97 46.86 50.01 56.50 30.64 18.44 10.40 0.39 0.37 0.33 0.60 0.24 11.71
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22                1.80 1.79 0.99 55.82 64.20 65.52 24.74 43.90 24.59 0.79 0.68 0.67 1.77 0.63 26.19
23                1.90 1.89 1.00 60.02 71.20 71.90 24.08 48.21 25.45 0.80 0.68 0.67 2.00 0.65 27.50
24                1.73 1.72 1.00 52.99 62.74 63.26 23.52 41.92 24.35 0.79 0.67 0.66 1.78 0.65 25.25
25                1.98 1.96 0.99 63.06 68.84 72.08 27.43 24.14 12.34 0.38 0.35 0.33 0.88 0.30 13.98
26                1.94 1.92 0.99 53.12 63.02 47.69 26.63 22.47 11.73 0.42 0.36 0.47 0.84 0.29 13.08
27                1.79 1.75 0.98 46.90 51.64 39.13 28.53 14.48 8.27 0.31 0.28 0.37 0.51 0.20 9.09
28                1.57 1.57 1.00 41.64 53.10 40.23 21.32 36.32 23.11 0.87 0.68 0.90 1.70 0.66 22.58
29                1.93 1.91 0.99 53.19 64.11 48.52 25.86 21.39 11.18 0.40 0.33 0.44 0.83 0.28 12.36
30                1.72 1.72 1.00 46.77 58.47 44.27 23.08 20.66 12.01 0.44 0.35 0.47 0.90 0.32 12.38
31                1.91 1.91 1.00 60.58 71.39 53.98 24.35 38.79 20.34 0.64 0.54 0.72 1.59 0.52 22.10
32                1.91 1.89 0.99 51.91 60.29 45.64 27.44 26.19 13.88 0.50 0.43 0.57 0.95 0.33 15.52
33                1.54 1.55 1.00 40.75 52.92 40.09 20.64 31.86 20.59 0.78 0.60 0.79 1.54 0.60 19.83
34                1.81 1.79 0.99 48.61 56.10 42.49 26.74 79.36 44.41 1.63 1.41 1.87 2.97 1.10 48.33
35                1.64 1.66 1.02 48.79 69.29 52.40 18.53 11.28 6.78 0.23 0.16 0.22 0.61 0.20 6.51
36                2.08 2.08 1.00 67.77 79.21 59.87 24.99 17.05 8.20 0.25 0.22 0.28 0.68 0.20 9.26
37                1.88 1.86 0.99 59.06 65.65 49.66 26.30 25.81 13.87 0.44 0.39 0.52 0.98 0.34 15.25
38                2.09 2.04 0.98 66.44 67.47 51.03 31.29 14.65 7.18 0.22 0.22 0.29 0.47 0.16 8.56
39                2.11 2.06 0.98 55.89 62.38 47.21 32.04 30.13 14.63 0.54 0.48 0.64 0.94 0.32 17.61
40                1.85 1.81 0.98 48.52 53.46 40.50 29.33 47.60 26.34 0.98 0.89 1.18 1.62 0.62 29.51
41                1.60 1.59 0.99 47.98 55.10 41.72 23.67 28.30 17.79 0.59 0.51 0.68 1.20 0.48 17.96
42                1.83 1.81 0.99 49.47 58.56 44.34 25.81 32.66 18.08 0.66 0.56 0.74 1.27 0.45 19.57
43                1.91 1.86 0.98 50.03 55.10 41.73 30.15 29.11 15.65 0.58 0.53 0.70 0.97 0.36 17.85
44                1.78 1.77 0.99 55.04 63.38 47.95 24.61 25.87 14.64 0.47 0.41 0.54 1.05 0.38 15.52
45                1.99 1.96 0.99 63.28 69.11 52.27 27.43 26.78 13.65 0.42 0.39 0.51 0.98 0.33 15.48
46                1.74 1.74 1.00 53.37 64.56 48.84 22.92 39.76 22.92 0.75 0.62 0.81 1.73 0.61 23.67
47                1.49 1.47 0.99 38.21 42.82 32.49 23.77 32.30 22.01 0.85 0.75 0.99 1.36 0.61 21.59
48                1.86 1.87 1.01 58.61 73.66 55.69 22.19 58.80 31.37 1.00 0.80 1.06 2.65 0.84 33.03
49                1.80 1.79 0.99 49.07 59.56 45.09 24.66 31.25 17.46 0.64 0.52 0.69 1.27 0.45 18.60
50                2.13 2.03 0.95 47.16 50.37 38.17 41.51 51.24 25.30 1.09 1.02 1.34 1.23 0.50 32.45
51                2.38 2.31 0.97 76.45 74.02 55.96 35.88 53.51 23.19 0.70 0.72 0.96 1.49 0.47 30.00
52                1.85 1.79 0.97 46.86 49.37 37.42 31.81 37.69 21.07 0.80 0.76 1.01 1.18 0.48 24.03
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53                2.13 2.11 0.99 69.48 78.67 59.46 26.31 23.43 11.08 0.34 0.30 0.39 0.89 0.26 12.77
54                1.97 1.91 0.97 50.35 54.10 40.98 32.92 14.30 7.48 0.28 0.26 0.35 0.43 0.17 8.82
55                2.01 1.97 0.98 63.85 67.29 50.90 29.07 41.79 21.17 0.65 0.62 0.82 1.44 0.49 24.44
56                2.16 2.12 0.98 69.77 72.11 54.53 30.66 28.60 13.50 0.41 0.40 0.52 0.93 0.30 16.22
57                2.12 2.10 0.99 68.84 75.39 56.99 27.72 34.73 16.58 0.50 0.46 0.61 1.25 0.39 19.31
58                2.07 2.05 0.99 66.73 73.93 55.90 27.08 20.32 9.93 0.30 0.27 0.36 0.75 0.24 11.39
59                1.97 1.95 0.99 62.72 71.84 54.32 25.50 41.23 21.11 0.66 0.57 0.76 1.62 0.52 23.43
60                1.78 1.78 1.00 48.97 63.11 47.76 22.47 25.58 14.34 0.52 0.41 0.54 1.14 0.39 14.88
61                2.01 2.00 0.99 64.68 74.12 56.03 25.61 55.63 27.80 0.86 0.75 0.99 2.17 0.68 31.16
62                2.06 2.03 0.99 66.30 72.84 55.07 27.42 49.95 24.55 0.75 0.69 0.91 1.82 0.58 28.21
63                2.30 2.23 0.97 72.59 69.11 52.27 36.92 35.33 15.88 0.49 0.51 0.68 0.96 0.32 20.42
64                1.98 1.95 0.99 62.84 68.20 51.58 27.65 44.81 22.98 0.71 0.66 0.87 1.62 0.55 26.05
Mean 1.90 1.88              0.99 55 63 55 27 38.5 20.7 0.72 0.63 0.71 1.48 0.52 22.79
SD 0.20               0.19 0.02 10 10 12 6 18.7 10.4 0.38 0.34 0.33 0.82 0.28 11.14
CV% 10.73 10.06              1.66 18 16 22 21 48.7 50.1 53.40 53.87 47.12 55.25 54.46 48.86
Min 1.49 1.47              0.93 28 25 32 18 11.3 6.8 0.22 0.16 0.22 0.43 0.16 6.51
Max 2.45 2.35              1.02 76 80 84 49 95.4 52.6 1.95 1.76 1.87 4.43 1.43 58.91
Media
n 1.91 1.90              0.99 54 64 54 26 33.7 18.7 0.64 0.54 0.67 1.22 0.46 20.12
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Figure 4.5 Relationship between mean peak concentration (Cmax) and dose for patients on biweekly schedule of  
MS-275 
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Figure 4.5 Relationship between median peak concentration (Cmax) and dose for patients on biweekly schedule of 
MS-275 
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Figure 5.7 Semi-logarithmic plot of concentration versus time profile for patient no. 1 (dose=2 mg/m2) 
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igure 5.8 Semi-logarithmic plot of concentration versus time profile for patient no. 2 (dose=2 mg/m2) F
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Figure 5.9 Semi-logarithmic plot of concentration versus time profile for patient no. 3 (dose=2 mg/m2) 
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Figure 5.10 Semi-logarithmic plot of concentration versus time profile for patient no. 4 (dose=4 mg/m2) 
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Figure 5.11 Semi-logarithmic plot of concentration versus time profile for patient no. 5 (dose=4 mg/m2) 
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Figure 5.12 Semi-logarithmic plot of concentration versus time profile for patient no. 6 (dose=4 mg/m2) 
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Figure 5.13 Semi-logarithmic plot of concentration versus time profile for patient no. 7 (dose=6 mg/m2) 
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Figure 5.14 Semi-logarithmic plot of concentration versus time profile for patient no. 8 (dose=6 mg/m2) 
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Figure 5.15 Semi-logarithmic plot of concentration versus time profile for patient no. 9 (dose=6 mg/m2) 
 
 
 
1
10
0 10 20 30 40 50 60 70 80 90 100
Time (hr)
Observed
Predicted
Number=9
Rsq=0.9821  Rsq_adjusted=0.9761  HL_Lambda_z=63.995
(5 points used in calculation)
Uniform Weighting
 
X vs. Observed Y and Predicted Y 
 
 
 
 225
 
 
Figure 5.16 Semi-logarithmic plot of concentration versus time profile for patient no. 10 (dose=6 mg/m2) 
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Figure 5.17 Semi-logarithmic plot of concentration versus time profile for patient no. 11 (dose=6 mg/m2) 
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Figure 5.18 Semi-logarithmic plot of concentration versus time profile for patient no. 12 (dose=6 mg/m2) 
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Figure 5.19 Semi-logarithmic plot of concentration versus time profile for patient no. 13 (dose=8 mg/m2) 
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Figure 5.20 Semi-logarithmic plot of concentration versus time profile for patient no. 14 (dose=8 mg/m2) 
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Figure 5.21 Semi-logarithmic plot of concentration versus time profile for patient no. 15 (dose=8 mg/m2) 
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Figure 5.22 Semi-logarithmic plot of concentration versus time profile for patient no. 16 (dose=8 mg/m2) 
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Figure 5.23 Semi-logarithmic plot of concentration versus time profile for patient no. 17 (dose=8 mg/m2) 
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Figure 5.24 Semi-logarithmic plot of concentration versus time profile for patient no. 18 (dose=10 mg/m2) 
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Figure 5.25 Semi-logarithmic plot of concentration versus time profile for patient no. 19 (dose=10 mg/m2) 
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Figure 5.26 Semi-logarithmic plot of concentration versus time profile for patient no. 20 (dose=10 mg/m2) 
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Figure 5.27 Semi-logarithmic plot of concentration versus time profile for patient no. 21 (dose=10 mg/m2) 
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Figure 5.28 Semi-logarithmic plot of concentration versus time profile for patient no. 22 (dose=10 mg/m2) 
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Figure 5.29 Semi-logarithmic plot of concentration versus time profile for patient no. 23 (dose=10 mg/m2) 
 
 
1
10
0 10 20 30 40 50 60 70 80 90 100
Time (hr)
Observed
Predicted
Number=23
Rsq=0.9686  Rsq_adjusted=0.9608  HL_Lambda_z=51.1051
(6 points used in calculation)
Uniform Weighting
 
X vs. Observed Y and Predicted Y 
 
 
 
 239
 
 
Figure 5.30 Semi-logarithmic plot of concentration versus time profile for patient no. 24 (dose=12 mg/m2) 
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Figure 5.31 Semi-logarithmic plot of concentration versus time profile for patient no. 25 (dose=12 mg/m2) 
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Figure 5.32 Semi-logarithmic plot of concentration versus time profile for patient no. 26 (dose=12 mg/m2) 
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Figure 5.33 Semi-logarithmic plot of concentration versus time profile for patient no. 27 (dose=12 mg/m2) 
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Figure 5.34 Correlation between peak concentration (Cmax) and % change in histone H3 acetylation after 24 hours 
in patients taking MS-275 on biweekly schedule 
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Figure 5.35 Correlation between dose administered (mg/m2) and % change in histone H3 acetylation after 24 hours in 
patients taking MS-275 on biweekly schedule 
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Figure 5.36 Correlation between dose administered (mg) and % change in histone H3 acetylation after 24 hours in 
patients taking MS-275 on biweekly schedule 
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Figure 5.37 Correlation between exposure (AUC) and % change in histone H3 acetylation after 24 hours in patients 
taking MS-275 on biweekly schedule 
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Figure 5.38 Correlation between apparent oral clearance and % change in histone H3 acetylation after 24 hours in 
patients taking MS-275 on biweekly schedule 
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